Controversies in Haematopoietic Stem Cell Transplantation by Hassan, Sandra
Controversies in Haematopoietic Stem Cell Transplantation
Hassan, Sandra
 
 
 
 
 
The copyright of this thesis rests with the author and no quotation from it or information
derived from it may be published without the prior written consent of the author
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/12849
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
1 
 
 
Controversies in 
Haematopoietic Stem Cell 
Transplantation 
 
 
 
Sandra Hassan 
 
 
 
A thesis submitted for the Degree of Doctor of Medicine 
University of London 2015 
2 
 
Abstract 
Progress in the understanding and practice of haematopoietic stem cell transplantation has 
come a long way since its inception. Despite this, there is ever-increasing controversy within 
most haematological malignancies about the role and timing of transplantation. Medical 
practice today is governed by ‘evidence-based medicine’ and guidelines. However, 
guidelines are generic, with little quality evidence base available in many scenarios to help 
clinicians make decisions about transplantation in patients who fall into those controversial 
categories. 
 
The morbidity and mortality associated with allogeneic transplantation remains significant. 
Autologous transplantation is a safer procedure but does not offer the same curative 
potential. Consequently, decisions about which patients should be transplanted, how and 
when, continue to cause controversy.  
 
I have identified four clinical scenarios within haematopoietic stem cell transplantation where 
guidelines are not clear about the specifics of practice but in which we have specific clinical 
experience at St Bartholomew’s. These are the outcomes of two melphalan conditioning 
doses in autologous stem cell transplantation in multiple myeloma, the outcomes of 
allogeneic stem cell transplantation in multiple myeloma, the outcomes of patients with 
refractory and relapsed acute myeloid leukaemia and myelodysplasia undergoing sequential 
transplantation and finally the outcomes of allogeneic stem cell transplantation in lymphoma. 
 
The aim of this thesis has been to collate and analyse patient data in each of these areas of 
debate, in order to make recommendations regarding future clinical practice. Following on 
from this, I have evaluated the role of haematopoietic stem cell transplantation today and its 
future directions. 
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1.1 The history of bone marrow transplantation 
In 2007, human bone marrow transplantation celebrated its 50th anniversary after fraught 
beginnings and a multitude of early failures left many to believe it would never succeed. 
 
Animal studies in the 1950s and 1960s lay the essential groundwork for human bone marrow 
transplantation. Several important concepts were established; that survival could be 
achieved following a lethal dose of radiation  or high dose chemotherapy if followed by an 
infusion of marrow cells from an animal donor,1-7 that this could result in ‘secondary 
syndromes’, what would later be identified as graft-vs-host disease (GVHD)8 and that this 
could be ameliorated by giving infusions from DLA (dog leucocyte antigen) littermate 
matched canines9-12 and the administration of methotrexate after the infusion.13-15 
 
Concurrently, similar observations were seen in humans. The first human allogeneic 
transplant was reported by Thomas in 1957 but, despite two patients undergoing transient 
engraftments, all six reported patients died.16 This and other early attempts at allogeneic 
transplantation in humans were unsuccessful, most likely due to a combination of poor HLA 
(human leucocyte antigen) matching, inadequate immunosuppression to allow acceptance of 
the foreign graft and the complications of graft vs host disease.17, 18 
 
As improvements occurred in the understanding of the HLA system, antibiotic and 
transfusion therapies, further attempts at human allogeneic transplantation began to 
demonstrate some success. The first successful allogeneic transplant was reported in 1965 
in a patient with refractory lymphoblastic leukaemia who received a bone marrow infusion 
made up in equal parts of six relatives following high dose TBI (total body irradiation). The 
patient engrafted rapidly and despite developing acute GVHD was in remission 12 months 
later with erythroid antigen analysis demonstrating they had the phenotype of one male 
donor.19 During the course of the 1970s, the use of sibling donors in patients with advanced 
leukaemia and aplastic anaemia resulted in a small cohort of long term survivors and the 
concept that allogeneic transplantation could represent a curative treatment strategy20, 21 
 
Following the observation that a small cohort of patients with refractory leukaemia could be 
cured with allogeneic transplantation, this drove haematopoietic stem cell transplantation 
(HSCT) to be used earlier in the course of the disease and in patients who were in remission 
with significantly improved survival outcomes.22-24 Over the course of the 1980s, the 
successes that had been reported in patients with acute leukaemias led to the utilisation of 
16 
 
allogeneic transplantation in other haematological malignancies and congenital 
haematological disorders such as thalassaemia and sickle cell disease. 25, 26 By the end of 
the decade, it was also being used for solid tumours.27 
 
Despite these successes, at least half of patients were dying of GVHD.  The combined use 
of ciclosporin and short course methotrexate was demonstrated to significantly reduce the 
occurrence of GVHD and remains standard practice today.28, 29  
 
In 1971, the first allogeneic transplant from an HLA-matched unrelated donor was reported.30 
This success led to the foundation of the Anthony Nolan Trust in the UK in 1974 and the use 
of unrelated allogeneic transplantation grew over the latter course of that decade. Similar 
registries were formed in other countries and in 1988 Bone Marrow Donors Worldwide was 
established allowing significant international expansion of unrelated allogeneic 
transplantation. 
 
In 1983, Santos et al demonstrated that a non TBI-containing conditioning regimen 
(busulphan and cyclophosphamide) could be used, opening up the use of transplantation to 
centres that did not have facilities to deliver TBI.31 
 
In the late 1970s, the observation of a graft-vs-leukaemia (GvL) effect was reported, firstly 
following the concurrent achievement of remission following a graft-vs-host reaction and 
subsequently the demonstration that the occurrence of GVHD was associated with a 
reduction in disease relapse.32, 33 Over a decade later, further demonstration of the GvL 
effect was reported with the use of immunosuppression withdrawal and the use of donor 
lymphocyte infusions (DLI) to achieve remission in those who relapsed post transplant.34, 35 
The understanding that tumour cells could be eliminated by donor T cells rather than high 
doses of radiotherapy and chemotherapy led to the development of reduced intensity 
conditioning (RIC). 36-38 Harnessing the immunological power of allogeneic transplantation 
and consequent DLI infusions to manipulate disease control opened up the doors of HSCT 
to older and less fit patients. Furthermore, the significant morbidity and mortality associated 
with myeloablative transplantation was significantly less using this approach. T cell depletion 
(TCD) was introduced as a strategy to try and avoid the complications of T cell mediated 
GVHD. However, it was associated with increased graft failure and relapse rates attributable 
to the loss of the graft-vs-tumour effect in addition to increased viral complications.39 This 
increased relapse risk was reported to be offset by repeated DLI infusions and TCD remains 
a favoured conditioning strategy in some centres, particularly where the risk of GVHD is 
higher, e.g. where there is an unrelated or mismatched donor. 
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The headway made in allogeneic transplantation re-ignited enthusiasm for autologous stem 
cell transplantation (ASCT) in the 1980s. Avoiding the need to identify an HLA-matched 
donor and the risks of graft versus host disease made this an attractive strategy. Early 
reports demonstrated significant morbidity and mortality but there were some successes in 
patients with leukaemia, myeloma and lymphoma.40-43  
 
In the late 1980s, the use of peripheral blood stem cells (PBSCs) rather than bone marrow 
began to be used in humans after its success had been demonstrated in animal studies.  
The use of chemotherapy and haematopoietic growth factors resulted in increased 
circulating PBSCs44, 45 and stem cells could be separated based on their CD34 expression.46 
Although the use of PBSCs carried an increased risk of GVHD when used in allogeneic 
transplantation, the higher number of stem cells compared to bone marrow harvests resulted 
in more rapid engraftments. Progress in cryopreserving autologous PBSC when patients 
were in remission was a significant step forwards in autologous transplantation. However, 
the difficulties of transplanting a graft that was not entirely disease free resulted in early 
relapses and despite attempts to purge the stem cell grafts, this problem has not been 
overcome.47-49 Despite this, ASCT continues to offer long remissions and improved overall 
survival and today accounts for the majority of stem cell transplant procedures.50, 51  
 
Following the demonstration that haematopoietic stem cells were present in cord blood, in 
1989 the first successful cord stem cell transplant (SCT) was reported.52 Following this, cord 
banks have been established in many centres offering potential stem cell donor options to 
those without sibling or matched unrelated donors. 
1.2 Where are we today? 
Over half a century since the first human allogeneic transplant, despite many obstacles and 
significant early failures, E. Donnall Thomas spearheaded progress in the field of stem cell 
transplantation (and was awarded the Nobel Prize for his pioneering efforts in 1990). Today, 
successful stem cell transplants are carried out for a variety of haematological and non-
haematological malignancies, congenital haematological disorders, autoimmune conditions 
and inherited metabolic disorders.  The formation of donor registries and cord banks in 
combination with advances in HLA typing to include molecular rather than serological typing 
mean that suitable stem cell donors are not only matched siblings, but also include matched 
volunteer unrelated donors (VUD), related haploidentical donors and cords with over 23 
million donors available worldwide.53 Improvements in supportive care have occurred with 
the development of hickman lines, better antibiotic, antiviral and antifungal therapies, pre-
emptive CMV DNA PCR analysis and treatment, improved blood product support and 
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treatment of GVHD have all contributed to improved outcomes over the last few decades.  
Furthermore, clinicians now have validated tools to help identify which patients are fit to 
proceed with transplantation.54 The 1980s saw the introduction of transplant registries such 
as the European Group for Blood and Marrow Transplantation (EBMT) and the Centre for 
International Blood and Marrow Transplant Research (CIBMTR) playing a bigger role in 
HSCT with working parties providing education, standards of practice and a means of 
collecting and analysing outcome data. 
 
There has been remarkable progress but there is a long way to go. The morbidity and 
mortality associated with allogeneic transplantation remains significant. Autologous 
transplantation is a safer procedure but does not offer the same curative potential. 
Consequently, decisions about which patients should be transplanted, how and when, 
continue to cause controversy. The introduction of new drugs are muddying the water further 
as their improved clinical responses and survival outcomes are now calling into question 
whether transplantation will continue to have a role at all in several disease settings. 
1.3 The British Society of Blood and Marrow Transplantation 
Over the last two decades, there has been a significant rise in the number of SCTs being 
performed in the UK. During this period of growth, it became apparent that in order to ensure 
stem cell transplantation was being performed to the highest standards, monitoring was 
required. The British Society of Blood and Marrow Transplantation (BSBMT) was formed in 
1995. At inception, its objectives were to define the role and to monitor the outcomes of 
patients having stem cell transplant procedures in the United Kingdom and Ireland. 
Consequently, it became responsible for collecting data on all stem cell transplants 
performed within all 55 BSBMT member centres in the UK and Republic of Ireland.  In 
addition to these initial aims, the BSBMT has extended its role as listed below.  
1.3.1 Stem cell transplant data collection 
As already mentioned, collating and maintaining a robust and complete data-set of all UK 
stem cell transplants lies at the heart of BSBMT. The EBMT produces data collection forms 
entitled MED-A and MED-B. The MED-A comprises two forms which are considered the 
Minimum Essential Data and the completion and submission of these forms is mandatory in 
order for a centre to hold full EBMT membership. The first report enables patient registration. 
This form collects data on patient age, gender and ethnicity, disease, performance score, 
CMV status, serology status and history of fungal infection pre-transplant. Information is also 
collected regarding SCT type, stem cell source, whether there has been any graft 
manipulation ex-vivo in addition to route of cell infusion, cell count and viability. HLA-match 
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type, donor gender, donor CMV/serology status, chronological number of transplant type, 
conditioning regimen and whether myeloablative or not is also required information for 
submission. Post-transplant data on type of GVHD prophylaxis used, engraftment data, 
chimerism data, the occurrence and treatment of acute GVHD or other complications within 
the first 100 days and whether further cellular products have been given is collected in 
addition to disease status at day 100. There is also an annual follow-up report that records 
post transplant complications. BSBMT is responsible for ensuring that annual follow-up data 
is submitted. It is also their role to check data quality and to clarify and request missing data.  
 
The MED-B forms consist of disease specific and HSCT specific forms (allograft and 
autograft). They collate detailed pre-transplant information on diagnosis, subtypes, 
cytogenetics etc, prior treatment and response in addition to detailed recording of post 
transplant complications.  The MED-B forms are not yet mandatory but form the basis of 
registry-based scientific studies and all transplant centres are encouraged to submit them in 
order to strengthen the data that can be produced. 
 
BSBMT produces an annual report with analysis of a rolling 5 year cohort in addition to a 
more comprehensive analysis of the previous year’s activity. Analysis includes patient 
demographics, logistical data (graft source, time to transplant), non-relapse mortality (NRM) 
at D100 and 1 year and overall survival (OS) at 1, 2 and 5 years in addition to transplant-
related complications and late effects. There are sub-analyses both by indication for 
transplantation and by transplant type. Transplant activity is compiled both by centre and 
region. The most recent was published in 2014 in relation to UK transplant activity between 
2006 and 2011. 
1.3.2 Transplant centre accreditation 
In 1998, the EBMT and the International Society of Cellular Therapy (ISCT) established the 
Joint Accreditation Committee – ISCT & EBMT (JACIE). Its role is to provide an inspection-
based assessment and accreditation process against established standards in stem cell 
transplantation, promoting high quality patient care and laboratory performance. JACIE is a 
committee of the EBMT and data submission to EBMT is required in order to achieve 
successful accreditation with JACIE.  The BSBMT acts as the interface between the EBMT 
and all UK transplant centres. It is the responsibility of BSBMT to ensure all UK transplant 
data is submitted to EBMT. The Transplant Accreditation Committee (TAC), a BSBMT sub-
committee, holds the duty of ensuring that sufficient laboratory, clinical and stem cell 
collection facility inspectors are trained for the purposes of JACIE inspections and 
accreditation. It is also responsible for organising the inspections themselves. The BSBMT 
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JACIE inspectors will provide transplant centres with detailed reports, following review by the 
JACIE office and medical director. 
1.3.3 Benchmarking 
All collected outcome data is collated so that benchmarking can occur. Local activity and 
outcome data is compared to the collated national data. This information is sent back to 
each UK transplant centre on an annual basis so that individual centre performance can be 
evaluated and compared to a unified national outcome standard. In addition to this, BSBMT 
also makes a comparison of UK data to the annual EBMT Transplant activity to allow 
international benchmarking to take place.  
1.3.4 Supporting clinical transplant decision making and transplant commissioning 
The BSBMT committee have produced a table which reviews the indications for transplant 
by disease type. Its aim is to provide an up-to-date, evidence-based guidance for which 
clinical scenarios stem cell transplantation should be performed in. It is recommended that 
this table is referred to by all transplant physicians and purchasers. There are separate 
tables for adult and paediatric practice. This data is used to support the Clinical Reference 
Group that provides guidance and strategic direction for the commissioning of stem cell 
transplantation. 
 
The table considers individual diseases by subtype and response to treatment. It then 
considers the role of autologous transplantation, sibling or unrelated donor allogeneic 
transplantation in each scenario. Recommendations are categorised into ‘S’ which is the 
standard of care, ‘CO’ which indicates the transplant is a clinical option and may be 
considered after assessment of risks and benefits. ’D’ indicates that performing a transplant 
in such a scenario is ‘developmental’ and further trials are required before this could be 
recommended and finally ‘GNR’ suggests a transplant would be generally not 
recommended. The BSBMT committee members that formulated this table also serve as an 
adjudication committee in scenarios where there are funding disputes or less common 
situations which may not be listed in the table. The committee serve to provide impartial 
expert advice about whether the transplants in discussion are appropriate. 
 
1.3.5 Training and education 
The BSBMT has a responsibility to provide training and support for UK transplant data 
managers. In addition to this it provides documents, guidelines and training days in relation 
to stem cell transplantation practice. 
21 
 
1.3.6 Clinical trials 
The ‘clinical trials committee’ is a BSBMT sub-committee, involved in overseeing both 
retrospective and prospective stem cell transplant studies with the aim of informing and 
directing UK stem cell transplantation. 
1.3.7 BSBMT scientific sub-committee 
Through the organisation of meetings and workshops, this subcommittee aims to encourage 
and develop the interactions between clinicians and scientists working in stem cell 
transplantation, in order to facilitate improved clinical-scientific research projects and 
collaborations.  
1.4 Summary of UK stem cell transplant outcome data 
In 2014, the BSBMT 5th report to specialist commissioners was published with a summary of 
outcome data for UK stem cell transplants performed between 2006 and 2011 in addition to 
a detailed analysis of transplant activity and outcomes in 2012.55 Between 2006 and 2011, 
15,088 adult transplants were carried out in the UK providing further evidence that transplant 
activity in the UK is rising year on year. The majority were first transplants with second and 
subsequent transplants accounting for just over 10%.  
 
Over 60% of all SCT procedures were autologous stem cell transplants and just over 50% of 
these were for patients with multiple myeloma. The BSBMT report confirms that this is a 
relatively safe procedure with an overall NRM of 2% and 4% at 100 days and 1 year 
respectively. Five year overall survival (OS) is 60%. Data for those aged over 60 years is 
comparable but they have a slightly higher NRM and consequently a lower 5 year OS.  
 
Analysis of allogeneic transplants revealed demonstration of the increasing reliance on non-
sibling donors. There were 2570 VUD transplants compared to 1903 sibling transplants. 206 
transplants were from alternative donors. The stem cell source was PBSC in 90%. 3% of 
adult transplants utilised cord blood cells. The use of RIC far exceeded myeloablative (MA) 
conditioning for almost all disease types with no difference in NRM and 1 year OS between 
the two conditioning approaches. Exceptions to this were in acute lymphoblastic leukaemia 
(ALL) where more ablative transplants are still being performed. The report comments that 
this disease is more common in the younger population and the efficacy of RIC 
transplantation is reported to be less clear compared to many other haematological 
malignancies, therefore explaining this discrepancy. There were also more ablative 
transplants performed in chronic myeloid leukaemia (CML) and myeloma, most likely 
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attributable to patient selection given that allogeneic transplantation for both disease 
subtypes is not standard of care. 
 
NRM at 100 days and 1 year was reported as 8% and 16% for siblings and 11% and 24% for 
VUD transplants respectively. Overall 5 year survival for siblings was 53% with 41% for 
VUDs. As with the autologous recipients, those over 60 years were identified to have 
marginally worse 5 year survival outcomes. 
 
Grade 3 or 4 acute GVHD was reported to affect 6% and 7% of sibling and VUD transplants 
respectively. 46% of adult patients were reported to develop chronic GVHD although with 
only 5% of all allogeneic transplant recipients developing extensive chronic GVHD. 
 
1.5 Summary of St Bartholomew’s outcome data from the BSBMT 
Between 2006 and 2011, 638 transplants were carried out at St Bartholomew’s Hospital; 544 
were first transplants which form the basis of the BSBMT centre analysis. Of these, 361 
were autologous SCTs, 87 were sibling allogeneic transplants, 93 were VUDs and 3 were 
from alternative donors (1 cord, 1 syngeneic and 1 mismatched family donor).  
 
Table 1 summarises the outcomes of autologous transplants at St Bartholomew’s in 
comparison to the BSBMT data over the same time period. Overall survival at 1 year and 5 
years is 88% and 53% respectively for the autologous SCT cohort. NRM at D100 and 1 year 
is 4%, comparable to BSBMT data. 202 ASCTs were for patients with multiple myeloma, 37 
for Hodgkin lymphoma and 77 for non-hodgkin lymphoma. Overall survival for all three 
disease subtypes was comparable or even superior to BSBMT data up to 2 years post 
transplant. However there is then a tailing off with inferior 5 year OS for multiple myeloma. 
No absolute numbers are provided in the BSBMT centre specific report but the St 
Bartholomew’s confidence intervals are much wider than the UK BSBMT dataset, suggesting 
that these discrepancies should be treated with caution. Similarly there is a discrepancy in 2 
and 5 year NRM outcomes across all disease types. The rising NRM over time is odd in the 
context of ASCT, as deaths beyond this time point are almost always disease related. 
Furthermore, this BSBMT data is discrepant with local data where NRM beyond 2 years is 
static. This leads either the accuracy of BSBMT data submission or methods for analysis to 
be questioned. Patients are often treated at more than one centre, and towards the end of 
life the majority of their care may occur locally rather than at their transplant centre. 
Consequently, clinical details at this stage are not always available or clearly documented. I 
suspect that some of the patients who are currently falling into the bracket of NRM have 
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Table 1:  Autologous stem cell transplant outcomes between 2006 and 2011  
(Amalgamation of BSBMT 5th report to specialist commissioners and St Bartholomew’s Centre report)  
  All ASCT  Barts All ASCT BSBMT MM Barts MM BSBSMT HL Barts HL BSBMT NHL Barts NHL 
BSBMT 
Number 361 (316 MM/HL/NHL)* 8552 202 4578 37 918 77 2535 
% engraftment failure 1 1 0 0 0 1 4 1 
Med engraftment time (d) 15 12 15 13 14 11 18 11 
                  
% OS 1 year (95% CI) 88 (84-91) 89(88-89) 93 (89-96) 93(92-93) 95(80-99) 92(90-93) 88(79-94) 83(81-84) 
%OS 2 years (95% CI) 80(75-83) 80(79-81) 85(79-89) 84(83-86) 89(74-96) 84(82-87) 77(27-60) 74(72-76) 
%OS 5 years (95% CI) 53(46-59) 60(59-62) 49(39-58) 59 (57-61) 76(55-88) 69(65-73) 57(42-70) 60(58-63) 
                  
NRM D100 (95% CI) 4 (2-6) 2(2-3) 2 (1-5) 1 (1-2) 5(1-16) 3(2-4) 8(3-15) 4(3-5) 
NRM 1 year (95% CI) 4(3-7) 4(4-5) 3 (1-6) 3(2-3) 5(1-16) 4(3-6) 8(3-15) 6(5-7) 
NRM 2 years (95% CI) 7(4-10) 6(5-6) 5(2-8) 4(3-5) 11 (3-23) 7(5-8) 15(8-23) 8(7-9) 
NRM 5 years (95% CI) 12 (8-17) 10(10-11) 18(12-26) 8(7-9) 16 (5-31) 12(9-14) 32 (19-46) 14(13-16) 
                  
% secondary malignancy 1 1 2 2 0 2 2 3 
% late graft loss 0 0 0 0 0 0 0 2 
% conception post SCT 1 0 0 0 7 3 0 0 
ASCT  autologous stem cell transplant; Barts St Bartholomew’s Hospital; BSBMT British society of Blood and  Marrow Transplantation; OS overall survival; NRM non-relapse mortality; MM multiple 
myeloma; HL Hodgkin Lymphoma; NHL Non-hodgkin lymphoma 
*39 done for solid tumours and 6 ‘miscellaneous’ – data for these sub-groups not included in this table
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actually relapsed and died of relapsed disease but that these events have not been 
captured. 
 
Tables 2, 3 and 4 summarise the outcomes of allogeneic transplants performed at St 
Bartholomew’s between 2006 and 2011, again in comparison to collated BSBMT UK data. 
Over 80% of both sibling and VUD transplants utilised RIC platforms. This is more than the 
overall UK data, which reports 61% of sibling and 69% of VUD transplants were reduced 
intensity. Without more data on factors that influence conditioning selection such as age and 
comorbidities, it is difficult to analyse this discrepancy further. It is interesting to note that no 
identified differences in survival outcome were seen in the BSBMT comparison between the 
two conditioning strategies.  
 
Looking at data for all allogeneic transplants, NRM data both for siblings and VUDs is higher 
at all time-points compared to BSBMT data, with a resultant negative impact on OS data. 
Importantly, the Kaplan Meier curves provided with the centre report demonstrate that 
outcomes for allogeneic transplantation lie within the BSBMT outcome confidence intervals. 
 
Making sense of these inferior percentages is difficult. Firstly there is a large patient number 
discrepancy between the St Bartholomew’s and UK data. Relatively small numbers of 
patients and consequent events e.g. death will have a relatively large impact on percentages 
in terms of OS and NRM. Furthermore, even when the datasets are broken down into 
disease cohorts (tables 3 & 4), it is unclear whether these datasets are directly comparable. 
Across all UK transplant centres, there will undoubtedly be differences in clinical practices. 
Different first line treatments, salvage therapies and transplant conditioning regimens will be 
used. Selection criteria for transplant or type of transplant in terms of age and comorbidities 
may differ. Patient risk assessments in terms of their need for transplant may again vary 
across different centres. All of these factors will come into play when analysing outcomes 
and in particular when making comparisons. 
 
If the outcomes are considered by individual disease-types (where data is available), the 
numbers suggest that outcomes for those with AML in CR1 and with Hodgkin lymphoma are 
relatively favourable compared to the UK BSBMT data. Those with AML not in CR1 and CLL 
appear to do worse. As already mentioned, with the even lower patient numbers once 
divided by diagnosis and wide confidence intervals, it is difficult to draw conclusions.  
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Table 2: Allogeneic stem cell transplant outcomes between 2006 and 2011  
(Amalgamation of BSBMT 5th report to specialist commissioners and St Bartholomew’s centre report)  
  All SIB Barts All SIB BSBMT All VUD Barts All VUD BSBMT 
Number 87 1903 93 2570 
% RIC 83 61 87 69 
% engraftment failure 2 2 2 3 
Med engraftment time (d) 17 14 17 13 
% OS 1 year (95% CI) 64(53-73) 71(69-73) 54(43-64) 62(60-64) 
%OS 2 years (95% CI) 57(46-67) 63(60-65) 46(36-56) 51(49-53) 
%OS 5 years (95% CI) 45(34-55) 53(51-56) 32(21-43) 41(39-44) 
NRM D100 (95% CI) 11 (6-19) 8(7-9) 22 (14-31) 11(10-12) 
NRM 1 year (95% CI) 22(14-31) 16(14-18) 29(20-39) 24(22-26) 
NRM 2 years (95% CI) 23(15-32) 19(17-21) 35(25-45) 30(28-32) 
NRM 5 years (95% CI) 27(18-37) 23(21-25) 45(33-56) 35(33-38) 
%Acute GVHD 11 34 9 49 
% Grade 3/4 aGVHD 6 6 6 7 
% Chronic GVHD 40  NR 40 33 
% Extensive cGVHD 3  NR 3 5 
% secondary malignancy 2 2 2 2 
% late graft loss 0 1 0 1 
% conception post SCT 1 1 0 0 
 
SIB Sibling; VUD Volunteer unrelated donor; NR Not reported 
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Table 3: Allogeneic stem cell transplant outcomes for leukaemia between 2006 and 2011  
(Amalgamation of BSBMT 5th report to specialist commissioners and St Bartholomew’s Centre report)  
 AML in CR1 AML not in CR1 ALL in CR1 ALL not in CR1 CML in CP1 CML not in CP1 CLL Other Leukaemias 
  Barts BSBMT Barts BSBMT Barts BSBMT Barts BSBMT Barts BSBMT Barts BSBMT Barts BSBMT Barts BSBMT 
Number 26 865 33 691 13 426 6 128 3 147 4 123 20 278 11 191 
% RIC 85 67 88 61 31 25 50 18 67 48 75 40 100 86 82 58 
% engraftment failure 0 2 3 2 0 3 0 5 0 3 0 6 5 (n=1) 4 0 5 
Med engraftment time 
(d) 
16.5 13 
17 13 
17 14 23.5 15 16 15 15.5 15 16 14 17 14 
% OS 1 year (95% CI) 76(55-89) 71(68-74) 
47(29-63) 53(49-57) 
62(31-
82) 
66(61-71)  NR 47(38-56)  NR   NR     NR  66(56-71) 65(40-82) 71(65-76) 82(45-95) 59(52-66) 
%OS 2 years (95% CI) 72(51(86) 60(56-63) 
34(19-51) 41(37-45) 
62(31-
82) 
58(53-63)  NR 41(32-50)   NR NR   NR 58(47-66) 60(36-78) 62(55-67) 64(30-85) 46(38-53) 
%OS 5 years (95% CI) 63(40-79) 47(43-51) 18(7-35) 33(29-38)  NR 49(43-54)  NR 30(20-39)   NR  NR    NR 45(35-55) 44(22-64) 51(44-58) 55(23-78) 39(30-47) 
NRM D100 (95% CI)  NR 5(4-7) 16(6-30) 11(9-13) 15(2-39) 13(10-16)  NR 16(10-22)   NR 5(3-10)   NR 12(7-19) 25(9-45) 11(8-15) 9(1-33) 12(8-17) 
NRM 1 year (95% CI)  NR 15(12-17) 25(12-41) 23(20-26) 23(6-47) 24(20-29)  NR 26(18-34)   NR 15(10-22)   NR 22(15-20) 35(16-55) 25(20-31) 9(1-33) 24(18-31) 
NRM 2 year (95% CI)  NR 19(16-22) 31(16-47) 28(24-31) 23(6-47) 27(23-32)  NR 29(21-37)   NR 19(13-26)   NR 24(16-32) 35(16-55) 30(24-36) 9(1-33) 30(24-37) 
NRM 5 years (95% CI) 5(0-20) 24(21-28) 40(23-57) 31(27-35) 23(6-47) 32(27-37)  NR 33(24-42)   NR 27(19-36)   NR 29(20-38) 40(19-61) 36(30-43) 18(3-44) 31(24-38) 
%Acute GVHD 12 42 
26 46 
15 50 50 60 33 
(n=1) 
41 25 
(n=1) 
47 30 46 0 47 
% Grade 3/4 a GVHD 4 5 10 7 0 9 17 11 33 10 0 8 5 (n=1) 12 0 11 
% Chronic GVHD 48 44 
47 49 
67 52 20 
(n=1) 
46 100 
(n=1) 
45 50 
(n=1) 
42 79 56 50 50 
% Extensive cGVHD 0 7 5 7 11 8 20 8 100 9 0 7 0 12 0 7 
% secondary 
malignancy 
5(n=1) 2 
0 3 
0 0 0 0  NR  2   NR 0 14 (n=2) 6 0 3 
% late graft loss 0 0 0 1 0 1 0 1  NR 2  NR 1 0 2 0 2 
% conception post SCT 5(n=1) 1 0 0 0 2 0 0  NR 0   NR  0 0 1 0 0 
 
CR1 Complete remission 1; CP1 Chronic Phase 1; NR Not reported
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Table 4: Allogeneic stem cell transplant outcomes for non-leukaemia between 2006 and 2011  
(Amalgamation of BSBMT 5th report to specialist commissioners and St Bartholomew’s Centre report)  
 MM 
  
HL 
  
NHL 
  
MDS 
  
BM aplasias 
  
MPS 
  
 Barts BSBMT Barts BSBMT Barts BSBMT Barts BSBMT Barts BSBMT Barts BSBMT 
Number 2 54 1 119 30 570 22 703 6 185 6 197 
% RIC 50 31 100 72 100 82 100 85 50 62 100 83 
% engraftment failure 0 4 0 2 0 3 9(n=2) 4 0 9 0 4 
Med engraftment time (d) 13 15 11 12 16 13 20 13 17.5 17 17 16 
% OS 1 year (95% CI) NR 68(53-79) NR 77(68-84) 77(57-88) 65(61-69) 41(21-60) 62(58-66) NR 83(77-88) NR 66(58-72) 
%OS 2 years (95% CI) NR 63(48-75) NR 72(62-79) 67(47-80) 58(54-62) 41 (21-60) 49(45-53) NR 81(74-86) NR 55(47-62) 
%OS 5 years (95% CI) NR 47(31-62) NR 61 (47-72) 54(32-73) 50(45-55) 41 (21-60) 41(37-45) NR 81(74-86) NR 38(28-48) 
NRM D100 (95% CI) NR 15(7-26) NR 12(7-18) 20(8-36) 11(9-14) 14(3-31) 11(9-14) NR 10(6-15) NR 9(5-13) 
NRM 1 year (95% CI) NR 25(14-38) NR  16(10-23) 23(10-39) 24(20-27) 32 914-51) 24(20-27) NR 15(10-20) NR 23(17-29) 
NRM 2year (95% CI) NR 25(14-28) NR 19(12-27) 33(18-50) 28(24-32) 32(14-51) 31(27-34) NR 17(12-23) NR 30(23-37) 
NRM 5 years (95% CI) NR 35(21-50) NR 27(16-39) 46(24-65) 33(28-37) 32 (14-51) 35(31-38) NR 17(12-23) NR 36(28-44) 
%Acute GVHD 0 55 100 38 28 43 14 42 33 18 20 41 
% Grade 3/4 a GVHD 0 14 0 4 10 6 5 7 0 1 20 12 
% Chronic GVHD 50 (n=1) 42 NR 39 82 47 50 44 50 (n=1) 20 80 46 
% Extensive cGVHD 0 6 NR 1 5 6 0 7 50(n=1) 2 0 5 
% secondary malignancy NR 0 NR 0 0 2 NR 5 NR 4 20 
(n=1) 
2 
% late graft loss NR 0  NR 1 0 2 NR 2 NR 3 0 3 
% conception post SCT NR 6  NR 7 0 0 NR 1 NR 4 0 0 
 
NR Not reported          MPS Myeloproliferative syndromes
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There is a striking difference in the incidence of acute GVHD reported with less than 10% at 
St Bartholomew’s compared to 34% and 49% for siblings and VUDs respectively across the 
UK. Local analysis quantifies the incidence of chronic GVHD at approximately 60%. This is 
in the setting of RIC-SCT which accounts for the majority of transplant procedures. This 
conditioning platform results in a small percentage of historically defined acute GVHD 
occurring before 100 days, consistent with the figures of 9-11% seen in table 2. However 
much of the ‘chronic’ GVHD that occurs is actually late onset acute GVHD that occurs on 
tailing of ciclosporin. For the majority of patients, immunosuppression withdrawal 
commences at day 90 and therefore these events are falling into the historically defined 
chronic GVHD bracket, hence the low reported incidence of acute GVHD and the higher 
incidence of chronic GVHD. Much of this is not limited or extensive chronic GVHD but rather 
grades II and III acute GVHD, with a small proportion of grade IV. 
 
The reclassification of GVHD and perhaps unclear documentation of grades of GVHD 
means that data reporting by non-clinical data managers is not likely to be entirely 
representative of true clinical practice.  
1.6 Limitations of the British Society of Blood and Marrow Transplantation 
The BSBMT centre report provides centre–specific Kaplan-Meier OS curves which 
demonstrate that St Bartholomew’s outcomes across all transplant types fall within the 
confidence intervals of the UK BSBMT data. To glean any other valid conclusions about 
local practice in comparison to the UK from the data provided in the BSBMT reports is 
difficult and limits the utility of this benchmarking exercise. Clearly collating data for over 
15,000 transplants from over 50 different centres is not an easy undertaking and a balance 
must be struck of what data can be obtained to provide a robust, informative data-set in a 
timely manner. Not all detailed data collected from the MED-A and MED-B forms is provided 
in the BSBMT reports. To produce an annual report with details regarding a patient’s prior 
treatments, performance score, comorbidities, conditioning regimen, to name but a few, 
would be a much more difficult undertaking and perhaps this is why only the most salient 
outcome data is provided, reserving the details for more comprehensive retrospective 
studies. This means that the annual report serves to ensure that centres are on the right 
track, but does not provide information that could serve to modify clinical practice. 
 
The BSBMT indications table aims to provide recommendations that are evidence-based 
where possible with references to support these recommendations. However, the guidance 
is broad. For example, in the guidance for myeloma, it is recommended that an autologous 
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stem cell transplant is the first-line standard-of-care ‘in patients suitable for intensive 
treatment’ but does not define what makes a patient suitable.  
 
It recommends a sibling allogeneic transplant in the first-line treatment of myeloma and 
states that suitability for a myeloablative versus reduced-intensity approach should be based 
upon biological suitability which includes assessment of age, comorbidities, advanced 
disease stage etc, without giving any strict definitions or guidance.  A matched-unrelated-
donor allogeneic transplant is a clinical option in ‘selected patients’ both first-line and at 
relapse but does not define which patients fit the ‘selected’ criteria. There are many 
scenarios in the table where transplants are a ‘clinical option’, usually reflecting a lack of 
consensus in the literature about the role of SCT in those scenarios. 
 
This broad guidance is necessary when creating a document that so many individual 
clinicians and transplant centres are required to follow. It would be near impossible to create 
guidelines with more strict definitions that all transplant centres would adhere to. 
Assessment of whether a patient is suitable for intensive treatment can cause disagreement 
between two clinicians so to provide detailed guidance with an expectation that all treating 
centres would adhere to it would be an unrealistic goal.  Ultimately, these treatment 
decisions are made at the discretion of the treating clinician overseen by the multi-
disciplinary team and local guidelines in that centre. 
 
The result of this, is that whilst all centres are following the same BSBMT guidelines, there 
may still be significant differences in which patients are receiving which types of stem cell 
transplants. This is particularly the case in scenarios where definitions are vague and the 
evidence is weak, such as age cut-offs or assessments of performance status. 
 
Lower-dose conditioning in autologous transplantation and RIC in allogeneic transplantation 
has resulted in patients with a lower performance status and of an older age to become 
eligible candidates for transplantation procedures.36, 37, 56 Whilst this has allowed SCT to 
become a viable treatment option for a wider range of patients, it also means there is an 
increasing grey area over which patients are appropriate for transplant. 
 
I have identified four clinical scenarios/areas where the BSBMT guidelines are not clear 
about the specifics of practice but in which we have specific clinical experience at St 
Bartholomew’s. I aim to review outcomes with the aim of trying to identify if more specific 
recommendations can be made within those scenarios which continue to cause controversy. 
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I will discuss the background, methods, results and discussion of each separately in this 
report. They are: 
 
1) Autologous stem cell transplantation in multiple myeloma – comparing outcomes of 
two melphalan conditioning doses 
 
2) Allogeneic stem cell transplantation in multiple myeloma 
 
3) Sequential transplantation in refractory and relapsed acute myeloid leukaemia and 
myelodysplasia 
 
4) Allogeneic stem cell transplantation in lymphoma 
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CHAPTER TWO 
Autologous Stem Cell Transplantation 
in Multiple Myeloma 
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2.1 Introduction 
Autologous stem cell transplantation in first response is considered the standard of care for 
younger patients with newly diagnosed Multiple Myeloma (MM) with increased progression-
free survival (PFS) and OS rates compared to conventional chemotherapy 50, 57, 58. 
  
Melphalan 200mg/m2 (MEL200) is considered the standard conditioning regimen for patients 
aged less than 65 years.59 Concerns over increased toxicity and treatment related mortality 
(TRM) have generally restricted the use of this conditioning regimen in older patients. 
However, the median age of diagnosis in patients with MM is approximately 70 years with 
only 15% of patients reported to be less than 60 years at diagnosis. 60 
 
Dose reduction of melphalan conditioning is well recognised in those with renal 
impairment.61 However, within the limited published data on how best to condition older 
patients, or those with comorbidities, there is little consensus on the optimal conditioning 
regimen that should be used. 
 
Mixed results have been reported regarding the use of MEL200 in older patients.  Equivalent 
survival has been reported using MEL200 conditioning when comparing patients aged >65 
years to younger, matched patients.62-65 However, there is likely to be considerable patient 
selection behind these equivalent outcomes. Only ‘older’ patients who were deemed fit for 
this approach by their treating physicians will have undergone this approach. Others have 
reported that whilst MEL200 provides a survival advantage compared to conventional 
chemotherapy in those aged >60 years, this is inferior to the survival advantage achieved by 
patients <60 years. 66 
 
Badros et al reported a TRM of 16% in patients >70 years receiving MEL200.56  As a result, 
they reduced their melphalan conditioning dose to 140mg/m2 (MEL140) for subsequent 
patients in this age group, and observed a reduction in TRM to 2%. Equivalent PFS and OS 
rates were achieved irrespective of dose. 44% of these patients went on to have a second 
ASCT at doses of either 200mg/m2 or 140mg/m2, making it difficult to evaluate the overall 
effect of dose on OS and PFS in the longer-term. 
 
Following on from this study, rather than not transplant at all, some centres elected to give 
older patients reduced-dose conditioning in whom there were concerns about fitness to 
tolerate MEL200. More recently, studies have reported on the safety and feasibility of ASCT 
in patients over the age of 65, with the majority of patients receiving MEL200, but a 
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subgroup in each study receiving varying doses between 100mg/m2, 140mg/m2 or 
180mg/m2. Little information is provided regarding the rationale for dose reduction and 
outcomes are based on the population as a whole, with no comment regarding the relative 
outcomes of the differing conditioning approaches.67-69 
 
Studies have reported mixed results using melphalan 100mg/m2 (MEL100). Whilst it has 
been reported that MEL100 is superior to conventional chemotherapy,70 this has not been 
confirmed in other studies looking specifically at patients aged >65.71  In studies comparing 
MEL100 to MEL200 in patients under the age of 65, although there was a significantly 
increased PFS with MEL200, this did not translate into a survival advantage.72 
 
When MEL140 plus 8Gy TBI was compared to MEL200, PFS and OS were found to be 
equivalent but the former was associated with higher toxicity. Thus, it was concluded that 
MEL200 was less toxic and should be the standard of care.73 
 
BSBMT guidelines recommend a first ASCT in myeloma patients ‘suitable for intensive 
treatment’. There are however no specific guidelines about what determines suitability and 
certainly no age thresholds, comments on performance status or indeed the type or dose of 
conditioning (table 5). 
 
Table 5: BSBMT indications for SCT in myeloma (taken from BSBMT Indications for SCT 
version Oct 13) 
 
 
Based upon the standard practice of using MEL140 in patients with renal impairment, 
practice at St Bartholomew’s has been extended to give MEL140 to patients aged >65 years 
and those with comorbidities in order to minimise anticipated excess toxicities in these 
patient groups.  
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2.2 Hypothesis 
Patients who receive MEL140 have poorer outcome because of comorbidities and the use of 
lower dose of chemotherapy.  
2.3 Methods 
2.3.1 Patients’ characteristics 
A total of 253 patients with multiple myeloma underwent ASCT at St Bartholomew’s Hospital 
between November 2004 and November 2011.  Patients were excluded from further analysis 
if they had received a previous ASCT (n=29), if they went on to consolidate treatment with 
either maintenance chemotherapy (n=9) or allogeneic stem cell transplantation (n=6), if they 
received melphalan conditioning at 100mg/m2 (n=9) or if they received MEL140 on account 
of poor stem cell harvest (n=2). Five patients were lost to follow-up. The remaining 193 
patients are included in this analysis.  
2.3.2 Induction therapy, PBSC mobilisation and autografting 
Patients received a variety of induction chemotherapy regimens as detailed in table 6. The 
higher percentage of patients with renal impairment in the MEL140 group explains the higher 
use of bortezomib-based induction chemotherapy in this category, in line with current 
treatment recommendations.61 Where more than one line of therapy was utilised prior to 
ASCT, this was because there was either progressive disease, stable disease or a sub-
optimal response to initial therapy and further therapy was given to maximise response 
before ASCT.  
 
Patients had stem cells mobilised using cyclophosphamide priming (1.5g/m2), followed by 
Granulocyte Colony-Stimulating Factor (G-CSF) administration from day 3. 
 
Patients received MEL140 or MEL200 on Day-2 or MEL140 on Day-3 if the creatinine 
clearance was <50ml/min. On Day D0, cryopreserved stem cells were re-infused and G-CSF 
was commenced on Day+4 and continued until neutrophil recovery (>1x109/L). 
 
All patients received antimicrobial prophylaxis with aciclovir, fluconazole and ciprofloxacin. 
All patients were commenced on cotrimoxazole following engraftment as prophylaxis against 
Pneumocystis jiroveci. 
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Table 6: Myeloma ASCT: Patient characteristics according to treatment group 
     MEL200 MEL140 P value 
No. of patients   140 53 - 
Male sex (%)   88 (62.8) 31 (58.5)  0.711 
Age (median)[range]   56 [28-67] 64 [41-72] <0.001 
Myeloma Isotype IgG (%) 87(62.1) 26(49.1) 0.039 
 IgA(%) 24(17.1) 7(13.2) 0.362 
 Light Chain Myeloma 
(LC-MM)(%) 
22(15.7) 20(37.7) 0.002 
 Non-secretory(%) 5(3.6) 0 - 
 Not known 2(1.4) 0 - 
International Staging Score 
(ISS) at diagnosis 
1(%) 54(38.6) 12(22.6) 0.029 
 2 (%) 33(30) 4(7.5) 0.005 
 3 (%) 23(16.4) 27(58.5) P<0.001 
 
  
Not known (%) 30(21.4) 10(18.9) - 
Creatinine Clearance (ml/min) 
median 
  108 79.0 <0.001 
Pre ASCT induction Bortezomib based(%)* 12(8.6) 7(13.2) 0.425 
 Thalidomide 
based(%)** 
88(62.9) 31(58.5) 0.642 
 Lenalidomide based 
(%)+ 
2 (1.4) 0 - 
 >1 line of novel-
agent(%) 
10(7.1) 9(16.9) 0.041 
  No novel agent(%)*** 28(20) 6(11.3) 0.158 
Pre ASCT response status CR(%) 34(24.3) 8(15) 0.199 
 VGPR(%) 13(9.3) 11(20.8) 0.020 
 PR(%) 80(57.1) 30 (56.6) 0.821 
 RR(%)(≥PR) 127 (90.7) 49(92.5) - 
  SD(%) 13(9.3) 4(7.5) 0.704 
*VD, velcade & dexamethasone; PAD, velcade, doxorubicin & dexamethasone 
**CTD, cyclophosphamide, thalidomide & dexamethasone; TD, thalidomide & dexamethasone 
+ RCD, lenalidomide, cyclophosphamide & dexamethasone 
***VAD, vincristine, doxorubicin & dexamethasone; CVAD, cyclophosphamide, vincristine, doxorubicin & 
dexamethasone 
CR Complete response; VGPR Very good partial response; PR Partial response; RR Response rate; SD Stable 
disease 
 
2.3.3 Response criteria 
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Disease response was assessed at the time of transplant and at 100 days following ASCT 
using the International Myeloma Working Group (IMWG) Uniform Response Criteria.74 
Progression-free survival was measured from time of ASCT date to date of progression or 
clinical relapse. Overall survival was calculated from ASCT infusion date to date of death. 
2.3.4 Statistical analysis 
The c2 test was used to compare proportions between groups. PFS and OS curves were 
plotted according to the Kaplan-Meier method and differences between curves were 
evaluated with log-rank tests. Univariate analysis of association of outcomes with risk factors 
was performed. These included conditioning dose (MEL140 vs MEL 200), age (<65 vs ≥ 65 
yrs), International Staging Score (ISS), myeloma isotype, number of lines of treatment pre 
autologous transplant, treatment with prior novel agent therapy, response pre and post 
transplant and body surface area (BSA) <2m2 vs ≥2m2. P values <0.05 reflected statistical 
significance. Cox regression analysis was used to perform multivariate analysis for all 
variables with a P value of <0.1. Data was analysed using SPSS v22 (IBM, New York).  
2.4 Results 
2.4.1 Patients 
A total of 193 patients were included in this retrospective study. 140 patients underwent 
MEL200 (median age 56 years, range 36-67) and 53 patients underwent MEL140 (median 
age 64 years, range 41-72).  
 
Patient characteristics in the two treatment groups are shown in table 6. The MEL140 group 
included 15 patients dose-reduced on account of renal impairment. This likely explains the 
increased percentage of patients with light chain myeloma (LC-MM) and lower creatinine 
clearance in this treatment group. These patients all had an elevated β2-microglobulin and 
as a result there was an increased proportion of patients with ISS stage 3 disease. The very 
nature of dividing patients into groups based upon melphalan dosing means that they are 
not and could never be equally matched. The necessity to dose reduce inherently reflects 
that those patients are either older, have renal impairment or have other comorbidities. This 
is important to note, because the non-inferiority of MEL140 compared to MEL200 is being 
assessed based upon the outcomes of two unequally matched groups. 
 
There are a proportion of patients in each group with unknown ISS. This is because St 
Bartholomew’s is a referral centre for ASCT and as such, patients have frequently been 
diagnosed and treated at other hospitals prior to referral and diagnostic information was not 
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always available. Similarly, cytogenetic data was unfortunately unavailable for a significant 
majority of patients as it was historically not performed as an upfront diagnostic test in most 
referral centres. The small proportion of patients in whom it was available would not have 
been of adequate size to draw any valid conclusions and so this data has not been collated. 
 
Patients were dose reduced on account of renal impairment (n=15), age ≥ 65 years (n=23) 
and other comorbidities (n=15) (table 7). Patients with poor performance status either had a 
reduced Karnofsky score or a combination of chronic medical comorbidities.  
 
Table 7: Reasons for dose reduction in MEL140 group  
 
 
 
 
 
 
 
 
 
 
 
CrCl Creatinine clearance; EF Ejection fraction; TLCO Transfer factor of the lung for carbon monoxide 
2.4.2 Response 
Table 8 summarises the responses observed at D100 post ASCT. Despite the MEL200 
group having a higher proportion of patients achieving CR prior to ASCT (24.3% vs 15% for  
 
Table 8: Response at D100 post ASCT 
Response MEL200 MEL140 P value 
CR(%) 61(44.5) 27(51.9)  0.554 
VGPR(%) 20(14.6) 10(19.2)  0.311 
PR(%) 54(39.4) 15(28.8)  0.096 
RR(%) (≥PR) 134(98.5) 52(100)  - 
SD(%) 2(1.5) 0  - 
CR Complete response; VGPR Very good partial response; PR Partial response;  
RR response rate; SD stable disease 
Reason for dose reduction N 
Renal impairment (CrCl<50ml/min) 11 
Renal & cardiac impairment (EF<50%) 1 
Renal & respiratory impairment (TLCO<50%) 2 
Renal impairment & hepatitis C 1 
Acute thromboembolism 2 
TLCO <50% 1 
Ejection fraction <50% 1 
Poor performance status 11 
Age >65 23 
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MEL200 and MEL140 respectively), there was no significant difference in CR post ASCT 
suggesting that the MEL140 group gained greater benefit in terms of CR conversion post 
transplant. 
2.4.3 Clinical outcomes 
Analysis of all patients demonstrated a median OS of 65 months with a 5 year OS of 57%. 
There was no significant difference in OS between the MEL200 and MEL140 groups; p=0.24 
(figure 1). Median PFS for all patients was 20 months and again there was no significant 
difference between the two conditioning groups (figure 2). 
 
Figure 1: Overall survival (MEL 200 vs MEL140) 
 
Figure 2: Progression free survival (MEL 200 vs MEL140) 
 
ISS was associated with a significant effect on OS across all patients with an ISS of 1, 2 and 
3 resulting in a median OS of 77, 74 and 39 months respectively; p=0.009 (figure 3). ISS had 
no significant effect on PFS (p=0.55).  
P=0.241 
P=0.633 
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Figure 3: Overall survival of all myeloma ASCTs by ISS 
  
Myeloma isotype was also associated with a significant effect on OS (median OS IgG vs IgA 
was 77 and 47 months respectively; p=0.022, (figure 4). This was replicated in the MEL140 
group, but in the MEL200 group, whilst the KM curve appeared similar, significance was not 
achieved. Isotype did not impact on PFS (p=0.823). 
 
Figure 4: Overall survival in myeloma ASCTs by myeloma isotype  
 
Prior induction treatment with novel agents demonstrated a trend to increased OS (median 
OS 74 vs 55 months; p=0.092) across all patients and within both conditioning subgroups. 
Median PFS in those treated with 1 line of novel agent-based induction, 2 or more lines of 
novel-agent based induction and no exposure to novel agents was 24,15 and 13 months 
respectively; p<0.0001(figure 5). This finding was replicated in both conditioning groups.  
 
P=0.009 
P=0.022 
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Figure 5:  PFS in myeloma ASCT by induction therapy 
 
Thirty-eight patients (19.6%) were equal to or over the age of 65. There was no significant 
difference in OS or PFS between patients <65 years and those ≥65 years across all patients 
(p=0.53 and 0.60 respectively).  There was also no impact within each conditioning group, 
when using 65 years as a cut-off.  
 
When patients were subdivided further, those under the age of 40 years (5 patients) had a 
median time to progression of 12 months which was significantly worse than the remaining 
cohort; p=0.034 (figure 6). However, with small patient numbers in this group this result 
should be interpreted with caution. 
 
Figure 6: Relapse post ASCT by age groups 
 
 
P<0.0001 
P=0.034 
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Univariate analysis demonstrated prior number of treatment lines, response pre-transplant 
and BSA did not impact on OS or PFS. Treatment response post ASCT did not impact on 
OS but did impact upon relapse outcomes. Those who achieved a CR had a significantly 
longer time to progression than any response inferior to this (24 vs 18 months respectively; 
p=0.049).  
 
Within the MEL140 group, the reason for dose reduction (age, renal impairment or 
comorbidities) had no impact on OS (p=0.74). However, reason for dose reduction 
demonstrated a trend towards significance for PFS. Median PFS for patients dose reduced 
on account of renal impairment, age or comorbidity at 29, 24 and 13 months respectively;  
p=0.058 (figure 7). 
 
Figure 7: PFS post MEL140 ASCT by indication for dose reduction 
 
Cox regression analysis demonstrated isotype and ISS significantly impacted upon survival 
in all patients. Within the MEL200 cohort, induction therapy with novel agents was also 
significant whereas in the MEL140 group, only myeloma isotype was significant. 
 
In order to try and further understand the impact of melphalan dosing, OS and PFS 
outcomes were further evaluated by body mass index (BMI) (average, overweight, obese), 
total melphalan dose in mg/kg and in those with a BSA of greater than or equal to 2m2 the 
impact of capping the dose. 63 patients (32%) had a BSA of ≥2m2. 13.5% and 19.2% of 
patients were overweight or obese by BMI criteria. In those with a BSA≥ 2m2, 67% of 
P=0.058 
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patients were capped at a dose of 2m2. This proportion was the same in those above and 
below 65 years and within the two conditioning cohorts. There was significant variability in 
which patients where capped with no clear correlate in terms of BSA or BMI. However, none 
of these measures or interventions impacted upon progression or survival outcomes. 
2.4.4 Toxicities 
Three patients in the MEL200 group died of infective complications within 100 days of ASCT. 
Only 1 patient died in the MEL140 group. This resulted in a transplant related mortality (<100 
days) of 1.75% and 2.11% for MEL140 and MEL200 respectively. Unfortunately, due to the 
retrospective nature of this analysis, the quality and availability of documentation regarding 
toxicity was inadequate in order to perform detailed and accurate toxicity analysis for side 
effects such as mucositis and infective complications. However, the length of stay in hospital 
was equivalent for the two treatment groups. 
2.5 Discussion 
Several studies have demonstrated that high-dose therapy with ASCT is superior to 
standard chemotherapy in patients <65 years. However, there has been no consensus to 
date on the most appropriate conditioning regimen for older patients or those with a reduced 
performance status. 50, 57-59 This retrospective analysis reports the findings of patients 
receiving either ‘standard’ MEL200 conditioning or MEL140 on account of renal impairment, 
age ≥65 years or the presence of comorbidities. There were no significant differences in 
PFS, OS or NRM between these two conditioning regimens. Therefore, in newly diagnosed 
patients with myeloma who fall into these adverse subgroups, ASCT with MEL140 is a viable 
and effective consolidation treatment strategy that appears to offer these patients similar 
survival benefit. The hypothesis that those undergoing MEL140 would have inferior 
outcomes has therefore not been supported. This finding is particularly striking given that the 
MEL140 cohort of patients were, by definition, a worse group in terms of their performance 
status and expected outcomes. 
 
In the treatment of myeloma today, most patients will receive multiple lines of therapy and 
classically, each with result in a shorter PFS than the previous one. The measurement of 
overall survival as an outcome measure of one line of treatment is therefore of limited value 
as clearly effects on OS will be multifactorial. PFS is a much more useful outcome measure 
to assess the impact of ASCT alone and it is therefore of great importance to identify that 
median PFS was exactly the same in the two conditioning groups at 20 months. PFS2, the 
time to second objective disease progression on next-line treatment or death from any 
cause, is becoming increasingly important as an outcome measure. A respectable PFS may 
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hide the impact of a treatment on the tumour’s drug resistance profile or indeed the patient’s 
ability to tolerate further lines of treatment. It would have been very useful to use PFS2 to 
identify what the impact of MEL140 was in terms of this group’s ability to receive and tolerate 
further lines of treatment. However, because a significant proportion of patients received 
their post transplant therapies back at their referring hospital, this data was unavailable. 
 
This was a non-randomised retrospective study and as such clinician choice in selecting 
which patients proceeded with ASCT was undoubtedly a factor in the equally successful 
results achieved by MEL140. Rather than using an arbitrary age cut-off, a more considered 
clinical approach evaluating age, along with the presence of comorbidities and performance 
status, should be taken when deciding who should undergo ASCT and with which 
conditioning regimen. This is particularly important in the absence of data suggesting that 
myeloma is biologically different in the older population75, 76 and that differences in outcome 
in the older patient population are more likely related to increased comorbidities and poor 
performance status. It has been reported that the presence of comorbidity in itself does not 
directly correlate with functional ability in older patients with malignancies.77 Therefore, this 
should not serve as a deterrent to ASCT and patients should be considered on an individual 
basis regarding their fitness to proceed to high-dose therapy. There may well be a referral 
bias, potentially resulting in under-treatment with ASCT in patients aged >65 years, who are 
otherwise fit to receive intensive therapy. This study highlights the benefits that may be 
achieved in this population group. 
 
As melphalan is renally excreted, there is concern regarding the risk of prolonged bone 
marrow suppression in those with renal impairment. In view of the increased toxicities 
reported when full doses were given to patients with renal impairment, dose reductions have 
been recommended.61, 78 Although the rationale for dose reduction is clearly different, in 
order to produce an adequately-sized patient cohort, with which to be able to make valid 
conclusions, all indications for dose reduction were grouped together. However, the three 
indications for dose reduction (age, comorbidity and renal impairment) were also analysed 
separately. Whilst indication had no impact on OS, there was a trend towards significance 
for PFS. Those dose-reduced on account of renal impairment had the longest PFS, with a 
median of 29 months. This is actually very impressive and is significantly longer than the 
PFS in the entire MEL200 cohort. Those dose-reduced on account of age had a median PFS 
of 24 months, in line with findings in the MEL200 cohort. Several studies have supported the 
use of ASCT in older patients and EBMT data has reported that the proportion of patients 
above the age of 65 has increased from 3% in 1991 to 18% between 2006 and 2010.79 This 
analysis supports that finding with 19.6% of patients in this study being over the age of 65. It 
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further validates the viability of ASCT in patients in this age group and unlike any other study 
has demonstrated the efficacy of a lower-dose conditioning regimen in this population.  
 
Those with comorbidities had a median PFS of 13 months. It is important to remember that 
this is a cohort of patients that were not considered fit enough to tolerate MEL200. If they 
had not received MEL140, they would not have undergone ASCT. Although no direct 
comparison to a non ASCT strategy was performed in this analysis, the survival outcomes of 
this subgroup may still be superior to a non transplant approach and this would be in 
interesting and important area of future of work. Furthermore, whilst they may progress 
sooner, their OS is not inferior to the remainder of the cohort. Therefore whilst recognising 
that there is an inferior progression-free survival, the MEL140 approach should be 
considered an appropriate treatment strategy in this cohort. 
  
The impact of ISS on OS was validated again in this study, with those with an ISS of 3 
having particularly inferior outcomes.80 Despite the MEL140 cohort having a larger 
proportion of patients with ISS 3, the impact of ISS on OS was not seen in this cohort. This is 
most likely due to patient numbers, and shorter follow-up time for this subset of patients as 
median OS was yet to be reached.  
 
A significantly longer time to progression was seen in those who achieved a CR post ASCT, 
although an impact on survival was not seen in this analysis. There is increasing evidence 
that achieving a complete remission post ASCT correlates with increased OS and PFS.81-85 
The increased conversion rate of patients achieving CR observed in the MEL140 group 
(14.5% pre-ASCT to 47.3% post ASCT) is therefore a potentially important finding. This 
observation suggests that this may well translate into an improved long-term OS in this 
population group, who would likely have fared poorly without ASCT. 
 
The treatment of myeloma has been revolutionised over the last decade by the advent of 
‘novel agents’. These include proteasome inhibitors such as bortezomib (Velcade) and 
immunomodulatory agents (IMiDs) including thalidomide, lenalidomide (Revlimid) and 
Pomalidomide (Imnovid). These drugs can be used in patients of all ages in the outpatient 
setting. Their arrival has significantly improved survival outcomes in patients with myeloma.86  
In this analysis, their use in induction prior to ASCT resulted in improved PFS with a trend to 
increased OS. The role and timing of ASCT in the era of novel agents, remains unclear. 
However, in this analysis, 81.4% of patients treated with MEL200 and 92.7% of MEL140 
patients were treated with novel-agent-based induction therapy. Therefore, the findings of 
45 
 
this study are applicable to the novel-agent era and support the practice of dose-reduced 
ASCT in those deemed unsuitable to receive the MEL200 standard. 
 
The observation that patients under the age of 40 have shorter times to progression is not 
supported by the literature and is likely to be the consequence of small numbers. 87, 88  The 
IMWG evaluated 10,549 patients and identified that those younger than 50 years had no 
differences in cytogenetic profile, tended to present with a lower ISS and demonstrated 
better OS.89, 90 
 
Unfortunately pharmacokinetic data was unavailable in this retrospective analysis and so 
whilst recognising the clinical non-inferiority of MEL140, there is little understanding of 
exactly what the difference is between MEL200 and MEL140 at a cellular level.  There is 
some recognition that there may be a genetic component to a patient’s melphalan 
metabolism and its consequent effects. However, to date there is no definitive marker for 
testing. There is also limited evidence on how best to approach dosing in those patients with 
an increased BSA. There was no association identified with BSA, BMI, dose capping or total 
melphalan dose with survival outcomes. Similar studies have also identified a lack of 
uniformity in the dosing strategy used in patients with a raised BSA but confirmed that this 
cohort of patients do not have inferior survival outcomes and that this should not be a 
deterrant to proceed to ASCT.91 The most recent consensus guidelines have suggested that 
patients should not be capped and dosing should be based upon actual weight.92 Given that 
no differences were seen in the capped vs uncapped group, this data would support those 
recommendations.  
 
In conclusion, MEL140 is a safe and effective conditioning regimen for older patients, those 
with renal impairment or other co-morbidities. The outcomes achieved by the MEL140 cohort 
are particularly striking because the patients conditioned with MEL140 had biological or 
clinical features that would, intuitively, result in worse outcomes. These observations 
suggest that the benefits of MEL200 and MEL140 may be equivalent and that the hypothesis 
of this work was not supported.  
 
A prospective clinical trial between MEL200 and MEL140 would be required to prove this 
definitively and recommendations for changing the standard of care cannot be made on the 
basis of these results alone. However, based upon my findings, I would suggest that the 
BSBMT recommendations could be modified, with a statement that the decision to transplant 
patients aged between 65 and 70 years should be based upon a full clinical assessment 
evaluating the presence of comorbidities and performance status rather than an arbitrary 
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age cut-off and that consideration may be given to dose reduction in cases where the patient 
is not considered fit to receive standard MEL200. 
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CHAPTER THREE 
Allogeneic Stem Cell Transplantation  
In Multiple Myeloma 
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3.1 Introduction 
The role of allogeneic stem cell transplantation in myeloma has been an area of controversy 
for over 25 years. Investigators in the late 1980s were excited about the curative potential an 
allograft could offer with the use of myeloablative conditioning. Indeed, small cohorts of long-
term survivors were identified using this approach.93 However, this was offset by an 
unacceptably high NRM in the order of 50%94, 95 predominantly secondary to infection and 
GVHD and organ toxicity and consequently, MAC allografts in myeloma were largely 
abandoned. 
 
The advent of RIC-SCT reintroduced allogeneic transplantation as a treatment option. This 
approach relied less on the high dose chemotherapy and radiotherapy that was utilised in 
ablative transplants to eradicate myeloma cells. Instead, it focused on the graft-vs-myeloma 
effect which had been proven by the success of DLI in patients who had not responded or 
had progressed post transplant.96, 97 Offering less toxicity and consequently a significantly 
reduced TRM compared to ablative conditioning, RIC-SCT widened the cohort of patients 
that could potentially undergo an allogeneic transplant. 37  
  
An EBMT review analysed data on 229 patients with myeloma who had undergone a RIC-
SCT.98 This included 28 different conditioning regimens, predominantly fludarabine-based 
(96%) with additional melphalan, TBI, busulphan, cyclophosphamide. Furthermore, 59% 
were T-cell depleted regimens with either Alemtuzumab, an anti-CD52 antibody, or anti-
thymocyte globulin (ATG). OS and PFS at 3 years was 40.6% and 21% respectively. D100 
TRM was 10%, increasing to 26% at 2 years. The majority of deaths were secondary to 
infection and GVHD.   
 
Further registry data analyses have compared RIC to MAC and concluded that whilst the 
RIC approach undoubtedly offered a significantly reduced TRM, there was no overall 
survival benefit because it also carried a significantly increased relapse rate.99 
 
Autologous stem cell transplantation is the standard of care following induction therapy in 
young fit patients with newly diagnosed myeloma.50, 57, 58 However, there is no survival 
plateau with this approach. Consequently, there have been several prospective studies 
comparing a tandem autologous transplant approach to autologous transplant followed by a 
RIC-SCT in those with a matched sibling donor.100-106 The studies varied in their design 
making comparison difficult. Garban et al only included patients deemed ‘high risk’ and used 
a T deplete approach with ATG conditioning. The remainder were more inclusive in their 
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patient cohort and used either TBI alone,101, 103, 104 TBI and fludarabine106 or the more 
intensive fludarabine and melphlalan conditioning regimen.102 The autologous arms also 
varied; whilst most studies used the now standard melphalan conditioning, melphalan doses 
differed amongst the studies as did the use of maintenance therapy post autograft. 
 
Whilst some of the above studies concluded that PFS and OS were equal using the two 
approaches, the Italian group and EBMT analysis demonstrated that the auto-allo approach 
resulted in an overall survival advantage. It was universally, and unsurprisingly, 
demonstrated that the auto-allo approach had a significantly higher TRM than the tandem 
autologous approach (cumulative TRM 10-17% vs 1-5% for tandem autograft) although this 
level of TRM is much more favourable than the data from the ablative era. 
 
The TRM associated with a RIC-SCT seems unjustified to some clinicians in an era where 
upfront novel agent therapy can potentially offer several years of progression-free survival. 
As a result, the role of RIC allografting in patients with relapsed myeloma has been 
investigated more recently.  Whilst patients with progressive myeloma undoubtedly have 
more treatment options available to them since the advent of novel agents, their prognosis 
remains poor. There is consequently an argument that the increased TRM associated with 
allogeneic transplantation is perhaps more justified in this setting.  
 
Retrospective studies have been performed in patients who have relapsed and have 
demonstrated it to be a viable treatment option. However, its cumulative TRM is 20-30% at 3 
years which is higher than studies where allogeneic transplant was performed at first 
response.107 In studies that performed a donor vs no-donor analysis comparing the outcome 
of patients undergoing a RIC with those undergoing salvage with novel agents, the 
transplant arm has shown superior PFS but no OS benefit.108, 109  
 
The BSBMT guidelines have recommended that for patients in first response with a sibling 
donor, an allogeneic transplant is ‘standard of care’ (table 5).  However, not all patients in 
first response with an identified sibling donor undergo an allogeneic transplant and it makes 
no recommendations about patient selection. For those patients in first response with a 
matched unrelated donor, or in patients who have relapsed, allogeneic transplantation is 
listed as a ‘clinical option’.  
 
With the role of an allograft still highly debated and conclusive evidence for there being an 
overall survival benefit still lacking, there remains a large question mark over which patients 
should be offered an allogeneic transplant and when.  Patient selection and timing of the 
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transplant remains at the discretion of the treating physician. The International Myeloma 
Working Group consensus statement has recommended that in the absence of convincing 
evidence for a survival benefit that allogeneic transplantation should only be performed in 
the context of a clinical trial.110 
 
It seems reasonably clear that in order to determine whether allogeneic transplantation really 
has a place, the key is to identify which patients are most likely to benefit from it. At St 
Bartholomew’s, a variety of patients have undergone allogeneic transplantation for myeloma. 
Practice has included transplantation of patients with all ISS scores and transplants have 
been performed both at first response and at relapse.  Centre practice has been to offer non-
ablative conditioning with fludarabine and cyclophosphamide. This low-intensity regimen has 
been demonstrated to have minimal toxicity whilst still achieving equivalent disease 
outcomes in other settings.111, 112 I have developed the hypothesis below in order to 
challenge perhaps the most controversial statement surrounding allogeneic transplantation 
in the BSBMT indications table. In addition, this retrospective analysis aims to assess the 
outcomes of allogeneic transplantation in patients with myeloma and attempt to identify 
which patients benefit most from it. 
3.2 Hypothesis 
The outcome after allogeneic transplantation for patients with multiple myeloma justifies the 
increased toxicity by decreasing relapse. 
3.3 Methods 
3.3.1 Patient eligibility 
A total of 35 patients with multiple myeloma underwent RIC-SCT between 1999 and 2011 at 
St Bartholomew’s.  They included patients of all ISS scores and patients who were 
transplanted both in first response and at relapse. Written informed consent was obtained 
from all patients and donors in accordance with the Declaration of Helsinki.  
3.3.2 Treatment protocol 
Transplant conditioning was with fludarabine 25 mg/m2 on D−6 to D−2 and 
cyclophosphamide 1 g/m2 on D−3 and D−2. In one case, the donor was a 1A mismatch and 
the recipient received Alemtuzumab in addition. Methotrexate (5 mg/m2 on D+1,D+3 and 
D+6), together with ciclosporin (5 mg/kg on D−2 then 3 mg/kg per day from D−1, tailing at 
day +100 or sooner in the presence of mixed chimerism) was used for GVHD prophylaxis. 
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Trough CSA levels were measured in whole blood twice weekly post-transplant. CSA was 
dosed to maintain levels between 150–300mcg/L. 
3.3.3 Supportive care 
All patients received antifungal and antimicrobial prophylaxis with fluconazole and 
ciprofloxacin until neutrophil engraftment. All patients were commenced on cotrimoxazole 
following engraftment as prophylaxis against Pneumocystis jiroveci. All patients received 
antiviral prophylaxis with aciclovir for a minimum of 6 months or longer if still on 
immunosuppression. Peripheral blood samples were monitored weekly for CMV re-activation 
by quantitative polymerase chain reaction (PCR). Patients with evidence of CMV reactivation 
were treated with pre-emptive valganciclovir.  
3.3.4 Patient evaluation 
Disease response was assessed at the time of transplant and at 100 days following HSCT 
using the IMWG Uniform Response Criteria.74 PFS was measured from time of SCT date to 
date of progression or clinical relapse. OS was calculated from SCT infusion date to date of 
death. NRM was defined as death in the absence of disease relapse or persistence. Acute 
GVHD was diagnosed and graded using current consensus criteria.113 Chronic GvHD was 
diagnosed and scored using Seattle criteria.114 
3.3.5 Statistical analysis 
Progression-free-survival and overall survival curves were plotted according to the Kaplan-
Meier method and differences between curves were evaluated with log-rank tests. Univariate 
analysis of association of outcomes with risk factors was performed. These included age, 
gender, haematopoietic cell transplant comorbidity index (HCT-CI), ISS, myeloma isotype, 
number of lines of prior treatment, prior novel agent therapy, response pre transplant, donor 
type, risk of CMV reactivation, major ABO mismatch, gender mismatch, and the occurrence 
of acute and chronic GVHD. P values <0.05 reflected statistical significance. Cox regression 
analysis was used to perform multivariate analysis on all factors with a P value of less than 
0.1.  
3.4 Results 
3.4.1 Patient characteristics 
A total of 35 patients with multiple myeloma underwent RIC-SCT between 1999 and 2011. 
Patient characteristics are listed in table 9. 82% patients were male and the median age at 
the time of transplant was 52 years (range 33-63). 74% had a matched sibling or other family 
member donor and with 1 exception, a 1A mismatched VUD, the remainder had matched 
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unrelated donors. Peripheral blood was the stem cell source in all cases. 11, 6 and 10 
patients had an ISS of 1, 2 and 3 respectively at diagnosis (data was unavailable on the 
remainder). 35%, 45% and 20% of patients had a HCT-CI of low, intermediate and high 
respectively. 
 
Table 9: Patient characteristics undergoing RIC-SCT for myeloma 
Total no.  of patients  35 
Male sex (%)  29(82.9) 
Age (median)[range]  52 [33-63] 
Myeloma Isotype IgG (%) 22(62.9) 
 IgA(%) 6(17.1) 
 Light chain myeloma(%) 2(5.7) 
 Non-secretory(%) 1(2.9) 
 IgD (%) 1(2.9) 
 Not known(%) 3(8.6) 
International Staging Score (ISS)  1(%) 11(31.4) 
 2 (%) 6(17.1) 
 3 (%) 10(28.6) 
 Not known (%) 8(22.9) 
Previous autologous transplant Yes(%) 24(68.6) 
 No(%) 6(17.1) 
 Not Known(%) 5(14.3) 
Pre transplant novel therapy Yes(%) 16(45.7) 
 No(%) 14(40) 
 Not known(%) 5(14.3) 
Pre transplant response status CR1(%) 10(28.6) 
 CR2(%) 3(8.6) 
 PR1(%) 14.1(40) 
 PR2(%) 3(8.6) 
 Not known(%) 5(14.3) 
Donor type Matched sibling 24 (68.6) 
 Matched VUD 8(22.8) 
 Mismatched VUD 1 (2.9) 
 Other (matched other 
family member) 
2(5.7) 
 
 
The patient group was heterogeneous. Two patients failed to harvest stem cells and had a 
RIC-SCT in first response, directly following induction chemotherapy. Ten patients had a 
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tandem autologous-allogeneic approach having achieved a CR following autograft. Eleven 
patients received maintenance or further chemotherapy following their initial autograft to 
improve response, prior to proceeding with RIC-SCT.  Four patients had their RIC-SCT 
following relapse and a second autograft and two had it directly following relapse, having 
failed to harvest cells for a second autograft. There was no data on the remainder.  
3.4.2 Engraftment and chimerism 
Patients received a median CD34+ cell dose of 6.05 x 106/kg (range 2.94-15.01) and median 
CD3+ T cell dose of 2.51 x 108/kg (range 0.5-15.7). Median time to neutrophil engraftment 
was 15 days (range 12-24). There were no cases of engraftment failure. Full donor 
chimerism (FDC) on whole blood was achieved in all assessable patients at a median time 
of 3 months.  
3.4.3 Non-relapse mortality and GVHD 
100 day NRM was 5% (n=2); both secondary to infection.  Cumulative 1 year NRM was 11% 
(n=4) with 1 patient having a GVHD-related death and the other dying in an accident. 3 year 
NRM remained at 11%. Acute GVHD (grade II-IV) occurred in 11.4% of cases. Chronic 
GVHD requiring systemic immunosuppression occurred in 62.1% of all evaluable patients. 
3.4.4 Response and outcome data 
Median follow-up of surviving patients was 80 months. Best responses post allograft were 
72% complete response (CR) and 28% partial response (PR) from all evaluable cases (17% 
data unavailable). Median OS from the time of transplant for all patients was 65 months 
(figure 8) with a 5 year OS of 57%. Median PFS was 29 months (figure 9).  
 
All relapses occurred by 41 months post transplant. Beyond this time point, a plateau was 
evident with 30% of patients not relapsing post transplant. A similar plateau is present but 
less clearly evident on the OS graph because some relatively early relapses manifested as 
significantly later disease-related deaths as patients were treated with further lines of 
treatment post transplant. One patient relapsed at 17 months post transplant and died 143 
months post transplant (figure 8). 
 
Univariate analysis demonstrated that patient gender, myeloma isotype, ISS, HCT-CI, donor 
type, previous autologous transplant, pre transplant response (CR vs <CR) and induction  
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Figure 8: Overall survival in myeloma RIC-SCT 
 
Figure 9: Progression free survival in myeloma RIC-SCT 
 
with novel agents compared to older regimens prior to transplant had no effect on PFS or 
OS.The presence of gender mismatch (male recipient with female donor), major blood group 
mismatch and presence of CMV reactivation risk (donor or recipient or both CMV IgG 
positive) also had no impact on PFS and OS.   
 
There were 7 patients under the age of 45 years. This cohort had a significantly worse OS 
compared to the remainder of the cohort with a median OS of 18 months vs 67 months; 
p=0.035 (figure 10). However, this is likely to be the effect of small sample size and this 
finding should be interpreted with caution. Age had no impact on relapse incidence.  
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Figure 10: Impact of patient age on OS in myeloma RIC-SCT 
 
Number of prior treatment lines had a significant impact on both OS and PFS. Patients who 
had received 1 or 2 prior therapies had a median OS of 78 months compared to 26 months 
in those who had received 3 or 4; p=0.018 (figure 11). Patients who had 1 or 2 prior 
therapies had a median PFS of 34 months compared to 13 months in those who had 
received 3 or 4; p=0.013 (figure 12). Prior number of treatment lines remained significant in 
multivariate analysis. 
 
Figure 11: Effect of number of prior treatment lines on OS in myeloma RIC-SCT  
 
P=0.035 
P=0.018 
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Figure 12: Effect of number of prior treatment lines on PFS in myeloma RIC-SCT 
 
Four patients (13.3%) developed acute GVHD grades II-IV and 62% of patients developed 
chronic GVHD. The occurrence of acute GVHD had no effect on PFS or OS, although with 
only 4 cases, an effect would have been difficult to detect. The occurrence of chronic GVHD 
demonstrated a trend towards an improved PFS; p=0.071 (figure 13). Median OS in those 
with and without chronic GVHD was 94 months and 62 months respectively; p=0.194 (figure 
14). The effect of chronic GVHD on both PFS and OS, may have been strengthened with 
larger patient numbers.  
 
Figure 13: Effect of chronic GVHD on PFS in myeloma RIC-SCT 
 
 
P=0.013 
P=0.071 
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Figure 14: Effect of chronic GVHD on OS in myeloma RIC-SCT 
 
Four patients received DLI; three for disease progression all of whom died within the 
following 12 months. One received DLI for low T-cell chimerism. This was followed by the 
development of full donor chimerism and the onset of GVHD 1 month later, but disease 
relapse still occurred 14 months later. The patient survived for 73 months post transplant, 
but ultimately died of disease progression.   
3.5 Discussion 
There is long-standing controversy surrounding the place of allogeneic transplantation in 
myeloma, with no convincing evidence to date for a survival benefit.110 Furthermore, there is 
ongoing debate about the type of conditioning, whether to transplant upfront or at relapse 
and whether it should be reserved solely for those with high risk disease. 
 
This is a retrospective analysis of 35 patients receiving fludarabine and cyclophosphamide 
conditioning as part of a non-ablative allograft. Median OS and PFS were 65 and 29 months 
respectively. This is in line with other reported studies where median OS has been reported 
at 49-79 months and PFS at 19-30 months.101, 102, 104  
 
Median OS and PFS for upfront autologous transplantation (MEL200) at St Bartholomew’s is 
65 and 20 months respectively.  These are clearly different groups of patients and direct 
comparison cannot be made. The survival assessment is not made from equivalent time-
points in the two cohorts and the allograft cohort consists of more heavily pre-treated 
patients with a sizeable proportion transplanted at relapse. However, it might suggest that 
P=0.194 
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there is unlikely to be a significant short-term overall survival benefit to be gained by having 
an allogeneic transplant when the cohort is considered as a whole.  
 
The key theoretical difference between the two transplant approaches is that reduced-
intensity allogeneic transplantation, through its graft-vs-myeloma effect, should produce a 
plateau in OS, so that a proportion of those transplanted will be long-term survivors who are 
cured from their myeloma. In this analysis, a plateau was evident in relapse incidence with 
30% of patients progression-free beyond 5 years. Median time to death following relapse/ 
progression was 23 months (range 4-125 months).  
 
Unlike many other haematological malignancies where relapse post allogeneic transplant 
carries a dismal outcome with few treatment options available, this study serves to 
demonstrate that for patients with myeloma this is not the case. This data demonstrates that 
despite relapse following allogeneic transplant, patients may go on to receive and potentially 
have long responses to combination chemotherapy and leads to consideration of what the 
definition of treatment failure is in this scenario.  PFS2 data in this setting would therefore be 
very instructive in order to understand what the impact of allogeneic transplantation is on 
consequent therapies for those who do relapse. Unfortunately, because of the retrospective 
nature of this analysis, many patients received subsequent therapies at other centres and 
therefore accurate data was not readily available to generate this data. 
 
This study has shown a cumulative NRM of 11% at 3 years and is therefore significantly 
lower than the 26% reported by the EBMT review.98 Almost 60% of patients in that review 
had T deplete conditioning with a significantly reduced occurrence of chronic GVHD (71% vs 
39%). They reported that patients who had undergone T cell depletion had a significantly 
increased NRM, likely related to infection. In addition, they had a reduced time to 
progression and OS, most likely a reflection of the reduced graft-vs-myeloma effect. Our 
NRM even compares favourably to studies reporting patients solely treated with upfront 
auto-allo approach (NRM 11-17%).102-104, 106 Considering that this patient cohort includes 
patients at relapse in whom NRM in allogeneic transplantation is higher,107 this study 
demonstrates that T replete conditioning with fludarabine and cyclophosphamide has 
minimal toxicity when compared to many other conditioning regimens. 
 
Sixty-two percent of patients had chronic GVHD which, again, is in line with other studies. 
Despite the high incidence of GVHD, there was only one GVHD related death, providing 
further support for the use of a T replete platform. The beneficial effect of chronic GVHD on 
both PFS and OS may have been strengthened with larger patient numbers but was not 
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detected at significance in this analysis. The use of DLI was ineffective in achieving disease 
control in all cases. All patients achieved FDC, with a significant proportion doing so 
following the tailing and cessation of CSA. Despite this, a significant proportion of patients 
went on to develop progressive disease. Evidence of the graft-vs-myeloma effect in this 
analysis is therefore limited.  
 
Some of the controversy surrounding the role of allogeneic transplantation in myeloma is 
related to the improving outcomes being achieved with novel therapies such as bortezomib, 
thalidomide and lenalidomide.115 Only one prospective study looking at the auto-allo 
approach included patients who had received novel agents (thalidomide) as part of their 
induction.105 Their outcomes were comparable to studies using older induction regimens. 
Our study identified no difference in OS or PFS in patients who had received novel agents 
prior to allogeneic transplantation. However, both this study and those already reported, are 
likely to be confounded by the fact that patients who received their induction/ treatment prior 
to transplant in the pre-novel agent era, will undoubtedly have received these drugs at the 
time of relapse or progression, making interpretation of overall survival in this context 
difficult.  
 
A weakness of this retrospective analysis was the patient heterogeneity. Patients had been 
treated with several different approaches prior to allogeneic transplant. This resulted in 
several groups utilising different treatment pathways, each with small numbers, making it 
difficult to compare outcomes with any validity. Auner et al reported that OS was better in 
those who had only had 1 previous autograft.116 In this study, receiving 1-2 lines of treatment 
resulted in significantly superior OS and PFS compared to those who had received 3 or 4. 
This is likely to reflect the evolution of more treatment-resistant disease. There were only 3 
patients identified to be in CR2 and three patients in PR2. Perhaps if larger numbers were 
available, the impact of treating upfront versus at relapse would have been more evident. 
Whilst lines of treatment do not equate completely with treatment in first response or at 
relapse, it does suggest that perhaps treating patients at relapse (who have usually had 
more lines of therapy) may be associated with worse outcomes, consistent with previous 
reports.107 Again, PFS2 data would be helpful to evaluate this area further. 
 
Allogeneic transplantation has the potential to induce a much higher proportion of CRs 
compared to autografting.117, 118 In this study, 40% of patients were in CR prior to transplant 
which rose to 72% following the procedure. In autologous transplantation, it has now been 
clearly demonstrated that those patients who achieve a CR both prior to and post transplant 
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have a superior PFS & OS.82, 119 However, in this study, achieving a CR vs PR pre-allo SCT 
had no significant effect on OS or PFS.  
 
There was no impact of ISS on PFS or OS. Unfortunately cytogenetic data was not available 
on the majority of the patients who had initially been diagnosed and treated at other centres.  
Previous studies in which patients were stratified by risk, used criteria such as high β2M and 
chromosome 13 deletions by FISH. They reported that those with del13q14 had a worse 
EFS and OS.120 Whilst β2M is still relevant (in combination with presentation albumin) for 
prognostication,80 chromosome 13 abnormalities in isolation are no longer considered 
predictive of outcome and instead numerous other cytogenetic abnormalities have been 
identified, which allow us to classify patients as high risk today.121, 122 Schilling et al 
suggested that the negative impact of t(4;14) could be overcome by allogeneic 
transplantation and whilst this group found that patients with del(17p) still fared poorly,123  
Roos-weil et al demonstrated that patients with both t(4;14) and del(17p) demonstrated no 
difference in EFS & OS, supporting the suggestion that allogeneic transplantation may allow 
these patients to overcome their poor risk.124  
 
Patients with ‘ultra-high risk myeloma’ have an estimated median survival of less than 24 
months utilising conventional therapies and ASCT. They comprise patients with ISS 3 and 
poor risk genetic abnormalities.125 This cohort of patients with ultra-high risk are increasingly 
seen as appropriate allogeneic transplant candidates in view of their otherwise poor 
outcome. The policy for patient selection at St Bartholomew’s has now changed to include 
consideration of those patients who are ultra-high risk and who have a suitable donor.  
 
This analysis unfortunately has several limitations. It was a non-randomised retrospective 
study and as such clinician choice in selecting which patients underwent allogeneic 
transplantation undoubtedly had an impact on outcomes. There were no clearly defined 
criteria regarding patient selection and as such the wide variety of patients made analysis 
difficult. A formal HCT-CI assessment was not performed prior to transplant and patient 
selection was at the clinician’s discretion. Logically, to offer a relatively controversial 
treatment choice with a significant risk of mortality in comparison to other myeloma 
therapies, it would be expected that only patients who were considered fit would have been 
considered appropriate. However, this retrospective analysis demonstrated that patients with 
a full range of HCT-CI scores were included, including 20% who were in the ‘high’ category. 
However, despite this HCT-CI had no effect on PFS or OS and despite the heterogeneous 
population, the low NRM with this approach has already been highlighted.  
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St Bartholomew’s is one of the largest UK centres performing allogeneic transplants in 
myeloma. However, with only 35 allogeneic transplants performed over a 12 year period, 
compared to over 200 ASCTs between 2006 and 2011, it is certainly not ‘standard of care’ 
as indicated in the BSBMT guidelines. This data is limited in providing any definitive 
conclusions about the role of allogeneic transplantation, although it is clear there is a small 
cohort who appear to have achieved long-term cure. Therefore the hypothesis that the 
outcome after allogeneic transplantation for patients with multiple myeloma justifies the 
increased toxicity by decreasing relapse is certainly supported in some cases, but is not 
universal and it remains difficult to know in whom that statement stands. 
 
The FC RIC-SCT does have a very low NRM in comparison to most reported allogeneic 
studies. However, the most likely outcome remains relapse, with a higher NRM risk 
compared to ASCT. This data-set is too small to make recommendations regarding optimal 
patient selection. However, if patients with poor risk cytogenetics are able to overcome their 
adverse outcomes, then this is clearly a population in whom there is more justification to 
consider the allogeneic approach. Further studies with larger numbers of patients are 
required to help us make well-placed evidence-based decisions regarding allogeneic 
transplantation in this disease. Ongoing research is required to determine how best to keep 
NRM low whilst minimising post transplant relapse. In the interim, I would suggest that 
allogeneic transplantation is recommended in the BSBMT tables as a clinical option in first 
response and at relapse for both sibling and unrelated donors. 
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 CHAPTER FOUR 
Sequential transplantation in  
refractory and relapsed acute myeloid leukaemia 
and myelodysplasia 
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4.1 Introduction 
The majority of patients with newly diagnosed acute myeloid leukaemia (AML) who receive 
intensive induction chemotherapy will achieve a complete remission.126 
 
For those patients that achieve a remission following induction, 50% will relapse. Studies 
have demonstrated that whilst a second CR can be achieved with salvage chemotherapy, 
relapse follows soon after, with a median 3 year OS of between 8-29% and just over 10% 
achieving long term remission.127-131 There is no standard of care with regards to salvage 
chemotherapy but allogeneic stem cell transplantation is recognised to be the most 
promising treatment strategy in this setting. 132, 133 
 
Approximately 20% of patients with AML will be refractory to induction therapy. Their 
prognosis is poor and salvage with chemotherapy alone is unlikely to result in a sustained 
remission. Again, allogeneic transplantation provides the best chance of prolonged survival 
in this setting.  
 
The BSBMT recommend allogeneic transplantation in patients with refractory disease as a 
clinical option based upon studies that report an OS of approximately 30% (table 10). 134, 135 
However, several studies have confirmed the importance of achieving a CR with salvage 
therapy before consolidating this response with an allogeneic transplant. Those patients not 
in remission at the time of transplant do worse and as such allogeneic transplantation in a 
second CR is classified as ‘S’ by BSBMT (table 10).136, 137 
 
Table 10: BSBMT Indications for SCT in AML (taken from BSBMT Indications for SCT 
Version Oct 13) 
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The median age of diagnosis with AML is 65 years. The introduction of reduced-intensity 
conditioning has allowed allogeneic transplantation to be offered to patients who would not 
have been deemed fit enough for a myeloablative transplant by virtue of their age or 
performance status. RIC-SCT offers a significantly reduced toxicity profile compared to 
myeloablative conditioning. It relies on the graft-vs-leukaemia effect, rather than disease 
eradication through high dose chemotherapy and TBI.37, 138  
 
There is evidence that conditioning intensity is important in controlling poor risk disease.139 
Therefore, there is concern that the reduced intensity approach may not be sufficient to hold 
aggressive disease such as primary refractory and relapsed AML whilst the GvL effect is 
allowed to occur. Furthermore, patients with poor risk disease are likely to have the most 
chemoresistant disease and the highest chance of relapse. They are consequently the most 
likely to struggle to achieve the remission status ideally required in order to proceed with 
allogeneic transplantation.  
 
The sequential allogeneic transplantation approach was introduced to deal with these 
concerns by first giving intensive chemotherapy to reduce the leukaemic burden and then 
proceeding immediately with RIC-SCT without awaiting count recovery or confirmation of 
remission.140 
 
Myelodysplastic syndrome (MDS) is another haematological disorder predominantly 
affecting the older population, with 80% of patients over the age of 60. It is recommended 
that patients with MDS who are high risk and under the age of 60 should have an allogeneic 
transplant (table 11).141  
 
Table 11: BSBMT Indications for SCT in Myelodysplastic Syndrome (taken from BSBMT 
Indications for SCT Version Oct 13) 
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There is debate about the role and type of treatment prior to transplant. As with AML, there 
is some evidence from retrospective studies suggesting that achieving a CR prior to 
transplant results in better outcomes.142 However, using AML-like induction chemotherapy to 
achieve this can be associated with delayed haematological recovery and treatment related 
toxicities that may actually make transplantation a less viable option. Again, the sequential 
approach allows these concerns to be bypassed by reducing disease bulk before proceeding 
directly to transplant. 
 
Since Schmid et al reported this approach in 2005 there have been several reports 
concurring that this strategy is effective (table 12).143-151 However, all groups have used T 
cell depletion with ATG as part of their conditioning and the majority have used TBI. The 
toxicity associated with TBI means that its use is potentially limited in older patients and 
those with comorbidities.152 
 
There is a clear rationale behind the sequential approach. However, given that the 
implicated patient population is older and more likely to have a higher HCT-CI, we performed 
a prospective single-centre study using the sequential approach with fludarabine and 
cyclophosphamide T-replete conditioning. This is a reduced intensity approach associated 
with low NRM in the non-sequential setting and therefore has the potential to widen the 
cohort of patients that may benefit from allogeneic transplantation in this setting.111, 153-156 
4.2 Hypothesis 
The sequential transplantation approach increases the probability of getting a patient to 
transplant and should be considered as standard of care for patients with relapsed and 
refractory AML and high risk myelodysplasia. 
4.3 Methods 
4.3.1 Patient eligibility 
Fourty-four patients were enrolled into the study. Patients with refractory or relapsed AML 
and high-risk MDS were all eligible. Patients had to have an identified donor at the time of 
entry into the study or have disease stable enough to allow a donor search to occur before 
commencing treatment. Refractory AML was defined as the presence of disease following 
induction chemotherapy (morphological evidence of >5% blasts on bone marrow) or relapse 
within 6 months of CR1. Four of the enrolled patients did not undergo transplantation; 2 with 
relapsed AML had an identified matched unrelated donor who was deemed unfit to donate 
by the donor registry and no other suitable donors could be identified within a suitable time-
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Table 12: Reported sequential transplantation studies in acute leukaemia and MDS  
NA Not available; FLAMSA fludarabine 30mg/m2, cytarabine 2g/m2, amsacrine 100mg/m2 days D-12 to D-9 
  Schmid et al140 Liu et al143 Saure et al144 Chemnitz et al145 Schneidawind et al146 
Study Type  Prospective Prospective Prospective Prospective Retrospective 
N  75 51 30 17 62 
Median F/U (m)  31.5 41 28 12 17 
Med age (range) yrs 52.3 (18-65) 30 (14-53) 49 (36-66) 57.4 (40-69) 55 (20-72) 
HCT-CI Low (%) NA NA 40 6 NA 
 Med/ High (%)   60 94  
Diagnosis Poor risk AML CR1 (%) 10.6 0 0 29 0 
 AML CR2 (%) 10.6 0 0 7 0 
 Relapsed AML (%) 37.3 19.6 (AML/ALL) 0 35 42 
 Refractory AML (%) 28 76.5 (AML/ALL) 0 29 58 
 High Risk MDS CR1 (%) 0 0 0 0 0 
 Untreated AML/ HR MDS(%) 0/13.3 0 66/33 0 0 
 MPS(%) 0 0 0 0 0 
Cytogenetics Favourable(%) 4 7.8 40 29 0 
 Intermediate(%) 42 35 23  66 
 Poor(%) 49 39 37  33 
Donor Matched MUD (%) 40 24 44 47 35 
 Matched SIB (%) 41.3 44 43 24 18 
 MM MUD/SIB (%) 18.7 32 13 29 46 
Chemotherapy  FLAMSA flu/ AraC/Etop FLAMSA FLAMSA FLAMSA 
Conditioning  4Gy 4.5Gy    
  Cyclo 40/60mg/m2 x2 Cyclo 60mg/m2 x2 Melphalan 100-200mg/m2 Treosulfan 10g/m2 x3 Flu/Bu/ATG 
  ATG 10-20mg/kg x3 Etop 600mg/d x2 Thiotepa 10mg/m2x2 <55yrs Cyclo 40/60mg/m2 x 2 Bu/Cy/ATG 
   ATG if VUD/MM SIB ATG 10-20mg/kg x3 (VUD) ATG 10-20mg/kg x3 TBI(4Gy)/Cy/ATG 
Neut Engraft (d)  14 12 13 18 17 
CR D30 (%)  88 94 97 94 NA 
aGVHD(%) {>Gr II)  45 32 73  (I-IV) 20 (III-IV) 20 21 
cGVHD Limited (%) 26 29 56 43 NA 
 Extensive(%) 19 21 20 14 26 
OS 1yr (%) NA 57 NA 62 NA 
 2 yr (%) 42 NA 70 NA 39 
 3yr (%) NA 48 NA NA NA 
DFS 1yr (%) NA 48 NA 55 NA 
 2yr (%) 40 NA 63 NA 26 
 3yr (%) NA 42 NA NA NA 
NRM <30d (%) 7 3.9 NA 5.8 NA 
 100d(%) 20 19 NA 12 NA 
 1yr(%) 33 NA 30 20 NA 
 2yr(%) NA NA NA NA 22 
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  Detrait  et al149 Cluzeau et al150 Krejci et al147 Buchholz et al148 Michallet et al151 
Study Type  Retrospective Retrospective Prospective Retrospective prospective 
N   40 17 60 27 26 
Median F/U (m)  6 14 37 35.9 na 
Med age (range) yrs 52 (32-66) 53 (32-64) 52 (20-63) 58 (19-69) 55 (24-67) 
HCT-CI Low/ med & high (%) na 59/41 42/58 na na 
Diagnosis Poor risk AML CR1 (%) 10 0 16.7 14.8 100 
 AML CR2 (%) 0 0 25 3.7 0 
 Relapsed AML (%) 62.6 65 18.3 0 0 
 Refractory AML (%) 10 35 40 55 0 
 High Risk MDS CR1 (%) 17.5 0 0 3.7 0 
 Untreated AML/ HR MDS(%) 0 0 0 0/18.5 0 
 MPS(%) 0 0 0 3.7 0 
Cytogenetics favourable(%) 0 0 10 0 0 
 Intermediate(%) 30 59 62 78 15 
 Poor(%) 52.5          41  17 22 85 
Donor Matched MUD (%) 35 48 48 63 31 
 Matched SIB (%) 45 35 25 22 35 
 MM MUD/SIB (%) 20 17 27 15 34 
Chemotherapy  FLAMSA Thio200mg/m2 x3 FLAMSA Clof 30mg/m2 x5 FLAMSA 
   Etop 200mg/m2 x3  Arac 1g/m2 x5  
   6MP75mg/m2 x14  5 rest days  
Conditioning  4Gy or BU Flu 30mg/m2 x4 4Gy 4Gy 4Gy or BU 
  Cyclo 40/60mg/m2 x2 Bu 3.2mg/kg x2 Cyclo 40/60mg/m2 x2 Cyclo 40/60mg/m2 x2 Cyclo 40/60mg/m2 x2 
  ATG 5mg/kg x3 ATG 2.5mg/kg x2 ATG 10-20mg/kg x3 ATG 4.5-7.5mg/kg x3 ATG 5mg/kg x3 
Neut Engraft (d)  NA NA 17 16 NA 
CR D30 (%)  NA 86.7 78 89 NA 
aGVHD(%) {>Gr II)  25 41 47 (1-IV) 52% (1-2 only) 21.7 
cGVHD Limited /Extensive(%) NA 0/7 39/16 21/8 17.4/4.3 
OS 1yr (%) 30 29.4 45 NA NA 
 2 yr (%) NA NA NA 56 58 
 3yr (%) NA NA 42 NA NA 
DFS 1yr (%) NA 17.7 38 NA NA 
 2yr (%) 29 NA NA 50 NA 
 3yr (%) NA NA 33 NA NA 
NRM <30d (%) NA 11.7 15 11 NA 
 100d(%) 14 NA NA 15 NA 
 1yr(%) 22 NA 25 NA NA 
 2yr(%) NA NA NA 35 13 
 3yr(%) NA NA 28 NA NA 
Table 12(cont): Reported sequential transplantation studies in acute leukaemia and MDS                   NA Not available
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frame. Two other patients died before they were able to proceed with transplant (one with 
MDS died from infection and the other from relapsed AML). Consequently, 40 patients were 
transplanted between September 2007 and February 2014. The hospital ethics committee 
approved the protocol and written informed consent was obtained from all patients and 
donors in accordance with the Declaration of Helsinki (appendices 1& 2). 
4.3.2 Treatment protocol 
Patients received daunorubicin 45mg/m2 from D-15 to D-13 and cytarabine 1500mg/m2 b.d 
from D-15 to D-9. After 2 rest days, RIC consisted of fludarabine 25mg/m2 on D-6 to D-2 and 
cyclophosphamide 1g/m2 on D-3 and D-2. GvHD prophylaxis was with methotrexate (5 
mg/m2 on days +1, +3 and +6), and ciclosporin (CSA), 5 mg/kg on day -2 and 3 mg/kg per 
day thereafter. Trough CSA levels were measured in whole blood twice weekly post-
transplant. CSA was dosed to maintain levels between 150–300mcg/L. Tapering was 
commenced at day +90. CSA taper was commenced earlier in those patients with mixed 
donor chimerism. DLI would be considered 30 days after discontinuation of 
immunosuppression in the presence of mixed chimerism or evidence of persistent disease. 
4.3.3 Supportive care 
All patients received antifungal and antimicrobial prophylaxis with fluconazole and 
ciprofloxacin until neutrophil engraftment. All patients were commenced on cotrimoxazole 
following engraftment as prophylaxis against Pneumocystis jiroveci. All patients received 
antiviral prophylaxis with aciclovir for a minimum of 6 months or longer if still on 
immunosuppression. Peripheral blood samples were monitored weekly for CMV re-activation 
by quantitative polymerase chain reaction (PCR). Patients with evidence of CMV re-
activation were treated with pre-emptive valganciclovir.  
4.3.4 Patient evaluation   
Neutrophil recovery was defined as time to a count of 0.5 × 109/L for 2 consecutive days. 
Chimerism was measured on whole peripheral blood samples by PCR analysis of variable 
number tandem repeat polymorphisms at days +30, +60, +90 and thereafter as appropriate. 
T lineage-specific chimerism was performed after immunomagnetic sorting of CD3+ T cells.  
 
Acute GVHD was diagnosed and graded using current consensus criteria.113 Chronic GvHD 
was diagnosed and scored using Seattle criteria.114 GvHD was managed by institutional 
protocol. Disease relapse was defined as detectable disease by morphology or cytogenetics. 
Patients were deemed to have persistent disease if detectable by bone marrow morphology 
assessed at day+30 and were censored at this date for relapse. The median follow-up of 
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surviving patients was 51 months. Patients who died before day+30 were excluded from 
engraftment and chimerism analysis. NRM was defined as death in the absence of disease 
relapse or persistence. 
4.3.5 Statistical analysis 
Survival curves were constructed using the method of Kaplan and Meier and differences 
between groups were assessed using the log-rank statistic.  Patients were censored at last 
follow-up when calculating overall survival. Univariate analysis of association of outcomes 
with risk factors was performed. These included age (60 yrs or ≥60 yrs), diagnosis, 
cytogenetics (adverse or intermediate), donor type, sex mismatch, major ABO mismatch, 
CD34+ and CD3+ cell doses, CMV risk, peripheral blood chimerism at day+30 and the 
presence of acute and chronic GVHD. P-values of less than 0.05 were considered 
statistically significant. Data were analyzed using SPSS v22 (IBM, New York). Cumulative 
incidence and multivariate analysis was performed using STATA. 
4.4 Results 
4.4.1 Patient characteristics 
Patient, donor and graft characteristics are summarized in table 13. Forty patients underwent 
sequential transplantation. The aggressive nature of acute myeloid leukaemia and the time-
scale involved in identifying donors meant that many patients with relapsed and refractory 
AML who may have been eligible for the study were not enrolled because a donor was not 
identified prior to commencing therapy. The median age of the patient cohort was 53 years 
(range 23-68 years). Eight patients (20%) were aged 60 years or over. Thirty-four patients 
(85%) had AML. 50% of AML patients were refractory, 30% had relapsed disease and 5% 
were untreated with bone marrow blasts between 20-30%. Patients with MDS made up 15% 
of the total cohort. Seven patients (17.5%) had undergone previous allogeneic 
transplantation. There were no patients with favourable risk cytogenetics. The proportions of 
those with intermediate and high risk are shown in table 13. Four patients had monosomal 
karyotypes. This was too small a group to perform separate analyses on. Whilst those 
treated in the latter stages of the study had FLT3 and NPM results available, the majority of 
patients were enrolled into the study before molecular studies had become routine 
diagnostic tests and therefore this data was not available for analysis. According to the HCT-
CI score, 35%, 30% and 35% of patients were classified as low, intermediate and high 
respectively.54 
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Table 13: Patient characteristics in sequential allograft study 
   N % 
   40  
Gender F  13 32.5 
 M  27 67.5 
Age Median (range)  53 (23-68)  
 ≥60yrs  8 20 
Diagnosis Refractory AML Total 20 50 
  Int CG 13  
  Poor CG 7  
 Relapsed AML Total 12 30 
  Int CG 10  
  Poor CG 2  
 Untreated AML Total 2 5 
  Int CG 1  
  Poor CG 1  
 Myelodysplasia Total 6 15 
  IPSS low 0  
  IPSS INT1 1  
  IPSS INT2 5  
  IPSS High 0  
HCT-CI Low  14 35 
 Intermediate  12 30 
 High  14 35 
Donor Matched Sibling  19 47.5 
 Matched VUD  20 50 
 Mismatched VUD  1 2.5 
ABO mismatch Yes  12 30 
 No  28 70 
Gender 
mismatch 
Female donor/male recipient 8 20 
 Any other combination 32 80 
CMV mismatch Yes  28 70 
 No  12 30 
Prev transplant Yes  7 17.5 
 No  33 82.5 
 
                      CG cytogenetics; IPSS International prognostic scoring system 
 
Patients were transplanted using HLA-matched related donors (n=19, 47.5%) or volunteer 
unrelated donors (n=21 52.5%). One VUD was a 1C single antigen mismatch. There was a 
major ABO mismatch in 12 cases (30%). In 70% of cases, there was a CMV reactivation 
risk. There were 9 cases of a male recipient and female donor (19.6%). Median donor age 
was 41 years (range 22-68 years). Given the median age of patients was 53 yrs, it was not 
surprising that there were significantly more sibling donors above the median donor age 
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compared to matched unrelated donors; (p=0.01). However, stem cell graft characteristics 
were not significantly different between related and unrelated donors.  
 
Intermediate resolution HLA-typing was used for Class I (HLA-A and HLA-B, HLA-C) and 
high resolution molecular typing for Class II (DRB1 and DQB1) alleles. Unrelated donors 
were fully matched for HLA-A, -B, -C, -DRB1, and DQB1. Stem cell source was granulocyte 
colony-stimulating factor-mobilized peripheral blood stem cells (PBSC) (n=39) or fresh 
unmanipulated bone marrow (n=1). Patients received a median CD34+ cell dose of 5.88 x 
106/kg (range 1.76-26.20) and median CD3+ T cell dose of 3.31 x 108/kg (range 0.36-13.37). 
4.4.2 Engraftment and chimerism 
Six patients died in the cytopenic phase. Excluding those, all other patients engrafted and 
median time to neutrophil engraftment was 20.5 days (range 11-29). FDC was achieved in 
78% of all assessable patients. Of those, 56% of patients had reached FDC by D30. Full T-
cell chimerism (FTCC) was achieved in 81% of all evaluable patients. Of these, 64% 
achieved FTCC by D30. No patients received DLI post transplant. 
4.4.3 Toxicity and non-relapse mortality 
Median duration of hospital stay was 38 days (range 30-127). Cumulative incidence of NRM 
with competing risks was 38%. Of the 6 patients who died in pre-engraftment, 5 were 
secondary to neutropenic sepsis (the remainder was secondary to refractory disease). 
Patient age had no statistical impact on overall NRM, although 50% (n=3) of deaths before 
D30 were in patients over 60. 41% of all NRM deaths were secondary to infection, 17.6% 
were due to acute GVHD and 23.5% were secondary to chronic GVHD. 17.6% were due to 
other causes including pneumonitis, subdural haemorrhage and liver failure. Nine patients 
had CMV reactivation; this included 1 patient with CMV colitis but there was no other CMV 
related disease. No other significant viral infections occurred. 
4.4.4 Graft vs host disease 
12 patients (35% of assessable patients) developed acute GVHD (grades II-IV) of whom 
25% (n=3) died from GVHD. Median time to acute GVHD was 38 days (range 24-97 days). 
Nine patients (33% of all assessable patients) had chronic extensive GVHD or GVHD on 
tailing ciclosporin and 44% of these died from GVHD or infection in the context of 
immunosuppression for GVHD. Median time to chronic GVHD was 159 days (range 133-
371). 
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4.4.5 Relapse and survival outcomes 
Median survival of all patients was 9 months. 1 year and 3 year OS was 42% and 30% 
respectively. Median PFS was 8 months. There were clear survival trends depending on 
diagnosis (figure 15). When patients with MDS and relapsed AML were compared to those 
with refractory AML, median OS was 25 vs 7 months respectively; p=0.029 (figure 16). 
Univariate analysis demonstrated that no other factors impacted upon OS. The impact of 
diagnosis on PFS was less marked (figure 17). 
 
Figure 15: OS using sequential allogeneic transplantation by diagnosis 
 
Figure 16: OS using sequential allogeneic transplantation comparing refractory AML to 
relapsed AML and MDS 
 
P=0.029 
P=0.114 
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Figure 17: PFS using sequential allogeneic transplantation by diagnosis 
 
89.7% of all assessable patients had no evidence of disease on their D30 bone marrow. 
Three patients had refractory disease on their D30 bone marrow. A further 9 patients 
relapsed post transplant. Median time to relapse in those not refractory at D30 was 211 days 
(range 76-671). Cumulative incidence of refractory or relapsed disease was 35%. 
 
Diagnosis had a significant impact on risk of relapse; p=0.005 (figure 18). No patients with 
MDS relapsed. Only one patient with previously relapsed AML relapsed again post 
transplant with all other relapses occurring in the refractory AML cohort.  
 
Figure 18: Relapse using sequential allogeneic transplantation by diagnosis 
 
The presence of poor risk cytogenetics also trended towards a statistical impact on relapse, 
p=0.08 (figure 19). There were no patients with good risk cytogenetics in this cohort. Median 
P=0.005 
P=0.178 
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time to relapse was not reached in those with intermediate risk cytogenetics, but was 212 
days in those with adverse risk. The number of MDS patients was too small to separately 
evaluate the impact of MDS prognostic scoring. 
 
Figure 19: Relapse using sequential allogeneic transplantation by cytogenetic risk in AML 
and MDS 
The presence of chronic GVHD demonstrated a striking disparity on the Kaplan-Meier graph 
with no patients who developed chronic GVHD relapsing. However, only a trend towards 
statistical significance was seen; p=0.087 (figure 20), most likely due to small patient 
numbers eligible for analysis beyond D100. Acute GVHD had no impact on PFS or OS. 
 
Figure 20: Relapse using sequential allogeneic transplantation by presence of chronic 
GVHD 
 
P=0.08 
P=0.087 
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A higher CD34 count (above the median of 5.88x106) was associated with a significant 
reduction in relapse; p=0.013 (figure 21).  
 
Figure 21: Relapse using sequential allogeneic transplantation by CD34 count above and 
below median 
 
The presence of a major ABO mismatch was surprisingly associated with an increased 
incidence of relapse, p=0.006 (figure 22). There was a similar trend towards significance for 
PFS (0.065) but there was no effect on OS. 
 
Figure 22: Relapse using sequential allogeneic transplantation by presence of major ABO 
mismatch 
 
P=0.013 
P=0.006 
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4.5 Discussion 
This study evaluated the outcomes of 40 patients with relapsed or refractory AML and  high 
risk myelodysplasia using a previously unreported sequential approach with intensive 
chemotherapy comprising daunorubicin and cytarabine followed by a reduced-intensity T 
replete fludarabine cyclophosphamide allogeneic transplant protocol. 
 
It has been demonstrated that patients with MDS or AML who undergo allogeneic 
transplantation with active disease have worse outcomes compared to equally matched 
patients in CR.157 The sequential approach was devised with the aim of reducing the burden 
of disease in order for the GvL effect to have sufficient opportunity to occur in those with high 
risk disease.140  
 
This is the only study to report this approach with no T cell depletion, even in the context of 
unrelated donors. This T cell replete strategy is an extension of the fludarabine 
cyclophosphamide conditioning approach used at St Bartholomew’s for fully matched 
allogeneic transplants with a very favourable toxicity profile reported.111, 155, 156 It offers a very 
low incidence of post transplant viral complications and a low demand of DLI. 
 
Despite the sequential strategy, four enrolled patients did not get to transplant highlighting 
the difficulties of successfully proceeding with SCT in this high-risk cohort. 
 
Cumulative incidence NRM was clearly significant at 38%. The range reported in the 
literature varies between 22-35%.140, 144, 145, 147, 148 Cause of NRM was split equally between 
infection and GVHD. The rationale behind T cell depletion is to minimise GVHD and its 
associated toxicities. However the incidence of both acute and chronic GVHD at 35% and 
33% respectively was lower than several T deplete studies (aGVHD 18-73%, cGVHD 7-
76%). The high NRM may be accounted for by the characteristics of the patients included in 
this study. Their median age was 53 years which was comparable to most (although not all) 
studies. 65% of patients had a HCT-CI of medium or high. Most sequential studies made no 
comment regarding HCT-CI, but two reported proportions of medium and high HCT-CI 
between 12-30% and only 3 had a comparable proportion to our own cohort.144, 145, 147, 150  
 
One-year OS was within the range reported by previous studies at 42% (29-62%). 3 year OS 
was 30%, under the reported range (42-49%). It is important to note that the median follow 
up of 51 months was significantly longer than any other reported study and most had not yet 
reached 3-year follow-up. These inferior survival outcomes may well be explained by the 
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patient cohort, which had a particularly poor disease characteristic profile. Unlike other 
reported sequential studies, the patient cohort in this study included no patients in CR and 
no patients with good risk cytogenetics, both of whom are reported to have better 
outcomes.131, 136 Furthermore, the proportion of patients with myelodysplasia was much 
higher in one study and given the superior outcomes seen in MDS patients in this study, this 
may well contribute to their improved survival outcomes.144 The only reported study 
comparable to this one in terms of age, HCT-CI and patient disease status had a short follow 
up at 14 months but interestingly reported the worst 1 year OS at 29% and a D30 NRM of 
11.7%. 
 
Breems et al demonstrated that there are factors that help to identify which patients with 
relapsed AML may benefit most from transplant.131 According to their prognostic scoring 
system, which includes age, previous transplant, cytogenetic risk and length of CR1, all of 
the relapsed AML patients in this study fell into the worse two prognostic categories with a 
predicted 5 year OS of 4-18%. The OS of patients with relapsed AML in this study was 
41.7% at 5 years and therefore significantly better than their predicted outcome outside of 
the sequential setting.  
 
There were only six patients with MDS in this study which makes drawing any robust 
conclusions about this group difficult. According to the WHO classification based prognostic 
scoring system (WPSS), all of the patients in this study had a score of high or very high. This 
gives them a predicted median survival of between 12 and 21 months.158 If the MDS patients 
in this study are looked at alone, there are no relapses and their median OS is not reached, 
with 67% OS at 5 years. Perhaps, larger patient numbers would change this data. However, 
it suggests that the sequential strategy might be particularly effective for patients with MDS. 
This is supported by data from Saure et al.144 Their OS data is the best of all reported 
sequential studies (2 year OS of 70%) and their cohort predominantly includes patients with 
MDS.144  
 
Patients who benefited less well from this approach were those with refractory AML and 
those with adverse cytogenetics. With an OS of less than 20% in both of these groups, it 
appears there is little to be gained from this approach compared to standard and possibly 
less toxic alternatives. 
 
This data clearly demonstrated the graft-vs leukaemia effect. Those patients who developed 
chronic GVHD, and did not succumb to its toxicities, did not relapse with an OS of 50% in 
this subgroup of patients. Therefore it is clear, that conditioning that aims to minimise GVHD, 
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is also minimising the potential benefits of GvL.  Work continues to try and pull apart GVHD 
and GVL. In the interim, the aim, although challenging, should be to select patients who are 
best able to tolerate the potential associated GVHD toxicities. 75% of the GVHD-related 
deaths were in patients above the median age of 51 years. Furthermore, of the 6 observed 
deaths in aplasia, 3 were in patients >60 years.  These deaths are clearly multifactorial, and 
age is only one factor, but it suggests that this treatment strategy and its associated toxicities 
are perhaps tolerated less well by the older population. 
 
A higher CD34 count was associated with a reduction in relapse. This has been 
demonstrated in other studies with larger patient numbers, outside of the sequential setting 
and furthermore that association has been reported to be most marked in high-risk diseases 
where there is more evidence of the GVL effect.159-161 This has been postulated to be 
immune-mediated, possibly linked to a natural killer(NK) cell mediated graft-vs-leukaemia 
effect in view of the fact that the majority of early peripheral blood lymphocytes post 
transplant are NK cells.162 The lack of OS benefit seen with an increased CD34 count may 
be due to the occurrence of increased GVHD, which has previously been reported to be 
associated with higher CD34 counts.163 In this analysis, the median CD34 count in those 
who had GVHD-related deaths was 8.3 x106 (range 4.6-26.2) compared to a lower median 
CD34 count of 4.4 (range 1.95-16.06) in those who had disease related deaths.   
 
The observation that the presence of a major ABO mismatch impacted adversely on relapse 
risk is interesting. Whilst there have been reports associating ABO mismatch with reduced 
survival, possibly because of delayed engraftment and the consequent associated risks, no 
association with increased disease relapse has been reported. Whilst, the sample size must 
be remembered, the effect is striking. I would hypothesise that the ABO mismatch allows 
pre-formed antibodies to cross-react with antigens on the donor cells. This leads to cytokine 
activation and perhaps results in subsequent damage to donor cells and subsequently less 
effective GvL. As a result of the impaired GvL effect, relapse is more likely. 
 
The rationale of using lower intensity chemotherapy and conditioning facilitated the delivery 
of treatment and transplantation to an older, less fit patient group, whilst maintaining 
comparable outcomes.  The sequential approach has the potential to avoid the toxicities 
associated with induction chemotherapy, which are less likely to work in patients with poor-
risk disease and ultimately may result in a failure to proceed with transplantation. There is 
also a potential financial and resource gain associated with avoiding potentially 2 or 3 cycles 
of intensive chemotherapy before a ‘standard’ allogeneic transplant.  
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NRM is high and OS is low compared to many other allogeneic transplant scenarios, but this 
is a cohort of patients with an otherwise dismal prognosis. This study has provided clear 
identification of those patients who are most likely to benefit; namely those with MDS and 
relapsed AML. Their outcomes were far superior to those predicted using conventional 
treatments.  I would recommend that patients with adverse cytogenetics and refractory AML 
have little to gain from this approach and perhaps less toxic, non-curative therapies or 
clinical trials are more appropriate. The significant early mortality in those over 60 suggests 
that perhaps this should approach be reserved for younger patients, despite the ‘lighter’ 
conditioning.  
 
Without a randomised prospective study comparing the sequential approach to conventional 
allogeneic transplantation, there is insufficient evidence to consider it standard of care and 
therefore the hypothesis in this study is rejected. However, there have been several studies 
using the sequential approach, all demonstrating acceptable outcomes in scenarios where 
prognosis is exceptionally poor. This study supports those findings and I would therefore 
suggest that the BSBMT makes an addition to its current recommendations such that the 
sequential approach should be considered in patients with relapsed AML and 
myelodysplasia as a clinical option. 
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CHAPTER FIVE 
Allogeneic Stem Cell Transplantation 
in Lymphoma 
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5.1 Introduction 
For both indolent lymphomas such as follicular lymphoma (FL) and high grade lymphomas 
such as Diffuse Large B Cell Lymphoma (DLBCL) and Hodgkin lymphoma (HL), autologous 
transplantation is the standard of care in those with primary resistant or relapsed disease 
(tables 14, 15 and 16).164, 165 
 
Table 14: BSBMT Indications for SCT in Follicular Lymphoma (taken from BSBMT 
Indications for SCT Version Oct 13) 
 
 
 
Table 15: BSBMT Indications for SCT in DLBCL (taken from BSBMT Indications for SCT 
Version Oct 13) 
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Table 16: BSBMT Indications for SCT in Hodgkin Lymphoma (taken from BSBMT 
Indications for SCT Version Oct 13) 
 
The introduction of RIC-SCT in the 1990s has resulted in a rise in the use of this treatment 
modality in virtually all lymphoma subtypes, following the unacceptable NRM that was 
reported with myeloablative conditioning.166-169 A graft-vs-lymphoma effect has been 
convincingly demonstrated by virtue of disease responses following withdrawal of 
immunosuppression, administration of DLI and the observation in some reports that chronic 
GVHD is associated with a reduced relapse rate.170-176 This has resulted in RIC-SCT offering 
a potentially curative role in many lymphoma subtypes, and particularly in subgroups that 
face an otherwise poor prognosis.  
 
However, whilst the NRM is reduced compared to MA conditioning, it remains significant and 
therefore its role in terms of patient selection and timing for most subtypes remains 
controversial.  Allogeneic transplant is considered standard of care in those who have 
relapsed following ASCT (tables 14, 15 & 16). However, there is an increasingly grey area 
over the role of allogeneic transplant at first relapse and whether there are scenarios in 
which it should be considered in place of an ASCT following salvage chemotherapy. 
Furthermore, in subtypes such as Mantle Cell Lymphoma (MCL) and Peripheral T Cell 
lymphoma (PTCL), the role of allogeneic versus ASCT as consolidation in first response and 
at relapse is another area of debate with the BSBMT recommending it as a ‘clinical option’ in 
both scenarios (tables 17 and 18). 
 
This chapter is a review of RIC-SCT performed in patients with lymphoproliferative disorders 
(LPD) between 2005 and 2013 at St Bartholomew’s Hospital. Patients with chronic 
lymphocytic leukaemia (CLL) were excluded from this report as they are subject to a 
separate analysis outside of this thesis. This retrospective analysis aimed to assess the 
outcomes of these patients and to try and identify which patients are being selected for  
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Table 17: BSBMT Indications for SCT in Mantle Cell Lymphoma (taken from BSBMT 
Indications for SCT Version Oct 13) 
 
 
Table 18: BSBMT Indications for SCT in Peripheral T Cell Lymphoma (taken from BSBMT 
Indications for SCT Version Oct 13) 
 
 
allograft and whether any cohorts can be demonstrated to gain particular benefit. In view of 
the histological heterogeneity included in this cohort, my approach will focus on the three 
subtypes with the largest patient numbers; DLBCL (including transformed follicular 
lymphoma), FL and MCL. Following whole group analyses, histological subtypes will be 
considered and discussed individually.  
5.2 Hypothesis 
a) Reduced-intensity T replete allogeneic transplantation is a reasonable standard of 
care in those with resistant and relapsed follicular lymphoma and transformed 
FL/DLBCL 
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b) Reduced-intensity T replete allogeneic transplantation is a reasonable standard of 
care in MCL in CR1 
5.3 Methods 
5.3.1 Patient eligibility 
A total of 72 patients with lymphoproliferative disorders underwent RIC-SCT between 2005 
and 2013 at St Bartholomew’s Hospital.  These included patients with DLBCL (including 
those transformed from FL), FL, PTCL, MCL, Waldenströms Macroglobulinaemia (WM), HL 
and marginal zone lymphoma (MZL). Written informed consent was obtained from all 
patients and donors in accordance with the Declaration of Helsinki.  
5.3.2 Treatment protocol 
Transplant conditioning was with fludarabine 25 mg/m2 on D−6 to D−2 and 
cyclophosphamide 1 g/m2 on D−3 and D−2. In five cases, the donor was an HLA single 
antigen mismatch and the recipient received Alemtuzumab in addition. Methotrexate 
(5 mg/m2 on D+1, D+3 and D+6), together with ciclosporin (5 mg/kg on D−2 then 3 mg/kg 
per day from D−1, tailing at day +100 or sooner in the presence of mixed chimerism) was 
used for GVHD prophylaxis. Trough CSA levels were measured in whole blood twice weekly 
post-transplant. CSA was dosed to maintain levels between 150–300mcg/L. 
5.3.3 Supportive care 
All patients received antifungal and antimicrobial prophylaxis with fluconazole and 
ciprofloxacin until neutrophil engraftment. All patients were commenced on cotrimoxazole 
following engraftment as prophylaxis against Pneumocystis jiroveci. All patients received 
antiviral prophylaxis with aciclovir for a minimum of 6 months or longer if still on 
immunosuppression. Peripheral blood samples were monitored weekly for CMV reactivation 
by quantitative polymerase chain reaction (PCR). Patients with evidence of CMV re-
activation were treated with pre-emptive valganciclovir.   
5.3.4 Patient evaluation 
Disease response was evaluated according to lymphoma consensus guidelines.177, 178 PFS 
was measured from time of SCT date to date of progression. OS was calculated from SCT 
infusion date to date of death. NRM was defined as death in the absence of disease relapse 
or persistence. Acute GVHD was diagnosed and graded using current consensus criteria.113 
Chronic GvHD was diagnosed and scored using Seattle criteria.114 
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5.3.5 Statistical analysis 
Survival curves were constructed using the method of Kaplan and Meier and differences 
between groups were assessed using the log-rank statistic.  Patients were censored at last 
follow-up when calculating overall survival. Univariate analysis of association of outcomes 
with risk factors was performed. These included age at time of transplant (60 yrs or ≥60 yrs), 
HCT-CI, diagnosis, stage, number of prior treatment lines, previous autologous transplant, 
presence of chemosensitive disease, disease status at time of transplant, presence of 
refractoriness to Rituximab, donor type, donor age, sex mismatch, major ABO mismatch, 
CD34+ and CD3+ cell doses, CMV risk and the presence of acute and chronic GVHD.  
Where previous autologous transplantation had occurred, time to relapse and the interval 
between autologous and allogeneic transplant were evaluated. 
  
All P-values were two-sided, and P-values of less than 0.05 were considered statistically 
significant. Data was analysed using SPSS v22 (IBM, New York).  
5.4 Results 
5.4.1 Patient characteristics 
Patient, donor and graft characteristics are summarized in table 19. The median age of the 
patient cohort was 53 years (range 22-66 years). Nineteen patients (26.4%) were aged 60 
years or over. Twenty patients (27.8%) had FL. 20.1%, 16.7% and 15% of patients had 
MCL, DLBCL (including transformed FL) and WM respectively. The remainder included HL, 
PTCL and MZL.  Further detail on patient characteristics in those with DLBCL, FL and MCL 
are shown in tables 20, 21 and 22 respectively. Median follow-up for surviving patients was 
58.5 months. 
 
Patients were transplanted using HLA-matched related donors (n=33, 45.8%), matched 
VUDs (n=34, 47.2%) or mismatched VUDs (n=5, 6.9%).  There was a major ABO mismatch 
in 19 cases (27.9%). In 61.8% of cases, there was a CMV reactivation risk. There were 17 
cases of a male recipient and female donor (23.6%). Median donor age was 42 years (range 
22-68 years).  
 
Intermediate resolution HLA-typing was used for Class I (HLA-A and HLA-B, HLA-C) and 
high resolution molecular typing for Class II (DRB1 and DQB1) alleles. Stem cell source was 
granulocyte colony-stimulating factor-mobilized PBSCs in all cases. Patients received a 
median CD34+ cell dose of 5.68 x 106/kg (range 0.81-44.88) and median CD3+ T cell dose of 
2.66 x 108/kg (range 0.27-8.82). 
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Table 19: Patient characteristics undergoing allogeneic transplant for lymphoproliferative 
disorders 
  N % 
Diagnosis DLBCL 12 16.7 
 FL 20 27.8 
 WM 11 15.3 
 MCL 15 20.8 
 PTCL 5 6.9 
 HD 6 8.3 
 MZL 3 4.2 
Gender M 42 58.3 
 F 30 41.7 
Age Med (range)  53 (22-66) 
Stage 1 1 1.4 
 2 2 2.8 
 3 13 18 
 4 49 68.1 
 NA 7 9.7 
HCI-CI Low 32 44.4 
 Int 25 34.7 
 High 15 20.8 
Lines of treatment Med (range)  4 (1-8) 
Previous ASCT Y 29 40.3 
 N 43 59.7 
Treatment lines post ASCT Med (range)  1 (0-4) 
Relapse time post ASCT <12 m 2 9 
 13-24 m 4 18.2 
 >24 m 16 72.7 
Chemosensitive  48 66.7 
Chemorefractory  14 19.4 
   NA 10 13.9 
Response pre RIC-SCT CR 38 52.8 
 <CR 34 47.2 
Rituximab refractory  15(of 50 who 
received Rituximab) 
30 
Year of diagnosis  (excluding 
PTCL & HD) 
Pre 2003 26 59 
 Post 2003 25 41 
Donor Matched SIB 33 45.8 
 Matched VUD 34 47.2 
 Mismatched VUD 5 6.9 
Major Blood Gp Mismatch Y 19 26.4 
 N 49 68.1 
 NA 3 4.2 
Female donor/male recipient  17 23.6 
Donor age median (range) MUD  32.5 (20-44) 
 SIB  53 (27-77) 
NA not available 
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Table 20: Patient characteristics of those with DLBCL(n=12) 
    % 
Age≥ 60 years Y 25 
  N 75 
HCT-CI Low 33.3 
  Int 58.3 
  High 8.3 
Previous Autograft Y 66.6 
  N 33.3 
Response pre allograft CR 50 
  <CR 50 
Rituximab refractory Y 25 
  N 75 
Chemosensitive Y 75 
  N 25 
Lines of treatment (median)[range]  5[3-8] 
Duration of last treatment response <12 mths 8.3 
(months) 13-24 33.3 
  >24 50 
  No durable response 16.7 
 
Table 21: Patient characteristics of those with follicular lymphoma(n=20) 
    % 
Age≥ 60 years Y 20 
  N 80 
HCT-CI Low 45 
  Int 30 
  High 25 
Previous Autograft Y 45 
  N 55 
Response pre allograft CR 55 
  <CR 45 
Rituximab refractory Y 45 
  N 55 
Chemosensitive Y 75 
  N 25 
Lines of treatment (median)[range]   4[3-8] 
Duration of last treatment response <12 mths 25 
(months) 13-24 5 
  >24 55 
  No durable response 15 
 
Table 22: Patient characteristics of those with mantle cell lymphoma(n=15) 
    % 
Age≥ 60 years Y 40 
  N 60 
HCT-CI Low 66.7 
  Int 20 
  High 13.3 
Previous Autograft Y 26.7 
  N 73.3 
Response pre allograft CR1 33.3 
 PR1/VGPR1 13.3 
  CR2 46.7 
 <CR2 6.7 
Rituximab refractory Y 16.7 
  N 83.3 
Chemosensitive Y 86.7 
  N 13.3 
Lines of treatment (median)[range]   2[1-6] 
Duration of last treatment response <12 mths 11.1 
(months) 13-24 11.1 
  >24 66.7 
  No durable response 11.1 
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5.4.2 Engraftment and chimerism 
Excluding those who died before engraftment, all other patients engrafted and median time 
to neutrophil engraftment was 15 days (range 11-29). Median time to platelet engraftment 
(>20x109) was 12 days. FDC was achieved in 84.3% of all assessable patients. Median time 
to achieve FDC of whole blood was 90 days. 
5.4.3 Toxicity and non-relapse mortality 
NRM at 100 days was 12.5% with a 3-year NRM of 25%. 47.6% of all deaths were 
secondary to GVHD, the majority of which were associated with infection related to 
immunosuppression. 38% of deaths were due to infection and 3 cases (14.3%) were due to 
other causes including intracerebral haemorrhage and renal failure. 79% of treatment-related 
deaths were in patients above the age of 50, with over half of those being in those over 60 
years (42.8% of all NRM deaths). Consistent with the overall study population, forty percent 
of deaths in those over 60 years were secondary to GVHD and 40% were secondary to 
infective causes. However, 50% of deaths in those aged over 60 occurred within the first 100 
days post transplant. Thirteen patients had CMV reactivation (18%) but there were no cases 
of CMV related disease. No other significant viral infections occurred. 
5.4.4 Relapse & use of DLI 
Twelve patients (16.7%) relapsed post transplant. Median time to relapse was 25.5 months. 
Of these, 7 patients were treated with DLI which resulted in a CR being achieved again in all 
cases. Six of these patients are still alive and one patient died of sepsis.  DLI was utilised in 
patients with diagnoses of FL (n=1), DLBCL (n=2), PTCL (n=1), MCL (n=1) and WM (n=2), 
demonstrating evidence of the graft-vs-lymphoma effect in all of these histological subtypes.  
Univariate analysis did not identify any pre or post transplant factors that impacted on 
relapse risk. The small number of relapse events may have contributed to the failure to 
identify any significant differences.  
5.4.5 Survival 
Five year PFS was 52%. Five-year OS was 60% for all patients. There was a clear plateau, 
with the overall survival remaining at 60% 10 years post transplant. Whilst survival 
differences were observed between different histological subtypes (5 year OS at 40% for 
PTCL and 78.6% for DLBCL), these were not statistically significant for either PFS or OS, 
with analysis limited by small patient numbers in some diagnostic categories; (figures 23 & 
24).  
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Figure 23: Overall survival in lymphoma allogeneic transplants by diagnostic groups. 
Indolent lymphoma includes FL, WM and MZL 
  
Figure 24: Progression free survival in lymphoma allogeneic transplants by diagnostic 
groups. Indolent lymphoma includes FL, WM and MZL 
 
With regards to pre-transplant variables, age had a significant impact on OS with 5 year OS 
of those above and below 60 years at 50% and 70% respectively; p=0.015 (figure 25). Whilst 
the PFS Kaplan-Meier demonstrated an almost identical trend, age did not quite reach 
statistical significance; p=0.08 (figure 26). Although numbers were smaller, those aged 
P=0.33 
P=0.156 
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under 40 (n=7) had a 5 year OS over 80%, an interesting observation but too small to draw 
conclusions from.  
 
Figure 25: Overall survival in lymphoma allogeneic transplants by age above and below 60 
years 
 
Figure 26: Progression free survival in lymphoma allogeneic transplants by age above and 
below 60 years 
 
Disease response prior to transplant was significant with 5 yr OS at 67% vs 47% for those in 
a CR at the time of transplant compared to any response less than this respectively; p=0.044 
(figure 27). Almost identical findings were seen with PFS; p=0.045 (figure 28). 
 
P=0.015 
P=0.08 
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Figure 27: Overall survival in lymphoma allogeneic transplants according to pre-transplant 
response  
 
Figure 28: Progression free survival in lymphoma allogeneic transplants according to pre-
transplant response  
 
In conjunction with this, patients who had chemosensitive disease at the time of transplant 
had significantly better OS than those with chemoresistant disease (5 year OS 65% vs 40%; 
p=0.049 (figure 29). The trend was replicated in PFS, although significance was not 
reached; p=0.061 (figure 30).  
 
P=0.044 
P=0.045 
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Figure 29: Overall survival in lymphoma allogeneic transplants according to chemosensitive 
vs chemoresistant disease at the time of transplant. Chemoresistant disease is defined as 
achieving less than a partial response with the last line of treatment prior to transplant. 
 
Figure 30: Progression free survival in lymphoma allogeneic transplants according to 
chemosensitive vs chemoresistant disease at the time of transplant.  
 
Having primary refractory disease or previous refractoriness to Rituximab (in those who had 
received it) had no impact on OS. Patients in whom treatment with Rituximab upfront would 
be considered standard of care in today’s practice were divided into two groups based upon 
the date of their diagnoses being before or after the introduction of Rituximab into standard 
practice.  Five-year OS was nearly 80% in the Rituximab group compared to less than 60% 
P=0.049 
P=0.061 
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in those who did not receive it upfront. However, there was no statistical significance in OS 
between the two groups.  
 
In those patients who were undergoing an allogeneic transplant having relapsed post 
autologous transplant, time to relapse post autologous transplant had a significant impact on 
OS. Neither patient who relapsed within 12 months of autologous transplant survived (n=2) 
compared to a 5 year OS of 50% and 64% for those with relapse between 12-24months and 
greater than 2 years respectively (p<0.0001). Similarly, and perhaps more strikingly,  if all 
patients were considered in terms of their last response time prior to salvage treatment and 
allograft, 5 year OS was 0%, 21.4% and 71.7% for those with a response time less than 12 
months, 12-24 months and greater that 24 months respectively; p=0.002 (figure 31). The 
same observation was seen with PFS (p=0.006). 
 
Figure 31: Overall survival in lymphoma allogeneic transplants by duration of last treatment 
response prior to transplant. Patients treated in CR1 excluded. 
 
The cohort of patients who had never achieved a sustained CR following any line of therapy 
prior to allogeneic transplant had a surprisingly good outcome with a 5 year OS of 80%.  
 
There was no impact of gender, HCT-CI, previous autologous transplant, number of lines of 
treatment in total or post autologous transplant, donor type, donor age, blood group 
mismatch, gender mismatch or CMV risk or reactivation on relapse, PFS or OS. CD34 and 
CD3 count had no significant effect on relapse, PFS or OS. Achievement of FDC 
significantly improved OS; p<0.0001.  
P=0.002 
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5.4.6 Graft vs Host Disease 
Eighteen (26.1%) of all evaluable patients experienced acute GVHD (grades II-IV) of whom 
28% (n=5) died from GVHD within 100 days. Median time to acute GVHD was 31.5 days 
(range 19-76 days). Of those who developed acute GVHD, 11 (61%) died in total; 8 within 
the first year from transplant. Cause of death was GVHD or infection in the context of 
systemic immunosuppression in all cases. A significantly worse outcome for those who 
developed acute GVHD (grades II-IV) was seen, with a 5 year OS of 37% vs 70% for those 
with and without acute GVHD; p=0.002 (figure 32). The same observation was seen for PFS; 
p=0.002. 
 
Figure 32: Overall survival in lymphoma allogeneic transplant by occurrence of acute GVHD 
 
43 patients (69%) of all assessable patients had chronic GVHD or GVHD on tailing 
ciclosporin and 13.9% of these died from GVHD or infection associated with GVHD 
treatment. Occurrence of chronic GVHD demonstrated a non-significant trend for improved 
OS (5 year OS of 73% vs 62%; p=0.168).  
5.5 Discussion 
The utilisation of RIC-SCT in lymphoma offers potential long term remission and its use is 
growing. However its role in terms of which patients are most suitable, prognostic factors to 
aid patient selection and when it should be used remains a subject of debate. This 
retrospective analysis of 72 patients with a mix of histological subtypes, using T replete 
conditioning, reports a 5 year OS and PFS of 60% and 52% respectively. 100 day NRM was 
12.5% which is consistent with the BSBMT data of 12% in the NHL cohort. Three year NRM 
P=0.002 
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was 25%. These results are consistent with other reports that have evaluated a 
heterogeneous lymphoma population and again confirm RIC-SCT as a viable and potentially 
curative treatment strategy in a heavily pre-treated group who otherwise carry a relatively 
poor prognosis.179, 180  
 
Acute and chronic GVHD that required treatment with immunosuppression occurred in 26% 
and 69% of all patients. Despite this relatively high incidence, overall NRM was not higher 
than other studies that utilised T deplete conditioning.179 Whilst DLI was used with success in 
7 patients, this conditioning platform places much less reliance on DLI as a therapeutic 
strategy, which is important where over 50% of donors were unrelated. 
 
Several prognostic pre-transplant factors were identified to be predictive of survival 
outcomes in this analysis. These included age above 60 years, disease status at transplant, 
chemosensitivity at time of transplant and duration of last response prior to allograft. These 
factors should certainly be taken into account when considering patient selection. Whilst 
having chemoresistant disease and being in less than a CR at the time of transplant have 
inferior survival outcomes, there is still a survival plateau for both these groups. Therefore a 
proportion of patients will still be cured and a discussion between clinician and patient should 
occur in such scenarios to consider the relative merits of a RIC-SCT over other options. In 
those patients above 60 years with short response times prior to transplant there is no 
plateau evident in the survival curves making the potential benefit of RIC-SCT more 
questionable. 
 
The biggest limitation of this retrospective analysis is the heterogeneous population, both of 
lymphoma subtypes and indeed patient characteristics. It is well recognised that different 
diseases respond differently to RIC-SCT and that patients with better disease characteristics 
are expected to have superior outcomes. To compare them en masse provides evidence of 
the utility of this conditioning platform but provides little valid information for directing 
ongoing decision making within each subtype. Some groups have particularly small numbers 
making analysis for them alone statistically non-viable. However, I will now discuss the three 
largest subtypes individually; namely DLBCL, FL and MCL. 
5.5.1 Diffuse large B-cell lymphoma 
DLBCL is the commonest histological subtype of NHL. First line treatment with R-CHOP 
chemotherapy is considered the standard of care for those considered fit to receive intensive 
treatment resulting in a reported overall survival of 70-93% and an event-free survival of 
61% to 79%.181-183 For those patients that relapse after successful initial treatment or those 
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that do not achieve a CR with first-line therapy, salvage chemotherapy followed by an 
autologous stem cell transplant is the standard of care.165  This is supported by the BSBMT 
recommendations (table 15). Using this approach, progression free survival for patients who 
have previously been treated with or without Rituximab is approximately 50% at 3 years. 
However, the outcomes are significantly worse if relapse has occurred within 12 months of 
treatment with Rituximab with a 3 year PFS of 23% in this group.184  
 
The role of allogeneic transplantation in DLBCL is less clear. The efficacy, at least in part, of 
allogeneic transplantation is attributed to the immune mediated graft-versus-lymphoma 
effect. There has been some doubt cast on how significant this is in DLBCL following reports 
that there is no significant reduction in relapse compared to autologous transplantation.166, 185 
However, the interpretation of studies where equal relapse rates were reported is muddied 
by unevenly matched patient groups with a worse cohort of patients receiving an allogeneic 
transplant, perhaps offsetting the potential benefits of GvL.  Other studies have provided 
support for the demonstration of GvL in this sub-type of lymphoma with a reduction in 
relapse rates compared to those patients undergoing autologous transplantation.186, 187 The 
successful use of immunosuppresion withdrawal and DLI to achieve disease control is 
further evidence of GvL in DLBCL.170, 171, 179 With unacceptably high TRM rates with 
myeloablative conditioning,166, 185 the focus is now on RIC-SCT and where this is placed in 
the treatment of DLBCL. 
 
This study included 12 patients with DLBCL. Table 20 summarises their characteristics. Ten 
of these were patients that had transformed from follicular lymphoma. 75% had undergone a 
previous autologous transplant. 25% were over the age of 60 years. The median number of 
treatment lines prior to transplant was 5.  75% had chemosensitive disease at the time of 
transplant and 50% were in CR. Five year OS was 78.6% and three patients (25%) relapsed 
or progressed following transplant. Of these, 1 died of disease, the other 2 both achieved CR 
following DLI administration and are long term survivors. There were 2 post transplant 
deaths, one secondary to progressive disease as already mentioned; the other was a late 
death at 57 months secondary to the development of nephrotic syndrome and renal failure, 
the aetiology of which was unclear. 
 
This data is favourable compared to the literature where TRM is reported at between 20%- 
39% at between 2 and 5 years. Overall survival for RIC-SCT in patients with DLBCL is 26-
52% at 3 to 5 years with a PFS of 25-48%.171, 188-192 It is unclear why there is such a 
discrepancy between our data and the literature; certainly in terms of patient characteristics 
the cohort seems comparable. It is a small cohort and perhaps if this group was expanded, 
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the outcome data would change. Is it the impact of being a group made up of predominantly 
transformed FL, rather than de novo DLBCL? This cohort has not been identified to have 
superior outcomes in the literature but given that there is stronger evidence for a graft-vs-
lymphoma effect in FL, perhaps this in turn is responsible for the improved responses seen 
in this cohort in the RIC-SCT setting. There has been speculation that the GVL effect in 
DLBCL may be limited but the superior OS in this study is supported by the occurrence of 
cGVHD in 10 patients (83%) and a better OS in those with GVHD. The successful use of DLI 
in 2 patients is further evidence of the GVL effect in DLBCL.188, 193-195 
 
Some studies have demonstrated that patients with indolent NHL do better that those with 
aggressive subtypes after RIC-SCT.179, 196 However, this study demonstrated that the DLBCL 
cohort had a superior, although not significant, OS compared to the indolent lymphomas 
(FL,WM and MZL) with a 5 year OS of 78.6% vs 56.6% respectively (p=0.138), an outcome 
that again may be confounded by the make-up of the DLBCL cohort. 
 
So where is allogeneic transplantation best placed in this lymphoma subtype? BSBMT 
guidelines recommend it as standard of care in those who are primary resistant but sensitive 
to salvage and in those who have relapsed post autograft. It is a clinical option to consolidate 
responses at relapse with allograft rather than autograft (table 15).  
 
Following the introduction of Rituximab to upfront DLBCL treatment, response rates with 
chemotherapy are improving and fewer relapses are occurring. However, when relapses do 
occur, especially if they occur early, autologous transplantation is less likely to offer 
benefit.184 Perhaps consideration should be given to this cohort of patients being taken 
straight to an allograft if a donor is available. There is however no evidence to support this 
strategy. In the cohort analysed in this study, four patients underwent RIC-SCT without 
having undergone a previous ASCT. One of these failed to harvest stem cells, another had 
poor cardiac function felt to be inadequate to safely proceed with an ASCT. The remaining 
two were both patients with previous FL who had never achieved a CR despite multiple lines 
of therapy and therefore never felt to have good enough disease control to proceed with an 
ASCT. This is clearly too small a group to analyse with regards to outcomes, although these 
cases highlight scenarios where RIC-SCT may be especially useful.  
 
An algorithm for who should be considered for allograft vs autograft has been proposed 
using a similar rationale whereby not only those who have relapsed post autograft but also 
those who are not likely to benefit from an autograft should be considered as allograft 
  
 
98 
 
candidates.197  However, clearly more data is needed to support this as a valid treatment 
pathway given the significant associated NRM. 
5.5.2 Follicular lymphoma 
Follicular lymphoma is an indolent lymphoma with many patients surviving for decades 
following diagnosis. Despite the introduction of Rituximab to first line treatments, which have 
undoubtedly improved outcomes,198, 199 there remains a cohort of patients with a more 
aggressive form of the disease who are more resistant to conventional chemotherapy and 
carry a worse prognosis.200, 201 
 
For those patients who relapse, salvage chemotherapy followed by an autologous stem cell 
transplant is considered the standard of care.164 This is supported by the BSBMT guidelines 
and studies have demonstrated an improved PFS and OS compared to chemotherapy alone 
(table 14). Studies in the pre-Rituximab era reported OS between 50-70% depending on the 
time point and study.202-204 More relevant to today’s practice, in those who have received 
Rituximab upfront and as part of salvage treatment, 3 year OS post ASCT has been reported 
as 92% compared to 63% in those who received salvage chemotherapy alone at relapse.205 
However, whilst a small cohort of patients have extremely long progression-free survival post 
autograft and may well be cured, as a general principle this transplantation strategy is not 
considered a curative one for the majority, and relapse or progression is the main cause of 
treatment failure.204 
 
The graft versus lymphoma effect in FL has been well demonstrated.172, 194, 195 As in other 
haematological malignancies, the reduction in disease relapse seen in early studies utilising 
myeloablative conditioning was offset by high TRM rates resulting in no OS benefit.167, 206 
However the role of RIC-SCT in FL is growing. It is the only definitive curative strategy and 
studies report PFS ranging between 43% and 76% and OS from 52% to 81%. TRM has 
been reported as ranging between 11% and 42% at 3 years.179, 188, 207-209   These wide-
ranging outcomes most likely stem from the differences in the study designs with all utilising 
different conditioning regimens, including differing patient cohorts and follow-up times.  
 
Most studies that have evaluated the outcomes of FL patients with RIC-SCT have included a 
proportion of patients who have had a previous autograft for whom the outcomes are 
worse.207, 209 However, the BSBMT guidelines recommend a RIC-SCT as a standard of care 
in those patients who have relapsed following autograft, if the patient is considered a 
suitable candidate. The role of allograft rather than an autograft in consolidating treatment of 
salvage chemotherapy-responsive relapsed disease is more controversial.  
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A prospective study which attempted to directly compare the outcomes of autograft vs RIC-
SCT at first relapse closed early due to poor recruitment.210  A retrospective study comparing 
the two treatment strategies concluded that whilst RIC-SCT was associated with a higher 
NRM and reduced relapse rate, there was no overall difference in OS.211  However, the two 
patient cohorts were clearly subject to selection bias and were not equally matched either at 
the point of transplant or in their subsequent management. Therefore it is very difficult to 
draw any valid conclusions about how the two strategies compare. 
 
BSBMT recommends RIC-SCT in first relapse, with either a sibling or MUD, as a ‘clinical 
option’. It states it may be especially appropriate in those who are considered at high risk of 
failure from an autograft which includes those who have had a short first response, a high 
FLIPI at relapse or who have failed to achieve a CR with salvage chemotherapy (table 14). 
So whilst it may be true that those who have not achieved a CR will not do so well with an 
autograft and may derive most benefit from an allograft, it is likely that the patients that are 
chemosensitive are the ones who will benefit most from either transplant strategy.  
 
So where does this leave us with regards to our own practice and patient selection? Practice 
at St Bartholomew’s Hospital is in line with BSBMT recommendations. Patients undergo an 
ASCT at relapse and if it is felt appropriate and a suitable donor available, are considered for 
a RIC-SCT if relapse occurs post ASCT. Table 21 summarises the characteristics of the 20 
patients with FL who underwent RIC-SCT. 20% were over the age of 60 years. 55% were in 
CR at the time of RIC-SCT, 45% were Rituximab refractory and 75% had chemosensitive 
disease at the time of transplant. They had undergone a median of 4 lines of treatment prior 
to allogeneic transplant. 45% had undergone a previous ASCT, a surprisingly low proportion, 
given that the standard of care is to perform an allogeneic transplant following relapse after 
ASCT. Looking at this group in more detail, 1 patient failed to harvest, 1 patient had an 
allogeneic transplant for FCR-induced aplasia and 1 patient elected not to have an ASCT 
previously, The remainder were all patients who had undergone multiple lines of treatment, 
most of whom had never achieved a CR and two who had very short responses following 
Rituximab-based chemotherapy, who were perhaps felt unlikely to sustain long-term benefit 
from an ASCT.   
 
The 5 year OS for FL patients was 57.4% with only 1 patient relapsing. 3 year NRM was 
30%, although small patient numbers may have adversely impacted upon this.  Numbers 
were small to adequately assess the impact of pre-transplant variables. However, donor type 
did significantly impact upon outcome with 5year OS for sibling vs MUD 87.5% vs 32% 
respectively (p=0.042).  
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Data submitted to BSBMT based upon autologous transplants performed in NHL at St 
Bartholomew’s shows a 5 year OS of 57% for all NHLs. These outcomes are similar to those 
demonstrated with the RIC-SCT approach. The autologous transplant patient cohort is 
mixed, including other NHLs and clearly these 2 datasets cannot be directly compared. 
However, if the outcomes really are so similar at the 5 year mark, then perhaps the prospect 
of long-term cure, at least for a proportion, makes the role of RIC-SCT seem more attractive. 
 
Returning to consider the first hypothesis of this chapter, it is certainly reasonable to place 
RIC-SCT as standard of care if relapse occurs post ASCT and therefore support the 
hypothesis. Analysis of this data has highlighted the question of which patients should be 
consolidated at first relapse with a RIC-SCT over an ASCT. Practical issues such as failed 
stem cell harvests and suboptimal organ function for ASCT make RIC-SCT a reasonable 
choice in this scenario. However, in terms of disease stratification, whilst suggestions have 
been made, to date there remains inadequate evidence in the literature to suggest that this 
should be standard of care, and for now, it therefore should remain as a clinical option.  
5.5.3 Mantle cell lymphoma 
Mantle cell lymphoma is a much less common subtype of NHL, accounting for 6% of all 
lymphomas. Over the last decade, the introduction of Rituximab, high dose chemotherapy 
regimens and the use of consolidation with autograft in first response, have improved 
outcomes with median OS reported as over 7 years.212, 213 However, these strategies are not 
curative and relapses continue to occur.  
 
As in other lymphoproliferative disorders, the role of allogeneic transplantation is growing but 
its place remains controversial. There has been clear demonstration of the GvL effect in 
MCL with successful use of immunosuppression withdrawal and DLI to eradicate disease 
post transplant and the simultaneous occurrence of GVHD and disease response.214, 215 
Again, as with other lymphoma subtypes, the use of myeloablative allogeneic transplantation 
has not demonstrated a survival benefit, most likely because of the high associated NRM.168 
Consequently, the focus again is on the role of RIC-SCT. 
 
Transplant strategy at St Bartholomew’s is to consolidate patients with MCL with an ASCT in 
first response. However, in those who are young, fit and who demonstrate poor disease 
characteristics (e.g. blastoid variant or high ki67) then a donor search would be commenced 
during first line therapy and the patient would be considered for a RIC-SCT in CR1. The 
characteristics of the 15 patients with MCL who underwent RIC-SCT are shown in table 22. 
Using this T-replete conditioning regimen, 5 year OS based upon 15 patients was 72.7%. 
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This compares favourably to other low grade lymphomas within this analysis and also to the 
literature which reports OS as between 37% to 62%.179, 215-221     PFS was 67% at 5 years. All 
relapses (n=3) occurred within 12 months post transplant and no late relapses have been 
observed. 1 patient received DLI and achieved disease control; the other 2 patients died 
from progressive disease.  Cumulative NRM in this subset of MCL patients was 13% at 3 
years. Whilst low early NRM has been reported in some studies215, 217 the majority of studies 
report a 2-3 year cumulative NRM between 20-32%.179, 216, 218-220 Interestingly 7 patients 
underwent RIC-SCT in first response. Of the remainder (n=8) who were transplanted at 
relapse, 4 underwent an ASCT at first relapse, 2 declined an ASCT at first relapse and 2 
proceeded with a RIC-SCT as their consolidation strategy following salvage therapy. 
 
This analysis suggests that RIC-SCT with this conditioning regimen is a viable treatment 
strategy with favourable outcomes compared to both other NHL subtypes within our own 
centre and to other studies. However, the small numbers must be remembered, especially 
when comparing to studies with much larger patient cohorts. 
 
Are these results secondary to patient selection? This retrospective analysis clearly has a 
selection bias in the patients being put forward for a treatment strategy not considered 
standard of care and known to carry a high NRM. The median age of patients in this group 
was 58 years, comparable to other studies. However, the cohort had 6 patients over the age 
of 60, but 66% with a HCT-CI of 0. This demonstrates that clearly patient selection is 
important in achieving good outcomes and that this is not by selection of age alone.  Four 
patients (27%) had undergone a previous autograft and this had no impact on OS which is 
consistent with most studies. Median number of treatment lines prior to allograft was 2 
(range 1-6), which is certainly lower than other reported studies and may be a factor in these 
favourable results. Those patients who had fewer than 3 treatment lines had 100% OS at 5 
years compared to 33% for those with ≥3 lines (p=0.045), consistent with similar 
observations in other, although not all, studies.216, 217 Twelve patients (80%) were in CR at 
the time of transplant. There was a trend to improved OS for this cohort compared with 
lesser responses with 5 year OS at 82.5% vs 33% (p=0.068). Of the 3 patients not in CR, 2 
had early death secondary to progressive disease.  Similarly, chemosensitivity predicted for 
superior outcomes with a 5 year OS of 91% vs 0% (p=0.005). Twelve patients had prior 
exposure to Rituximab. Two were Rituximab refractory and were deemed chemoresistant at 
the time of transplant. Both died of progressive disease within 6 months of transplant. Just 
under half had a matched unrelated donor. This is not identified as a prognostic factor in 
most studies.222 Although there was a difference between survival outcomes between donor 
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types (88% vs 57% 5 year OS for sibling and VUD respectively) this was not significant 
(p=0.133). 
 
Whilst RIC-SCT may well be a reasonable treatment option, the literature remains unclear 
regarding which patients should be selected for allograft over autograft. The largest study 
performed by the Centre for International Blood and Marrow Transplant Research (CIBTMR) 
is a retrospective, non-randomised analysis of patients with chemosensitive disease 
undergoing ASCT or RIC-SCT either early (having received 2 or less lines of treatment) or 
later on in their disease. No differences in overall survival between ASCT or RIC-SCT were 
seen, mainly due to the higher TRM of the RIC allografts (25% vs 3%). Treatment with either 
transplant modality produced better outcomes when performed earlier in the disease course. 
They concluded that in the absence of a survival benefit, patients in first response should 
have an ASCT. Those who are considered to carry a lower TRM risk (by virtue of a lower 
HCT-CI) or who are at greater risk of disease relapse, should be considered for a RIC-SCT 
in first response.219 This is consistent with the BSBMT and EBMT guidelines which list 
allogeneic transplantation as a ‘clinical option’ in patients with a CR/PR1 or greater, 
suggesting it is most appropriate in those with high risk disease or with an ‘acceptable’ 
predicted NRM (table 17).211 
 
In a disease that retains a high likelihood of relapse following autologous transplantation, the 
key to prolonged survival is RIC-SCT.  If patient selection can be optimised to keep NRM 
down, it has the potential to further improve survival for at least a cohort of patients with this 
disease.  This analysis would suggest that patients with chemosensitive disease, in CR, who 
are not heavily pre-treated are the most likely to benefit. 
 
To return to the second hypothesis in this chapter, the numbers available in this 
retrospective analysis do not provide sufficiently strong data to support RIC-SCT being 
standard of care in CR1, and therefore the hypothesis must be rejected, for now. However, 
the outcome data in this lymphoma subtype is very good and this success appears to be 
secondary to a combination of good patient selection and transplanting early in the disease. 
If the same outcomes were replicated with larger numbers, this would provide a strong 
rationale for RIC-SCT to become standard of care in CR1 for MCL. 
5.5.4 Waldenströms Macroglobulinaemia 
WM is a rare lymphoproliferative disorder with an indolent course for the majority.  A 
retrospective analysis identified that only 21% of patients required treatment at 100 months 
following diagnosis.223 When treatment is required, response rates to combination 
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chemotherapy are high and even at relapse, good responses may be achieved again. 
However, ultimately the disease will become resistant to conventional chemotherapy. 
Furthermore, prognostic stratification tools have identified the heterogeneity of this disease 
with a less indolent subgroup that carries a 5 yr OS of 36%.224 
 
Its rarity, in combination with identifying patients who are suitable for transplantation means 
that evidence is limited with regards to the role of stem cell transplant. Unlike the lymphoma 
subtypes discussed previously, autologous transplantation is not recognised as a standard 
treatment strategy in those with relapsed or resistant disease. Rather, both autologous and 
allogeneic transplantation are considered a ‘clinical option’ in these scenarios (table 23).169, 
225  
 
Table 23: BSBMT Indications for Waldenströms Macroglobulinaemia (taken from BSBMT 
indications for SCT version Oct 13) 
 
 
There are several reports of the use of autologous transplantation both in relapsed disease 
and in first response. Five year OS is reported between 63% to 100% with a TRM of less 
than 10%.226 The largest retrospective series of 158 patients with relapsed disease reports 
5yr OS of 68% and 3 yr TRM 8%. The problem of course, is that this is not a curative 
procedure.227 
 
As with other lymphoma subtypes, the use of MA conditioning in WM has resulted in 
unacceptable TRM. 169, 225 Reports of RIC-SCT in WM have demonstrated evidence of GVH 
activity and have a lower TRM. 173, 174 Kyriakou et al reported a retrospective analysis of 49 
patients undergoing RIC with a 5 year OS of 64%, 5 year PFS of 49% and 3 year TRM of 
23%. Whilst all of these had fludarabine based conditioning, over half were T cell 
depleted.228 Similar retrospective studies using non TCD conditioning have reported similar 
outcomes.229 
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This study included 11 patients with WM with a five year OS of 53%. There were no relapses 
in surviving patients. Five patients died resulting in a cumulative 3 year NRM of 45%. Four of 
these were secondary to infection, and one to chronic GVHD. None of the patients had 
undergone a previous autologous SCT. Only 2 were in CR at the time of transplant and 5 
were considered chemosensitive. Median number of treatment lines prior to transplant was 
3. Seven patients had been treated with Rituximab. Three patients were over the age of 60 
and all died of treatment related causes. Interestingly only 1 patient had an allograft after 
2007. It is unclear whether this reflects a change in practice because of the high NRM in this 
subgroup or the rarity of finding a suitable transplant candidate with this diagnosis. 
 
This data is too small to inform clinical practice with any validity. Whilst one of the potential 
advantages of RIC-SCT is that those who are older and with a worse performance status 
may benefit from it, it is clear that if our practice had been restricted to those under 60 years, 
outcomes in terms of survival and NRM would be superior. Bachanova et al suggests that 
RIC-SCT be reserved for younger patients with relapsed but chemosensitive disease, a high 
International Prognostic Scoring System for WM (IPSSWM) and a good performance 
status.226 Clearly more data is needed to assist clinicians in how to identify who will benefit 
most from transplantation in this disease group. 
5.5.5 Hodgkin lymphoma 
Hodgkin lymphoma carries a favourable prognosis for the majority. However, 10-20% of 
patients are primary refractory and a similar percentage will relapse.230, 231 Standard of care 
in both scenarios is salvage chemotherapy followed by an ASCT.232  Relapse following 
ASCT carries a poor outlook with a median survival of 25 months. Early relapse within 6 
months of ASCT holds an even bleaker outlook with a median survival of 15 months.233 For 
those patients who relapse following ASCT, allogeneic stem cell transplant is recommended 
(table 16). 
 
Despite this being a generally younger patient cohort, unacceptably high NRM associated 
with MA conditioning has resulted in the focus again lying with RIC transplantation.234 
Analysis of RIC-SCT in refractory/relapsed HL reports a PFS and OS of 20-40% and 40-64% 
at 2-4 years respectively. NRM is reported between 15-25% at 1-2 years.235-240 These 
studies have demonstrated evidence of the GvH effect in HL and also suggest disease 
status and chemosensitivity impact upon outcomes. 
 
This analysis included only 6 patients with HL, all under the age of 50. Three were primary 
refractory and the others had relapsed disease. The longest prior response period of these 
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three patients was 7 months. Five had undergone a previous ASCT, 3 were considered 
chemosensitive and only 1 patient was in a CR at the time of transplant. Three patients died 
before 100 days from acute GVHD, TTP and an intracerebral bleed. There were no relapses. 
The NRM is clearly high, but patient numbers are very small. 
 
RIC-SCT is considered standard of care for those with relapsed disease (table 16). 
However, outcomes are worse compared to other lymphoma subtypes. There has been 
suggestion that more intense conditioning may be required in order to allow disease control 
whilst the GvL effect is given time to occur. It has also been suggested that allograft should 
perhaps be considered earlier in the disease course or in those in whom the benefit of an 
ASCT is likely to be less, for example those who remain PET positive despite response.241 
Further studies are required in order to be able to answer these questions and guide our 
practice in where allograft is best placed. 
5.5.6 Peripheral T cell lymphoma 
T cell lymphomas are characterised by a worse prognosis than B cell lymphomas with a 5 
year OS of 41%.242 The BSBMT guidelines suggest that as with other lymphoproliferative 
disorders, ASCT is considered standard of care at relapse and allogeneic transplant is 
considered standard of care for those who relapse post ASCT or in those who are primary 
resistant (table 18). 
 
Demonstration of disease control by virtue of DLI and withdrawal of immunosuppression 
again provides evidence of graft-vs-lymphoma in this subtype.175, 176 OS and PFS following 
RIC-SCT are reported at 46% to 81% and 30%-64% respectively at 3 years. NRM is 
reported as 12-27%.176, 243-247  
 
The small cohort of 6 patients in this study had a 5 year OS of 40%. Three patients died of 
treatment related causes; 2 of these were over the age of 60.  One patient relapsed but was 
salvaged with DLI. The numbers are too small to draw any conclusions. However, what is 
interesting is the patient selection. Four out of the 5 patients had 1 line of treatment. They 
were all in CR with chemosensitive disease and no prior autograft. This suggests patients 
are being selected to consolidate their CR1 with an allograft that offers a curative potential 
rather than waiting until later in the disease course. Transplantation in CR1 is a ‘clinical 
option’ according to BSBMT and this may well be an appropriate strategy but larger numbers 
are required to provide more useful guidance on this (table 18). 
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CHAPTER SIX 
Discussion 
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6.1 Introduction 
Progress in our understanding and practice of haematopoietic stem cell transplantation has 
come a long way since its inception in the 1950s.  Despite this, there is ever-increasing 
controversy within most haematological malignancies about the role and timing of 
transplantation. The more we understand, the more treatment options we have, the more 
questions are raised about exactly which patients should undergo SCT, when and with what 
conditioning regimen. Medical practice today is governed by ‘evidence-based medicine’ and 
guidelines. However, in the field of SCT, guidelines are generic, with little quality evidence 
base available in many scenarios to help clinicians make decisions about transplantation in 
patients who fall into those controversial categories. 
 
Haematopoietic stem cell transplantation at St Bartholomew’s Hospital demonstrates 
increasing activity year-on-year, in-line with national data reported by BSBMT.  This rise is 
multifactorial. Increased early identification of factors that confer poor-risk in many 
haematological malignancies, use of reduced-intensity conditioning and availability of 
matched unrelated and alternative donors are some of the reasons behind the increasing 
number of patients proceeding to SCT.  
 
I have looked at the outcomes of SCT in four different clinical scenarios to try and elucidate if 
local practice at St Bartholomew’s hospital can shed light into and inform practice in these 
areas of debate. 
 
6.2 Autologous stem cell transplantation in myeloma 
I evaluated the use of reduced-dose conditioning in ASCT using a MEL140 approach in 
patients with newly diagnosed myeloma with renal impairment, who were older than 65 
years or with comorbidities felt to preclude them from the standard MEL200.  Following 
these results, my hypothesis was rejected. The data demonstrated the use of MEL140 to be 
a safe and effective approach in this cohort of patients. Whilst accepting the limitations 
carried by this retrospective analysis and the smaller number of patients in the MEL140 arm, 
I would recommend that this is a viable approach in patients who would otherwise not be 
deemed suitable for ASCT.  Although the MEL140 approach has not been directly compared 
to a non-transplant approach in this patient group, the equal outcomes in comparison to the 
MEL200 cohort infer that these patients are likely to be achieving an improved PFS and OS. 
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Prospective studies directly comparing MEL140 and MEL200 and comparing MEL140 
versus chemotherapy alone would be helpful additions in evaluating the role of this 
approach.  
 
For decades,  patients with myeloma were treated with melphalan and prednisolone and had 
short life expectancies, with a median survival of 3 years.248 During the 1990s, treatments 
changed and 4-6 months of vincristine, adriamycin and dexamethasone followed by high 
dose melphalan and ASCT became the standard of care in patients under the age of 65. 
This strategy improved survival and quality of life outcomes.50, 249 Today, for the majority of 
patients, decisions regarding upfront myeloma treatment are focused upon whether the 
patient is considered an appropriate candidate for autologous transplantation. For those that 
are, ASCT remains the backbone of first line treatment. 
 
Various strategies have been investigated to try and further improve ASCT outcomes. 
Attempts at purging the stem cell harvest to reduce contamination by malignant cells have 
had no beneficial effect on outcomes.250, 251 Tandem autografts remain a matter of debate in 
terms of whether there is a survival benefit. Randomised studies have concluded that those 
patients that achieve less than a VGPR following their first transplant are the most likely to 
benefit from the tandem approach. However these studies have been criticised for not being 
applicable to patients being treated with today’s induction regimens, and studies are 
ongoing.252-254 
 
Since the landmark studies identified a survival benefit from ASCT, treatment in multiple 
myeloma has changed significantly and improvements in survival have been dramatic, with 
the greatest survival gains seen in those under 50 years of age.255 These improvements are 
attributed to the arrival of novel agents including thalidomide, bortezomib and lenalidomide, 
amongst other factors, such as improved supportive care. These novel agents have all been 
demonstrated to have significantly better response rates than their historical counterparts, 
with significantly higher proportions of patients achieving CR.256-263  
 
The importance of achieving a CR has been well described with improved depth of response 
correlating with improved overall survival.82, 83, 264 In the pre-novel agent era, one of the 
rationales behind proceeding to ASCT was that the CR rate following induction treatment 
alone was only 5-10% and this could be increased by consolidation with high-dose therapy.  
However, the reported PFS and OS benefit associated with achievement of CR has yet to be 
demonstrated in many of the trials reporting the successes of novel agent combination 
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therapies by virtue of their high CR rates. Only two have reported an improved PFS with 
novel therapy induction262, 265   
 
Definitions for how CR is measured have evolved over time. More recently, it has been 
reported that those patients who are able to achieve an immunophenotypic CR have a 
significantly higher PFS compared to those with a ‘traditional’ CR or even stringent CR 
where the normalisation of the serum free light chain ratio is an additional requirement. 
Median time to evidence of recurrent disease is only 3 months if a non-immunophenotypic 
CR is achieved.266, 267  Furthermore, it is not simply achieving a CR that is predictive of 
improved outcomes. Having a sustained CR for greater than 3 years unsurprisingly results in 
vastly improved OS outcomes.268 
 
So why the discrepancy between the improved CR rates and lack of survival benefits with 
these novel agents? The median follow-up for most studies evaluating novel agents is less 
than four years. This time-frame is likely to be too short to identify any significant survival 
differences and this may be something that becomes more apparent with longer follow-up. 
Gene expression profiling has also demonstrated that the survival benefit seen with CR is 
not universal but is unique and critical to survival gains in those patients identified as high 
risk.269  
 
There has been some suggestion that given the improved response rates to novel agents, 
that ASCT should be deferred until later in the disease’s natural history.   A meta-analysis of 
nine randomised trials demonstrated no survival differences according to the timing of the 
transplant.270 Furthermore, there is some concern that such an approach, where patients 
receive consecutive treatments with combination chemotherapy, rather than high-dose 
melphalan up-front, may allow cytogenetic subclones to emerge that will make 
responsiveness to treatment increasingly difficult. This is most likely to be true for those with 
high risk cytogenetics at presentation.271  Genomic studies comparing minimally treated and 
more heavily treated patients have demonstrated that those treated with multiple lines of 
therapy have a worse gene expression profile with a very poor outcome to high dose 
melphalan and ASCT, suggesting the evolution of drug refractory disease.272  
 
The question has been pushed further with some questioning whether autologous 
transplantation has a place at all in the era of novel agents. Retrospective data comparing 
combination chemotherapy versus ASCT have demonstrated no differences in PFS or 
OS.273, 274  It has been observed that those who undergo an ASCT upfront spend less time 
overall actually receiving therapy and consequently suffer fewer treatment-related symptoms 
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and side-effects, resulting in an improved quality of life - a factor missing from evaluation in 
many studies.59  However these studies were not randomised and had short follow-up. The 
only prospective trial to date has reported an increased PFS in the tandem ASCT arm. This 
is in comparison to the non-transplant arm where patients received  six further cycles of 
melphalan, prednisolone and lenalidomide following induction with lenalidomide and 
dexamethasone, but survival data is awaited.275 
 
To date, the treatment approach in myeloma has been relatively uniform and the only 
question traditionally asked at diagnosis is whether the patient is young enough and fit 
enough to undergo ASCT. However, it is increasingly clear that not all myeloma is the same. 
Our understanding of cytogenetic risk stratification in myeloma has increased significantly 
and there have been variable reports on bortezomib overcoming adverse cytogenetic risk.-
276-278 However, meta-analyses of patient cohorts with poor risk cytogenetics post ASCT is 
yielding discrepant results. Sonneveld et al reported that patients with 17p deletion who 
received PAD induction, ASCT and bortezomib maintenance had significantly improved PFS 
and OS compared to the VAD arm.265  Whilst there was a significant improvement between 
the two treatment arms, the 17p deleted PAD arm did not equal the outcomes of those with 
non-adverse cytogenetics.  Most other studies have observed that despite bortezomib-based 
induction, those with poor risk cytogenetics including t(4;14) and 17p deletion, have been 
identified to gain minimal benefit from ASCT.102, 279, 280 
 
At the other extreme, there is a small cohort of patients who remain in CR over a decade 
following their ASCT and survival curves in two studies with long follow-up have both 
demonstrated a plateau with approximately 10% patients alive and disease-free between 11 
and 14 years post ASCT.84, 281 Perhaps these patients have been cured.  Is there a unifying 
predictive factor in those with such impressive responses? Understanding which patients are 
most likely to have a sustained benefit would be extremely important in defining the role and 
utilisation of ASCT in the future.   
 
At present, ASCT is not considered a curative procedure for the vast majority. Indeed in St 
Bartholomew’s own results, which are comparable to reports in the literature, median PFS 
was between 20 months. Whilst the NRM is very low, it carries significant short-term 
morbidity. So can we say goodbye to ASCT in myeloma? Not yet. There is no convincing 
evidence-base to date to suggest that we have a better treatment strategy. Data on current 
novel agents and those on the horizon is promising but until longer follow up is able to 
demonstrate a survival benefit with or without ASCT, the door cannot yet be closed on 
transplantation. 
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Furthermore, there is more to contemplate than survival benefits alone. It has been clearly 
demonstrated that novel agents in combination result in better responses, but that this 
carries a higher risk of toxicities. We are already seeing that despite better survival 
outcomes, lenalidomide used as post ASCT maintenance carries a higher risk of secondary 
malignancies.282 If the future of myeloma treatment is a series of successive combination 
therapies, there would need to be heavy consideration into the inevitable associated 
toxicities and the impact this would have on quality of life. By the same token, if the risk of 
toxicities, and mucositis in particular, were better understood then this too could play a role 
in patient selection and perhaps melphalan dosing. Work here is underway with identification 
of single nucleotide polymorphisms that seem to predispose some patients to more severe 
mucositis. However, this still remains some distance away from altering clinical practice.283 
 
Ultimately the question is not - what is the correct dose of melphalan? or - is ASCT a thing of 
the past? but recognising that myeloma treatment, like most other malignancies, is not a one 
size fits all approach.  Further understanding of myeloma tumour biology and gene 
expression profiling to allow the development of accurate methods of risk and likely 
response stratification are the key to being able to utilise the increasing armoury of novel 
drugs and transplantation to maximise benefits and minimise unnecessary toxicities. 
6.3 The role of allogeneic transplantation in myeloma 
The role of allogeneic transplantation in myeloma remains highly contentious. Guidelines 
vary from suggesting it should only be performed within a clinical trial because there is no 
evidence base to support its efficacy to the BSBMT guidelines which suggest that a sibling 
allogeneic transplant can be considered standard of care.110, 284 This led to my hypothesis to 
examine whether the benefits of reduced relapsed in allogeneic transplantation in myeloma 
outweighed the risks of associated toxicities. 
 
This discrepancy and lack of consensus is reflected in the numbers of transplants being 
performed. Whilst autologous transplantation in myeloma is the most common indication for 
a transplant, with over 4,500 being performed between 2006 and 2011 in the UK, myeloma 
is the least common indication for  an allogeneic transplant with only 54 being performed in 
the UK over the same time period.55 Low patient numbers add to the difficulty of interpreting 
data and making evidence-based treatment recommendations, but therefore the cohort of 35 
patients analysed in this report from a single-centre is actually an impressive number when 
considering overall activity in this area and the majority of patients undergoing this approach 
in the UK do so at St. Bartholomew’s Hospital. 
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Allogeneic transplantation continues to draw interest because the utilisation of a disease-free 
donor cell graft and the immune-mediated graft-vs-myeloma effect drawn upon using 
reduced-intensity conditioning have the potential to achieve long-term cure in a disease 
which is otherwise considered incurable.  
 
Our data produced PFS and OS outcomes in line with other studies in the literature, despite 
the patient cohort comprising both those being transplanted up-front and those at relapse. 
The TRM of 5% at 100 days and 11% at 3 years is exceptionally low. T depleted 
conditioning has already been recognised to have a detrimental impact on survival in 
myeloma, most likely due to the loss of the graft-vs-myeloma effect.98 This analysis 
reinforces the use of the T replete conditioning regimen, comprised of fludarabine and 
cyclophosphamide, where both safety and efficacy are well-demonstrated. This conditioning 
platform has been reported to have a favourable toxicity profile in the context of other 
haematological malignancies.111, 155, 156 However, the remarkably low TRM is even more 
relevant in myeloma where high TRM rates have been one of largest obstacles in the way of 
allogeneic transplantation.  
 
So is allogeneic transplantation standard of care in myeloma? The answer currently has to 
be no and therefore my hypothesis must be rejected. There is no data either in this analysis 
or in the literature that categorically demonstrates a survival advantage utilising the 
allogeneic approach. However, there is a survival plateau with over 25% patients remaining 
in long term remission. It has been difficult to identify a specific patient cohort who will 
particularly benefit in this analysis. It is been demonstrated to be equally difficult to draw 
conclusions in a much larger EBMT registry-based analysis that evaluated the outcomes of 
different treatment pathways to transplant. Despite over 7000 patients in the analysis, and 
identification that the best survival outcomes are achieved by those who undergo a tandem 
auto-allo approach in first response (within 8 months of each other), there is no comment on 
statistical significance and no definitive conclusions about how best to utilise allogeneic 
transplantation.285  
 
As NRM declines, the greatest obstacle continues to be progressive disease. Given the 
median time to death following relapse was 23 months, perhaps the role of allogeneic 
transplantation should be considered differently to other malignancies. Does progression 
post transplant make it a complete failure? Progression following an ASCT is virtually 
guaranteed but of course the difference is the toxicity profile of an ASCT is considered low 
enough to justify a life-prolonging but non-curative strategy. A RIC-SCT is also life-
prolonging in the majority, especially if the NRM is as low as reported in this analysis.  
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Perhaps the challenge therefore extends to identify not only which patients are most likely to 
be cured but also those that may achieve prolonged remissions. This approach would only 
be justified if quality of life was reasonable, and it is well recognised that the morbidity 
associated with chronic GVHD may well compromise that. 
 
In order to try and improve on the high disease progression rate post transplant, there is 
increasing research on post transplant maintenance therapies with novel agents to use 
either prophylactically or at relapse, in synchrony with DLI, or where DLI has failed. These 
have been recognised to have immunomodulatory effects that may be able to enhance the 
graft-vs-myeloma effects without aggravating GVHD. Results are encouraging, although in 
many cases, the duration of response remains limited and there are concerns about drug-
related toxicities.286-288 
 
A limitation of this analysis is the absence of cytogenetic data; this is recognised as 
increasingly important prognostically and is now recommended as a standard diagnostic 
test. Given that there is data to support the ability of allogeneic transplantation to overcome 
poor risk cytogenetics, this is a cohort of patients where due consideration should be given 
to performing an allogeneic transplant. 123, 289 It will be very interesting to evaluate their 
outcomes and identify whether this is a cohort where allogeneic transplantation has the 
power to change their fate.  
6.4 The role of sequential allogeneic transplantation in refractory AML, 
relapsed AML and myelodysplasia 
The sequential allogeneic transplant strategy in patients with refractory and relapsed AML, 
and MDS, allows patients with poor-risk disease to receive intensive chemotherapy and 
proceed directly into a T replete RIC allogeneic transplant. This theoretically enables 
patients to avoid the delays of getting to transplant because of difficulty achieving remission 
or chemotherapy-related complications and allows analysis on an “intent to treat basis”, 
since most studies of transplant in these settings do not include the denominator of patients 
who receive salvage therapy but never make it to transplant. Given concern over rapid 
disease progression in these poor-risk patients, this approach also allows for less delay 
whilst awaiting the graft-vs-leukaemia effect. My hypothesis therefore was to consider 
whether this approach should be standard of care in patients with refractory and relapsed 
AML and high risk MDS. Of note, even with this approach, four of the enrolled patients did 
not proceed to transplant as planned, further demonstrating the difficulty of getting to 
transplant in this patient cohort. 
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The data from St Bartholomew’s reports an OS comparable with other sequential 
approaches reported in the literature, despite a very poor patient cohort in terms of 
cytogenetic remission, remission status and HCT-CI. There was a high NRM of 39% at 3 
years for all patients.  However, the prognosis for the majority of patients without transplant 
in this cohort is dismal and such a high NRM must be weighed against the alternative, which 
is inevitable death secondary to disease for the majority. 
 
Despite this, there were some relatively clear findings to help inform patient selection for this 
strategy. Patients with relapsed AML, with a CR1 greater than 6 months, demonstrated a 
clear benefit. Their OS at 5 years was 41.7% which was significantly better than their 
predicted outcomes.131  Whilst numbers were small, patients with MDS also seemed to have 
better survival outcomes than expected with no patients relapsing. Larger numbers are 
needed to confirm this observation, but it is in line with other MDS sequential outcomes and 
appears to be a very promising treatment strategy in these patients.144  On the basis of these 
findings I would recommend this transplant strategy as a clinical option in these two groups 
of patients. Patients with refractory AML and those with high risk diagnostic cytogenetics had 
particularly poor outcomes and on the basis of this data, I would not recommend using the 
sequential approach in them. For this patient population less toxic treatment strategies or 
clinical trials are more appropriate. 
6.5 The role of allogeneic transplantation in lymphoma 
According to BSBMT guidelines, for patients with DLBCL or indolent lymphomas, allogeneic 
SCT is only standard of care if a patient has relapsed following an ASCT.  In those patients 
at first relapse it is considered a ‘clinical option’ and similarly patients with PTCL and MCL 
can be considered for an allogeneic SCT in first response as a ‘clinical option.’ 
 
The cohort in this study produced outcomes in line with the literature with a 5 year OS of 
60%, PFS of 52% and NRM of 25%. With regard to which patients are most likely to benefit 
from allogeneic transplantation, recurrent themes emerged, firstly as a whole cohort 
analysis, and then again by histological subtypes. Based on this data, I would advocate the 
use of RIC-SCT in patients <60 years, with chemosensitive disease, who are in a CR and 
who have progressed greater that 12 months after their last treatment.   If all these criteria 
are met, outcomes are likely to be most favourable. Those patients under the age of 40 have 
particularly good outcomes with OS >80% at 5 years and I would particularly recommend 
this treatment strategy in younger patients, keeping in mind other desirable criteria.  
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However, this not a tick-box exercise and there will be patients with poor-risk disease who 
do not meet these desired criteria. Whilst those with chemoresistant disease and less than a 
CR at the time of transplant have inferior survival outcomes, there is still a survival plateau 
for both these groups. Therefore clinicians and patients must have informed discussions in 
these scenarios about the potential risks and benefits of an allogeneic SCT. 
 
Of course, histological subtype is important and transplant decisions and their timing are 
clearly dependent on the subtype. There is no evidence at present to answer the question 
regarding whether first relapses should be consolidated with autograft or allograft. St 
Bartholomew’s retrospective data reports similar 5 year OS with both strategies. This 
comparison is not based on equally matched patient populations, being taken from two 
independent data analyses. However, it does not suggest the strategy that is overwhelmingly 
most successful. Survival differences are more likely to emerge in the long-term, because 
the allograft cohort will produce a cohort of long term survivors through its immune-mediated 
graft-vs-lymphoma effect. Whilst there may also be a handful of long-term survivors in 
patients treated with ASCT,204 this is not the expectation for those with low grade NHL.   
 
The patients in this retrospective analysis are too heterogeneous and too small in number to 
make recommendations regarding RIC-SCT and its role in the various lymphoma treatment 
pathways. In DLBCL and follicular lymphoma, I would suggest that there should not be an 
‘autopilot’ response whereby patients in first relapse automatically proceed to salvage 
chemotherapy and an ASCT. In appropriate patients, there should at least be consideration 
of which consolidation strategy is most appropriate. This work supports pre-existing data that 
patients with FL who have previously undergone an ASCT have inferior outcomes post 
allograft.207, 209 Therefore to maximise its potential benefits, performing it earlier in the 
disease may result in the best outcomes. Furthermore, in the Rituximab era, patients can 
now be identified who are less likely to benefit from an autograft at first relapse and these 
patients should be considered for allograft in first response.197  More data is clearly needed 
to support this as a valid treatment pathway given the increased NRM associated with the 
allogeneic approach. 
 
The data for MCL RIC-SCT is particularly encouraging with 5 year OS of 73% and NRM of 
only 13%. This analysis would suggest that patients with chemosensitive MCL, in CR, who 
are not heavily pre-treated are the most likely to benefit from the allogeneic approach.  On 
the basis of small numbers in this analysis, I cannot recommend that RIC-SCT in first 
response should be standard of care, but certainly should remain as a clinical option. Larger 
numbers may change this recommendation in the future. 
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The remaining LPD subtypes are difficult to make specific recommendations about due to 
small numbers in this analysis and limited data in the literature with which to comment on the 
place of allogeneic transplantation. For those patients, consideration of the pros and cons on 
an individual basis will have to continue until more evidence becomes available on when 
allogeneic transplantation is best placed in these patients. 
 
The treatment landscape in lymphoproliferative disorders is changing. Numerous new drugs 
have emerged across all histological subtypes including several new classes of molecularly 
targeted agents. These have demonstrated varying degrees of efficacy.290, 291 Furthermore, 
genomic profiling is resulting in the identification of new targets and ongoing development of 
novel therapeutic strategies. 
  
Idelalisib, an oral PI3K inhibitor, has been identified as an effective treatment strategy in 
those with relapsed or refractory low grade lymphoma.292 The Bruton Kinase inhibitor 
Ibrutinib has demonstrated efficacy in mantle cell lymphoma.293 Whilst these have all 
improved the treatment options for those with relapsed disease, response duration is finite 
and these are not considered curative options. However, further research may demonstrate 
they have benefit as pre or post transplant therapies. 
 
Perhaps the only therapeutic development amongst the LPDs to impact on transplantation is 
Brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate. This has demonstrated 
significant activity in relapsed or refractory HL. Its use as salvage therapy and in particular 
as a bridge to transplant has been demonstrated. More recently, its favourable impact on 
post RIC outcomes is being reported with improved PFS compared to patients not treated 
with the drug pre-transplant.294-296 
 
As follow-up periods are extended, and newer agents are utilised in different treatment 
settings, the role and timing of transplantation may well continue to evolve. To conclude, 
RIC-SCT is a viable and potentially curative treatment strategy. Some disease subtypes, 
namely DLBCL (predominantly transformed FL) and MCL appear to demonstrate particular 
benefit in this analysis. More data is required to know which patients should be selected for 
RIC-SCT, when this should happen and whether this should be earlier in the disease course, 
instead of an ASCT in selected patient cohorts. With the data currently available, 
consideration should be given to the patient’s age, disease response, sensitivity and 
duration of their last treatment response when considering if a patient is an appropriate 
candidate for RIC-SCT and its likely success. 
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6.6 Where is allogeneic stem cell transplantation heading? 
In the diseases I have discussed so far, recurrent themes emerge. There are many 
scenarios in malignant haematology where prognosis is extremely poor. Allogeneic stem cell 
transplantation is the only truly curative treatment strategy in these cases. There are two 
fundamental problems - firstly the associated toxicities, and secondly the significant rate of 
relapse that still occurs post transplant. If allogeneic transplantation could be administered 
without its associated toxicities and with more assurance of its curative potential, the fate of 
many would undoubtedly be different.  Instead, at present, we are focused upon how to 
identify those whose disease confers such poor risk that the gamble of SCT is worth it.  
Whilst we deliberate over the relative merits of transplantation in individual cases, research 
is headed in differing directions in order to try and deal with these conflicts.  
6.7 How can toxicity be reduced? 
A major break-through here was the introduction of reduced intensity conditioning. This has 
clearly reduced but not eliminated the NRM and much work is still needed. Improved 
supportive care with better transfusion support, pre-emptive screening for CMV reactivation 
and fungal infections and better antimicrobials may all help. We now have scoring tools to 
help identify those at risk of particularly high NRM which enables clinicians to reconsider in 
those cases whether transplantation is actually the best treatment strategy.297 The 
introduction of T cell deplete conditioning was also done with the aim of trying to eliminate 
the toxicities of T cell mediated GVHD.39 The consequent realisation that reducing GVHD 
also reduced the beneficial GVL effect means that research now is focussed on trying to pull 
apart the two. Work is ongoing to try and differentiate the immune mechanisms by which 
these two processes occur in order to try and manipulate them differentially. However, whilst 
some steps are being made in understanding the different immune mechanisms involved, it 
will be some time before this has a significant impact on clinical practice.298, 299 
6.8 How can post transplant disease relapse be reduced? 
Post transplant strategies to reduce disease recurrence are predominantly focused upon 
manipulating and trying to enhance the GvL effect.  
 
One strategy is to use vaccinations directed against tumour-associated antigens to ‘boost’ 
the GvL effect that is so crucial to long term remissions.300 This strategy theoretically relies 
upon vaccination being administered in the early post transplant period to induce in vivo 
generation of large numbers of anti-tumour lymphocytes without induction of immune 
tolerance. The early post transplant period is felt to be an ideal time to introduce disease-
antigen targeted vaccines to take advantage of the rapid lymphocyte proliferation that is 
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occurring in this time period. This strategy can be boosted further by the use of adoptive 
transfer of vaccine primed lymphocytes. This has been performed successfully both from the 
patient and from healthy donors, although there are difficult ethical issues regarding 
vaccination of healthy donors. Further vaccination is then administered to the patient 
following chemotherapy and transplant to induce further stimulation of the GvL effect.301-304 
Work is ongoing with animal studies and early phase trials to try and develop this treatment 
strategy. 
 
Other strategies have been to utilise maintenance therapies post transplant to try and 
sustain prolonged remissions. Whereas tyrosine kinase inhibitors (TKIs) are frequently used 
post transplant for patients with CML and Philadelphia positive ALL, efforts are now focused 
on the administration of drugs that can maximise the GvL effect. Most work has focused 
upon immunomodulatory drugs and hypomethylating drugs in myeloma, LPDs and myeloid 
disorders.305, 306 Research is ongoing in this area and to date the results are variable with 
some concern about increased risks of acute GVHD with the use of lenalidomide.307 
Work in the haplo-identical transplant field has generated more immunotherapeutic 
strategies to try and prevent relapse whilst minimising GVHD. NK cells originating from the 
donor have been shown to demonstrate alloreactivity against neoplastic cells that manifest 
themselves when KIR molecules on the surface of donor’s NK cells are not engaged by 
certain HLA class I molecules on the surface of hosts’ cells.308 309 There has been interesting 
data reporting that infusion of NK enriched cells can result in sustained disease control with 
no evidence of GVHD.310, 311 This area of adoptive immunotherapy is again work in progress 
but if progress is sustained, may expand the benefits of GvL to patients who would not 
otherwise be considered fit for a transplant.311 
6.9 Can patient stratification be improved? 
6.9.1 Patient stratification in AML 
As discussed previously, for the majority, the role of allogeneic transplantation in those with 
relapsed or refractory AML carries little debate. Even if remission can be achieved with 
salvage chemotherapy, the prognosis in this setting is so poor, that SCT is considered 
standard of care and the only potential way of achieving a durable remission.133, 135 
For those with AML in first remission, more considered thought is required to determine who 
should undergo an allogeneic transplant. Acute myeloid leukaemia is the commonest 
disease indication for an allogeneic transplant.55 The majority of patients with AML will 
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achieve a remission following induction chemotherapy.126 However, sustaining a remission is 
much more difficult.  Fifty percent of patients under the age of 60 years will relapse within 
three years and in those over the age of 60, this rises to 85%.312 
The decision of whether post-induction therapy should be consolidation chemotherapy alone 
or involve an allogeneic transplant is based upon the likelihood of relapse. Relapse in those 
patients with adverse risk is 70-90% if treated with chemotherapy alone or 30-50% if 
consolidated with a myeloablative transplant.313 BSBMT recommendations from 2013 are 
that those patients with intermediate or adverse risk should have an allogeneic transplant in 
CR1. They define adverse risk as those with poor risk cytogenetics by MRC criteria, those 
with secondary or therapy-related AML and those who fail to achieve a CR with induction 
therapy. All eligible patients with relapsed AML should be considered for an allogeneic 
transplant.284 
It is clear from clinical practice that these divisions of risk are not entirely predictive of 
outcome; there are patients with ‘good risk’ who have early relapses and those with ‘poor 
risk’ who demonstrate durable remissions despite not undergoing transplantation. However, 
setting aside patient fitness and donor availability, risk stratification remains the biggest 
determinant in making the decision to recommend a SCT.  Our ability to do this accurately is 
incredibly important, given the significant risk of morbidity and mortality implicated in 
recommending a transplant. However our ability to stratify risk, whilst evolving, remains 
imperfect. 
Identification of cytogenetic and molecular abnormalities are fundamental to making 
decisions about which patients in CR1 should have a SCT. Cytogenetic abnormalities are 
detected in approximately 55% of patients with AML and are divided into three prognostic 
groups.314 Large meta-analyses have confirmed that those patients with intermediate and 
poor risk cytogenetics acquire benefit from an allogeneic transplant with an increased OS 
compared to those treated with chemotherapy alone. Those with good risk karyotype do not 
however demonstrate a survival benefit from SCT.315, 316 
Forty to fifty percent of patients with AML have a normal karyotype and fall into the 
intermediate risk category. Despite the unifying label, this relatively large cohort of patients 
demonstrate significant variability in their survival outcomes. Consequently they are the 
subject of the greatest area of controversy regarding the identification of which patients 
should undergo a SCT in CR1. 
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Molecular genetics are helping to subdivide this category into more clinically relevant 
prognostic categories. In 2008, Schlenk et al reported the outcomes of 872 patients with 
normal karyotype in whom molecular genetic analyses were performed. They identified that 
those with mutations in NPM1 and CEBPA demonstrated improved outcomes and that SCT 
was particularly beneficial to patients with FLT3 ITD mutations who carried a worse 
prognosis.317 Further studies have built upon this and there is now reasonable consensus 
that those with biallelic CEBPA mutations and NPM1 mutations carry good risk and should 
not have a SCT in CR1, unlike those with FLT3 ITD mutations.318-321 This clinical practice, 
based upon molecular genetics, has not formally made its way into consensus guidelines, 
but there is little debate amongst transplanting clinicians that these results are fundamental 
in determining relapse risk in today’s practice. 
More recently, numerous other recurrent somatic mutations have been identified. It is clear 
from whole-genome sequencing that there is a complex interplay of genetic events which is 
likely to account for hetererogeneity in clinical outcome seen within AML.322 Determining the 
clinical relevance of these mutations is difficult because it is likely that allele burden and the 
presence of molecular abnormalities in combination impact upon outcome. However, strides 
forward are occurring and there is now evidence that more extensive mutational analysis 
may allow better discrimination of those considered intermediate risk by standard 
cytogenetic criteria.323 Integrated genetic profiling may in time assist in identifying those most 
likely to benefit from SCT or indeed from novel targeted therapies.  
Whilst much of the focus is on how to pull apart those with normal karyotype, it is important 
to remember that even those with ‘favourable risk’ have no guarantees of long-term 
remission. The adverse prognosis of KIT mutations in those with favourable cytogenetics 
has already identified this as a separate cohort that may benefit from c-KIT inhibitors or even 
SCT.324 
The commonest cause of transplant failure in AML remains relapsed disease. The presence 
of MRD positivity in those considered to be in CR by conventional criteria prior to SCT has 
been identified as a predictor of increased relapse and reduced survival post transplant.325 
Similarly those patients that took more than one cycle of chemotherapy to achieve CR1 have 
a significantly worse prognosis post transplant, independent of all other factors.326 Both of 
these factors are undoubtedly a reflection of chemo-resistant disease with the data 
suggesting that SCT is unable to overcome the inherent treatment resistance in these 
patients.  Further work is needed to understand the role of MRD in determining the role and 
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timing of transplant and whether those with chemo-resistance may benefit from a non-
transplant strategy. 
The risk carried by the disease is only half of the equation. The reality is that if allogeneic 
SCT carried no associated NRM, it would be recommended as a consolidation strategy in all 
patients with AML. It is not that it is ineffective in those with ‘good risk’ disease, merely that 
the associated NRM is too high to overcome the potential survival benefit. Consequently, 
only those with the highest risk of relapse have the potential to increase their survival despite 
the NRM risk.327 
In the same way that disease risk stratification is needed, stratification of NRM risk is also 
required. Consideration of the risk of age, comorbidity and likelihood of GVHD are essential 
when making decisions regarding transplantation. Better supportive care, better HLA-
matching and tools to help identify appropriate patients will all help to reduce NRM.297, 328-330 
If patients are selected with care, those that undergo the procedure are more likely to 
achieve the potentially curative benefits. 
6.9.2 Patient stratification in myelodysplasia 
Allogeneic SCT is the only curative treatment strategy available to those with 
myelodysplasia.  Most current practice is based upon the recommendation that those with 
low risk disease (low or INT-1) based upon the IPSS  do not gain benefit from SCT, whereas 
those with INT-2 or high risk disease should proceed to allogeneic stem cell transplant if 
there is an available donor.141 
There has been concern that the IPSS score is only validated as a prognostic tool at 
diagnosis and that it excluded those with Chronic Myelomonocytic Leukaemia and 
treatment-related MDS. It also does not take into account the impact of age or comorbidities 
and was validated prior to the introduction of hypomethylating agents into the treatment of 
MDS.331 However the same outcomes and recommendations have been made using the 
IPSS with SCT compared with best supportive care or hypomethylating drugs. The WPSS 
score has been demonstrated to be a better tool with which to estimate the timing of SCT.332, 
333 
It is well recognised that those MDS patients with less disease burden prior to SCT have 
reduced relapse post transplant. It might be expected that the introduction of the less 
intensive azacytidine might result in better outcomes compared to intensive induction 
therapies. The results of two retrospective studies have failed to demonstrate a difference in 
  
 
122 
 
post-transplant outcomes, although prospective studies are underway to evaluate this 
further.334, 335 
Like in AML, the factor most likely to impact upon the role of SCT is improved risk 
stratification. The impact of monosomal karyotype in MDS continues to cause controversy 
but it has been reported to have a 2 year OS of 6% post SCT.336-338 If replicated, this 
suggests that allogeneic transplant is not an appropriate strategy with which to manage this 
sub-group.  Significant progress has been made in identifying a multitude of point mutations 
implicated in MDS.  There has also been demonstration that detection of these may allow 
the identification of cohorts of patients with a worse prognosis than is predicted by current 
scoring methods.339, 340 Further studies will then be required to identify whether this poor 
prognosis can be overcome by SCT. 
6.10  Can allogeneic transplantation be avoided altogether? 
6.10.1 Chimeric antigen receptor T cells 
Advances in gene therapy have been progressing steadily over the past decade with the 
development of chimeric antigen receptors (CARs). These are fusion proteins incorporating 
both antigen-binding and T-cell activation domains. 341 Autologous T cells are genetically 
modified to express CARs and any cell surface molecule can be targeted.  Most work to date 
has been done with anti-CD19 CAR T cells which recognise and kill CD19+ target cells. 
CD19 is expressed on most malignant B cells and therefore these have been used with good 
clinical effect in a variety of B cell malignancies including ALL, indolent NHL, CLL and 
DLBCL.342-346 
These promising results are leading to further research to identify effective surface 
molecules that can be targeted for other malignancies such as AML and myeloma.347 348 
Whilst there is a risk of cytokine release syndrome and B cell aplasia, excellent responses 
have been demonstrated in patients with refractory disease. At present CARs are utilised to 
achieve response prior to transplant or in those who have relapsed post transplant. 
However, if their efficacy is demonstrated to be sustained, it is possible this treatment could 
avoid the need for allogeneic transplantation altogether 
6.10.2 Targeted drug therapies 
The development of targeted drug therapy that results in high response rates with prolonged 
remission is another treatment strategy to try and bypass the need for allogeneic 
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transplantation and its associated toxicities all altogether. I will now discuss how targeted 
therapies have changed the role of transplantation in CML, probably the best demonstration 
of success in this area, and CLL below. 
6.10.2.1 Targeted drug therapies in chronic myeloid leukaemia 
The story of CML is a remarkable tale of the evolution of stem cell transplantation in 
haematological malignancy.  
 
In 1974, the first successful allogeneic transplants in CML were reported in 4 patients with 
syngeneic donors who remained in remission and philadelphia chromosome negative 2 
years post transplant.349 IBMTR data reported ongoing successes, utilising HLA matched 
sibling donors, with clear demonstration of a survival plateau between 14-19 months post 
transplant. Their report also clearly demonstrated that those transplanted in chronic phase 
had significantly better outcomes than those transplanted either in accelerated or chronic 
phase, both in terms of survival and disease recurrence.350 
 
With the development of unrelated donor registries, allogeneic transplantation grew and in 
2000, CML, alongside AML, were the most common indications for an allogeneic 
transplant.351 Recognition of the T cell mediated GvL effect drove the development of 
reduced-intensity conditioning in many haematological malignancies and just as plans were 
underway to compare myeloablative and RIC platforms in clinical trials, the game-changing 
tyrosine kinase inhibitor, Imatinib, arrived on the scene.352 
 
Imatinib has revolutionised CML treatment over the last decade. Follow-up data has reported 
that 8 year OS and PFS are 85% and 92% respectively when used first line in chronic 
phase.353 Even before formal follow-up data was available, the use of SCT in CML was 
already on the decline.354 Today, the demonstration of such successful results using an oral 
tablet with reported minimal toxicity has resulted in SCT no longer being recommended first 
line in patients in chronic phase.355 
 
However, 15-25% of patients will fail or be intolerant to Imatinib. SCT remains the treatment 
of choice in patients who present in or develop accelerated (AP) or blast phase (BP). One of 
the consequences of TKI therapy, is that more patients will now be transplant candidates in 
AP or BP when it is well documented that survival and relapse outcomes are significantly 
worse.350 Transplantation in BP is only successful in 10% of cases.356  
 
  
 
124 
 
Three year OS data in the Imatinib era is reported at between 72-74% following SCT with no 
negative impact on outcomes observed by prior TKI treatment.356-358 EBMT data has 
observed improving SCT outcomes over time.354 Post transplant strategies that allow MRD 
monitoring and consequent utilisation of the synergy between TKIs and DLI may improve 
outcomes further.359, 360 
 
Treatment with TKIs started in 2001 – we now have 14 years of follow-up with 8 years 
formally reported in the literature. Over that time, compliance issues, intolerance and 
development of mutations are challenges that have been added to the equation.  For a 
patient diagnosed in their 20s, there is no real data in the TKI era about his prospect of 
reaching old-age. Attempts to discontinue Imatinib following prolonged and convincing 
molecular remissions have demonstrated that approximately half of those patients will 
relapse within 6 months.361 Quality of life (QoL) assessments have revealed that many 
patients on Imatinib have a reduction in QoL due to drug side effects and one study reported 
a significantly superior QoL in those who had a SCT compared to those on Imatinib.362, 363 
 
So whilst other diseases look on in hope, there is still a clear, albeit modified, role for SCT in 
CML and still much work to be done on the quest to make CML a disease where SCT truly is 
a thing of the past. Researchers and clinicians managing other haematological malignancies 
are however still hoping to find their ‘Imatinib-equivalent’ in order to avoid the ongoing 
morbidity and mortality associated with allogeneic stem cell transplantation.  
6.10.2.2 Targeted drug therapies in chronic lymphocytic leukaemia 
CLL is the commonest adult leukaemia. In 2007, EBMT presented a consensus statement 
whereby those patients with poor-risk CLL should be considered for an allogeneic stem cell 
transplant. Poor risk included patients who did not respond to or relapsed within 12 months 
of treatment with a purine analogue, those who relapsed within 24 months following an initial 
response to purine analogues or an ASCT or those carrying p53 abnormalities.364 
  
The introduction of RIC-SCT was of particular importance in CLL because the median age at 
diagnosis is 70 years, meaning that in the era of myeloablative conditioning, SCT was not an 
option for many.365  
  
Over the last few years, there has been an explosion of activity in the development of new 
drugs in CLL. Bruton’s tyrosine kinase (BTK) holds a central role in the activation of several 
constitutively active pathways and has therefore become an attractive target to try and inhibit 
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therapeutically. Ibrutinib is an oral, irreversible BTK inhibitor and appears to be the most 
promising development in the recent spate of new therapeutic advances. With a 26 month 
PFS and OS of 75% and 83% respectively, its outcomes are significantly better than other 
single agents are able to achieve in a cohort of relapsed/ refractory patients with a median of 
4 treatment lines and an otherwise profoundly poor prognosis.366, 367 Its toxicity profile is also 
very favourable with minimal grade 3 or 4 events. Furthermore, its outcomes in those with 
refractory CLL with 17p deletion, although not equal to the remainder of the cohort, are again 
superior to outcomes with other treatments.366  
 
PI3K is another essential kinase involved in activation of pathways of importance in cellular 
proliferation, survival and differentiation. Idelalisib is an oral PI3K inhibitor which has also 
demonstrated favourable outcomes, albeit with a shorter duration of follow-up reported to 
date.  In combination with Rituximab, a 92% OS at 12 months has been reported. It too has 
demonstrated favourable results in those with 17p deletion.368  
 
Other studies are underway including BCL2 inhibitors and the development of chimeric 
antigen receptor (CAR) T cells.344, 369  The arrival of these novel agents has resulted in those 
with classically poor-risk CLL, especially those with 17p deletion, having more treatment 
options available. The follow-up data on these drugs remains short but their impressive 
outcomes have the potential to change the standards with question-marks already hanging 
over the place of SCT in our current treatment algorithm. 
 
Despite excellent response rates, the proportion of patients achieving a CR with Ibrutinib or 
Idelalisib monotherapy is low. This suggests that SCT will continue to have a role, either at 
the point of relapse or in a defined poor-risk cohort as consolidation. 370 
 
These are exciting times for CLL. Oral agents that allow patients of all ages to achieve 
excellent clinical responses whilst avoiding the toxicities of chemotherapy is a huge stride 
forwards and will inevitably change our current practices. However, longer follow-up data, 
and further prospective trials comparing these new drugs either alone or followed by SCT  in 
comparison to our current treatment practices are  needed in order to guide clinicians on 
how best to utilise these novel agents in conjunction with SCT.  
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6.11 Conclusion 
I have evaluated four areas of stem cell transplantation practice at St Bartholomew’s 
Hospital and in conjunction with a review of the literature, I have made recommendations 
regarding ongoing practice in these controversial areas. The spectrum of controversy is 
however much wider than the areas I have evaluated in this research. 
 
Haematopoietic stem cell practice is continuously evolving and the future of SCT is unclear. 
Will it evolve into a highly refined treatment with minimal toxicity and high cure rates or will it 
become yesterday’s news, trumped by novel therapies with minimal toxicities? Research into 
the genomics of haematological malignancies is gaining pace, and undoubtedly, being able 
to refine disease-stratification across all malignancies is fundamental to personalising their 
approach to treatment as a whole, including the role of transplantation. However, progress in 
the development of molecularly targeted drugs, immunomodulatory and gene therapies may 
significantly change the way SCT is incorporated into treatment pathways in the future. 
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Appendix 1: Sequential trial ethics approval 
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Appendix 2: Sequential study protocol 
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